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Abstract 
 
A detailed understanding of the human immune system is crucial for developing 
novel pharmaceuticals to fight a range of diseases. The glycolipid α-galactosyl 
ceramide, α-GalCer, has been shown to stimulate the proliferation of murine 
spleen cells and activate the immune system. Stimulation occurs through 
binding of the glycolipid to the protein CD1d. Subsequent presentation of the 
CD1d−glycolipid complex to invariant Natural Killer T cells (iNKT cells) initiates 
the proliferation of a host of cytokines leading to an immune response. The 
therapeutic potential of α-GalCer is currently being explored; however the 
induction of both Th1 and Th2 cytokines by this agent is likely to limit its 
therapeutic application. The crystal structure of human CD1d in complex with α-
GalCer reveals a key hydrogen bond between the N-H of the amide group of 
the glycolipid and the side-chain O-H of Thr 154 located on the α2 helix of the 
CD1d molecule; however, the carbonyl group of the amide is not directly 
involved in binding. Carbonyl group replacements should therefore behave 
similarly but may involve more selective iNKT cell induction as well as improved 
hydrolytic stability. Significantly, analogues of α-GalCer have been shown to 
induce iNKT cell-derived cytokines more selectively through a skewed Th1-Th2 
response. To date, very few alterations around the amide bond have been 
explored. To investigate its importance in iNKT cell stimulation, a range of α-
GalCer and threitol ceramide (ThrCer) analogues has been synthesised in 
which the amide functionality in these two leads has been replaced with 
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different carbonyl functional groups. These compounds have been tested for 
iNKT cell induction and in particular their Th1/Th2 response, which determined 
their therapeutic potential. Labelled derivatives of α-GalCer and ThrCer have 
also been designed and synthesised to find application in lipid trafficking 
studies. 
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1. Introduction  
1.1.   The immune system, an overview 
The immune system is a very complex “machinery” that involves many different 
proteins interacting with each other. In humans first line of defence against 
invaders such as viruses, bacteria and parasites consists of physical barriers, 
namely skin and mucous membranes that line our digestive, respiratory and 
reproductive tracts. The innate immune system serves as a second line of 
defence, providing a quick response to common invaders.1 The innate immune 
system is a universal and ancient form of host defense against infection. Innate 
immune recognition relies on a limited number of germline-encoded receptors. 
These receptors have evolved to recognise the conserved products of microbial 
metabolism, which are produced by microbial pathogens, but not by the host. 
Recognition of these molecular structures allows the immune system to distinguish 
infectious non-self from non-infectious self. Toll-like receptors (TLR) play a major 
role in pathogen recognition and initiation of inflammatory and immune 
responses.2 The weapons of the innate immune system include the complement 
proteins, professional phagocytes, and natural killer (NK) cells.  
 
The adaptive immune system involves great variability and rearrangement of 
receptor gene segments, and therefore provides specific recognition of foreign 
antigens, immunological memory of infection, and pathogen-specific adaptor 
proteins. However, the adaptive immune response is also responsible for allergy, 
autoimmunity, and the rejection of tissue grafts. 
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Innate immunity is responsible for most inflammatory responses which are 
triggered by macrophages, polymorphonuclear leukocytes, and mast cells through 
their innate immune receptors. Adaptive immunity supports the innate immune 
system in specific recognition of proteins, carbohydrates, lipids, nucleic acids, and 
pathogens, using the same activated, but not antigen-specific, effector cells 
generated by innate immune recognition. Thus the two systems are intimately 
linked in their use of the same effector cells. The key differences between the 
innate and adaptive immune systems are summarised in Table 1.1.2 
 
Property Innate immune system Adaptive immune system 
Receptors 
 
Distribution 
Recognition 
Self Non-self 
discrimination 
Action time 
Response 
Fixed in genome 
Rearrangement is not necessary 
Non-clonal,                              
All cells of a class identical 
Conserved molecular patterns 
(lipopolisaccharides, mannans, 
glycans) 
Perfect: selected over 
evolutionary time 
Immediate activation of effectors 
Co-stimulatory molecules 
Cytokines (IL-1β, IL-6) 
Chemokines (IL-8) 
Encoded in gene segments 
Rearrangement is necessary 
Clonal                                           
All cells of a class distinct 
Details of molecular structure 
(proteins, peptides, 
carbohydrates) 
Imperfect: selected in 
individual somatic cells 
Delayed activation of effectors 
Clonal expansion or anergy         
IL-2                                      
Effector cytokines: (IL-4, IFNγ ) 
 
Table 1.1.   Differences between innate and adaptive immunity. Table adapted from 
ref 2. 
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1.2.   Invariant natural killer T (iNKT) cells 
Natural killer T cells (NKT cells) are a major population of innate-like T-
lymphocytes. These multifunctional lymphocytes can mediate an immune 
response to tumours and play an important role in the host‟s defense mechanism 
against microbial infections as well as a function in maintaining immune tolerance.3 
 
NKT cells possess properties of the natural killer (NK) cells of the innate immune 
system, and of traditional T cells of the adaptive immune system. They mature in 
the thymus and co-express the αβ T cell antigen receptor (TCR) and NK receptors 
NK1.1 or NKR-P1A. In contrast to the αβ receptors of traditional T cells, which are 
incredibly diverse, the repertoire of receptors expressed by NKT cells is quite 
limited. Traditional T cells recognise peptides presented by either class I or class II 
major histocompatibility complex (MHC) molecules, whereas NKT cells recognise 
lipids and glycolipids presented by CD1 proteins (Figure 1.1).1 
 
Four categories of T cell have been referred to as natural killer T cells. Of these, 
the most abundant and well-studied are so-called type 1 iNKT cells, also referred 
to as invariant natural killer T cells (iNKT cells) because of their expression of an 
antigen-speciﬁc T-cell receptor (TCR). iNKT cells are unique lymphocytes that 
bridge the innate and adaptive immune system. The invariant α chain of the iNKT 
cell TCR consists of a canonical Vα14–Jα18 (V – variable, J – joining region) chain 
in mice, and a homologous Vα24–Jα18 chain in humans, which is paired with a 
more variable β chain (Vβ2, Vβ7, Vβ8 in mice, and Vβ11 in humans).4  
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Figure 1.1.   Schematic view of the ligand-specificity of iNKT cells compared 
with conventional T cells. Peptide antigens presented by MHC class I 
molecules are recognised by diverse T-cell receptors (TCRs) expressed 
by CD8+ T cells, while peptide antigens presented by MHC class II 
molecules are recognised by diverse TCRs expressed by CD4+ T cells. 
Semi-invariant Vα14i TCRs expressed by iNKT cells recognise 
glycolipids presented by CD1 proteins.  
  Figure adapted from ref. 5 Permission to reproduce figure was obtained 
from Elsevier through RightsLink® - licence number 2812640815855.  
 
iNKT cells are mainly found in the thymus, liver and bone marrow. They are also 
present in smaller amounts in the spleen and the peripheral blood, but are rare in 
the lymph nodes.6-8 The maturation of iNKT cells begins in the thymus, where an 
uncommitted precursor thymocyte rearranges and expresses a CD1d-specific 
Vα14i TCR at the double-positive (DP) stage, and is then positively selected by 
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CD1d-expressing DP thymocytes (Figure 1.2).6 Positively selected Vα14i T cells 
mature into double-negative (DN) and CD4+ T cells, whilst the expression of CD8 
cells induces negative selection by increasing the affinity of the TCR for CD1d. 
After selection, NK1.1-Vα14i T cells are exported to the periphery of the spleen or 
liver,7,8 where a hypothetical second signal is required for the acquisition of the 
mature NK1.1+ phenotype (Figure 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.   Schematic view of the development of Vα14i T cells in the thymus. 
T cell receptor (TCR) with random αβ rearrangement is first expressed 
by an uncommitted precursor thymocyte at the double-positive (DP) 
stage. DP cells with CD1d-specific Vα14i α-chain (Vα14–Jα18) are 
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positively selected by CD1d-expressing DP thymocytes. They mature 
into double-negative (DN) and CD4+ T cells and are exported to 
peripheral organs where a hypothetical second signal is required for the 
expression of mature iNKT cells. Positive selection of T cells with TCRs 
that are specific for MHC–peptide complexes leads to maturation of 
mainstream CD4+ and CD8+ T cells.  
  Figure adapted from ref 9. Permission to reproduce figure was obtained 
from Elsevier through RightsLink® - licence number 2812641351351.  
 
   
Mouse Vα14i and human Vα24i T cells have cytolytic activity,10,11 and they rapidly 
induce the expression of various cytokines      including IL-4 and interferon-γ 
(IFNγ)     after TCR stimulation. Vα14i T-cell-derived cytokines can, in turn, 
activate several other cell types, including NK cells,12,13 conventional T cells14, 
macrophages15 and B cells,16 and recruit myeloid dendritic cells (DCs).17 iNKT 
cells are able to require T helper 1 (Th1) or Th2 type of cytokine response. The 
Th1 pattern includes pro-inflammatory cytokines (typified by IFNγ), whereas the 
Th2 pattern includes regulatory cytokines such as IL-4, IL-5 and IL-13.9 
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1.3.   CD1: lipid antigen-presenting molecules 
CD1 molecules are a family of highly conserved antigen-presenting proteins that 
are similar in function to classic MHC molecules. However, whilst classic MHC 
molecules present peptide antigens to receptors located on T cells, CD1 
molecules are able to bind and display a variety of lipids and glycolipids, which 
they then present to receptors located on CD1-restricted T cells.18,19 Based on 
similarities between their nucleotide and amino acid sequences, the five known 
isoforms of the CD1 family have been divided into two groups, Group I (CD1a, 
CD1b, CD1c, and CD1e present in humans) and Group II (CD1d present in 
humans and mice).20 In humans, one copy of each of the five CD1 molecules is 
encoded on chromosome 121 in the order CD1d, CD1a, CD1c, CD1b, CD1e 
(Figure 1.3.A). Mice and rats appear to have duplicated CD1d (Figure 1.3.B) and it 
is postulated that the genes for CD1a, CD1b, CD1c and CD1e have been lost in a 
chromosomal translocation event.22 
A         
 
 
 
 
B 
 
 
 
Figure 1.3.  (A) The order of CD1 proteins encoded on human chromosome 1.  
  (B) Duplicated CD1d proteins located on mouse chromosome 3. 
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CD1 proteins are heterodimers and most closely resemble class I MHC molecules 
in their overall structure. A transmembrane heavy chain, comprising α1, α2 and α3 
domains, is non-covalently associated with β2-microglobulin (β2m). The antigen-
binding sites of CD1 molecules are deep hydrophobic pockets that accomodate 
the alkyl chains of lipid antigens, leaving the more polar parts of the antigen 
accessible at the molecular surface for recognition by T-cell receptors.  
Antigens presented by CD1 molecules range from endogenous cellular lipids and 
foreign lipids derived from intracellular parasites, to extracellular lipids of self or 
foreign origin.23,24 CD1a has been found to bind and present glycolipids and 
mycobacterial lipopeptides such as the sphingolipid sulfatide (1, a sulfate ester of 
β-galactosylceramide)25 and didehydroxymycobactin (2) (DDM).26 The CD1b 
isoform is able to bind lipids with very long alkyl chains (e.g. C80), such as the 
mycolic acids, which are important components of mycobacterial cell walls.26 CD1c 
has been shown to present mycobacterial isoprenoid lipids (3), which contain 
unusual alkyl chains consisting of repeating branched, saturated units.27,28 Some 
lipids, including phospholipids and sphingolipids, have been shown to bind multiple 
CD1 isoforms including CD1a, CD1b, CD1c and CD1d. The CD1e molecule differs 
significantly from other CD1 family members. It is the only protein to be converted 
into a soluble lysosomal form, and in contrast to other CD1 isoforms, is not 
expressed at the cell surface.29 However, CD1e remains immunologically relevant 
and is required for the presentation of the mycobacterial PIM6 antigen by CD1b to 
specific T cells and for the in vitro conversion of PIM6 to PIM2 by α-mannosidase.
30  
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Figure 1.4.  Examples of the ligands presented by CD1 molecules.  
 
iNKT cells characteristically express a semi-invariant TCR that specifically 
recognises the CD1 family member, CD1d. The finding that both mouse and 
human iNKT cells were autoreactive to cells expressing CD1d, resulted in 
considerable research in this CD1 subset.31  
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Intracellular trafficking of mouse and human CD1d is depicted in Figure 1.5. CD1d 
molecules are synthesised in the endoplasmatic reticulum (ER) and are 
transported through the Golgi and then directly to the plasma membrane via the 
secretory pathway. At the cell surface, nascent CD1d molecules are internalised 
via clathrin-cloated pits – and directed either through the recycling endosomal 
system or deeper in the endocytic system to lysosomal antigen loading 
compartments (MIIC), before being re-exported to the cell surface. The route of 
intracellular trafficking appears to depend largely on the nature of the cytoplasmic 
tails that bind the adaptor protein (AP)-3, directing their trafficking to sorting 
endosomes. Murine CD1d contains tyrosine-based motifs and is efficiently 
directed toward late endosomal MIIC compartments, whereas human CD1d, which 
cannot bind (AP)-3 is mainly distributed in the early endosomal system.32 
Additionally, a small fraction of human CD1d molecules physically associate with 
MHC class II molecules during trafficking33 and are transported through the 
endosomal system to MIICs prior to their expression on the cell surface (Figure 
1.5). 
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Figure 1.5.   Overview of CD1d intracellular trafficking. CD1d molecule is 
synthesised in the endoplasmic reticulum (ER). Both human and mouse 
CD1d are transported through the Golgi to the cell surface and 
internalised via clathrin-coated pits before being directed into early 
endosomes. Human CD1d is next re-exported directly to the cell surface, 
while mouse CD1d and rare human CD1d associated with MHC class II 
molecule are trafficked deeper into late endosomes  or lysosomes (MIIC) 
before reaching plasma membrain.32 
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1.4.  α-Galactosylceramide: the most potent activator of iNKT cells 
 
α-Galactosylceramide (α-GalCer) is one of the most potent agonists of CD1d and 
the strongest activator of human and mouse iNKT cells. α-GalCer was first 
discovered by the Kirin Pharmaceutical Research Corporation during a screen for 
agelasphins (AGLs) that could prevent metastasis of transplanted tumours to the 
livers of mice. A series of agelasphins was originally isolated from the marine 
sponge Agelas mauritianus, collected in the Okinawa Sea.34 Although a number of 
β-galactosylceramides were already known, the AGLs were the first cerebrosides 
with an α-galactosyl linkage (Figure 1.6). Very interestingly all AGLs showed 
antitumour activity. 
 
 
 
 
 
 
Figure 1.6.  Agelasphins isolated from the marine sponge Agelas mauritianus. 
 
α-GalCer 8 is a synthetic glycolipid (also referred to as KRN7000), and is a 
derivative of the isolated agelasphin AGL-9b 6, which was developed for 
 R = 
4, agelasphin-7a 
5, agelasphin-9a 
6, agelasphin-9b 
7, agelasphin-11 
-(CH2)11CH3 
-(CH2)12CH3 
-(CH2)11CH(CH3)2 
-(CH2)CH(CH)3C2H5 
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experimental studies and clinical trials (Figure 1.7). The α-GalCer structure 
consists of a galactopyranose combined with a ceramide through an α-glycosidic 
linkage. The ceramide part comprises a phytosphingosine base, which is N-
acylated with hexacosanoic acid (Figure 1.7). 
            
 
 
 
 
 
8, α-GalCer 
 
Figure 1.7.  Structure of α-galactosylceramide (α-GalCer) 8. 
 
The affinity of CD1d to α-GalCer was first measured by Naidenko et al. in SPR 
assay,35 in which biotinylated α-GalCer was immobilized on a BIAcore chip and 
CD1d was passed on the lipid, followed by affinity measurements. The 
dissociation data from this experiment were fitted onto a 2-component dissociation 
model with the following results (Table 1.2): 
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CD1 type Ligand Kon 
(M-1 s-1) 
Koff 
fast 
(s-1) 
Koff 
slow 
(s-1) 
Kd (nM) 
fast slow 
Mouse Bio-α-GalCer 6.3 x 104 0.1 4 x 10-3 1587.3 63.5 
Human Bio-α-GalCer 1.0 x 105 0.08 4 x 10-3 800.0 40 
 
Table 1.2.   Dissassociation data from SPR assay35 with human and mouse CD1d 
protein and biotinylated α-GalCer.  
 
McCarthy et al.36 reported half-life of α-GalCer in CD1d – 593 min measured in 
SPR half-life assay in which biotinylated human CD1d was refolded with α-GalCer 
and other antigens (shorter acyl and/or sphingosine chains) and loaded onto a 
BIAcore chip. The loading was monitored by 9B antibody that recognises the 
galactose headgroup and CD1d. 
 
Although the expression of α-GalCer in marine sponges could not be linked with 
any physiologically relevant function, the striking properties of this ligand have 
provided early support for the hypothesis that the conserved TCRs of NKT cells 
evolved to recognise conserved lipids. It is widely assumed that α-GalCer is only a 
mimic of the natural ligand that is recognised by Vα14i and Vα24i T cells, as this 
lipid is not present in mammals and nearly all natural glycolipids are β-linked 
glucosylceramides.37 Nevertheless, α-GalCer very effectively stimulates iNKT cells 
in a CD1d-dependent manner, resulting in the rapid production of large amounts of 
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Th1 (IFNγ) and Th2 (IL-4) types of cytokines (Figure 1.8), and the expansion of 
antigen-specific T- and B cell responses.12,16,38 
 
 
Figure 1.8.   Activation of iNKT cells results in the release of large amounts of 
different cytokines, strongly activating the immune system. 
 
 
Efficient stimulation of the immune system by α-GalCer made this antigen a 
promising adjuvant for the generation of optimal therapeutic and vaccination 
strategies against a range of infectious diseases and cancer. Clinical trials with 
soluble α-GalCer or α-GalCer-pulsed antigen-presenting cells (APCs) aimed at in 
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vivo reconstitution and activation of human NKT cells have been carried out39-41 
and provided both promising and challenging results. Recent phase I studies on 
patients with lung cancer,42 as well as those with recurrent head and neck 
cancer,43 demonstrated the safety and effectiveness of α-GalCer-pulsed APCs in 
anti-tumour therapy. 
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1.5.  Crystal structure of the α-GalCer-CD1d complex 
Crystal structures of mouse44 and human CD1d,45 with and without α-GalCer, have 
been determined and show how the glycolipids bind inside the protein (Figure 1.9). 
     
A                                                                   B 
    
 
 
 
 
 
     
 
                α-GalCer    
                hCD1d        
                β2m 
 
Figure 1.9.   Cartoon (A) and surface (B) representation of the crystal structure of the   
hCD1d-α-GalCer complex. The galactose head group is exposed for 
recognition by the iNKT T cell receptor. Figure generated from 1ZT445 
with Pymol.  
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The CD1d protein is formed of three domains, namely α1, α2 and α3, comprising 
the heavy chain, which is non-covalently associated with β2-microglobulin (β2m). 
Both murine and human CD1d molecules contain a large, hydrophobic pocket in 
the centre of the α1-α2 domain. This antigen-binding groove has two channels that 
meet at the surface of the protein. Lipid chains of a dialkyl glycolipid are then held 
inside the CD1d molecule by hydrophobic interactions. The acyl chain (26 carbon 
atoms) of α-GalCer occupies the longer pocket A‟, leaving the shorter C18 
sphingosine chain to occupy the F‟ channel. Both lipid tails in α-GalCer terminate 
at the end of the pockets A‟ and F‟ thereby determining the maximum number of 
atoms in each chain (Figure 1.10). This finding explains why α-GalCer is one of 
the most potent agonists of CD1d and binds with one of the highest affinities and 
also why other antigens with longer lipid tails are not suitable since the longer lipid 
chains cannot fit in the binding pockets. Dialkyl glycolipids with fewer atoms in 
either of the chains are unable to fully occupy the hydrophobic binding pockets, 
resulting in an increased rate of lipid dissociation from the CD1d molecule. 
The observed mode of glycolipid binding leaves the polar galactopyranose head 
group exposed over the lipid-binding groove for recognition by the iNKT TCR 
receptor. Analysis of the crystal structure of the α-GalCer-CD1d complex has 
identified key hydrogen bonds between the glycolipid and protein (Figure 1.11). 
The role of these hydrogen bonds is not only to stabilise the glycolipid, but also 
critically to orient the sugar moiety in such a fashion that it can be recognised by 
the TCR. 
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Figure 1.10.    The lipid tails of α-GalCer fit tightly in two hydrophobic pockets of CD1d 
A‟ and F‟. 
 
The oxygen atom 1‟-O of the α-GalCer glycosidic forms a hydrogen bond with the 
side-chain OH of Thr154 (Thr 156 in mouse CD1d), which is located on the α2 
helix of the protein. The 2‟-OH of the galactose forms a second hydrogen bond to 
the side-chain of Asp151 (Asp153 in mouse CD1d), which is also located on the 
α2 helix. The 3-OH hydroxyl group of the phytosphingosine chain is hydrogen-
bonded to the α1 helix Asp80 whereas Asp 80 of mouse CD1d binds the 3-OH and 
4-OH hydroxyl groups of the phytosphingosine.44 In combination, these hydrogen 
bonds anchor the exposed sugar polar head group in a position parallel to the 
plane of the α helices, which is crucial for the antigenicity of α-GalCer (Figure 
1.11). 
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Figure 1.11.   Hydrogen bond formation between the amino acid residues of hCD1d   
and α-GalCer found in the hCD1d-α-GalCer complex. Figure generated 
from 1ZT445 with Pymol. 
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1.6  Crystal structure of the α-GalCer  CD1d  TCR ternary complex 
 
A co-crystal structure of human CD1d  α-GalCer with the human iNKT T cell 
receptor (Figure 1.12) has also been described (3.2 Å resolution) and reveals 
valuable insight into how the TCR recognises the glycolipid-protein complex.46 The 
structure shows the T cell receptor locating almost  parallel  to  the  long axis of 
the CD1d  α-GalCer binding cleft and positioned over the extreme end of the CD1d 
molecule, directly above the F‟ pocket, which is occupied by the sphingosine 
chain. 
A semi-invariant human NKT cell TCR comprises an invariant α-chain and CDR3α 
loop (Vα24–Ja18, where V is „variable‟ and J is „joining‟) and a restricted Vβ11-
containing β-chain repertoire (Figure 1.13). The ternary structure shows that the α-
chain contributes more interactions with the CD1d-α-GalCer complex than does 
the β-chain (approximately 82 versus 32 contacts, respectively), and also provides 
more buried surface areas (BSA) (65.5% versus 34.5%, respectively).  
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                  iNKT TCR                     hCD1d 
                  α-GalCer                       β2m 
 
 
Figure 1.12.  Crystal structure of the iNKT TCR  α-GalCer  hCD1d ternary complex.   
Cartoon representation was obtained with PyMol from 2PO6.46 
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A                                                              B     
 
 
 
 
 
 
Figure 1.13.   (A) Parallel docking mode of iNKT TCR CDR loops on to human CD1d-
α-GalCer. (B) Footprint of the iNKT TCR on the surface of CD1d- α-
GalCer.  
 Figure adapted from ref 46. Permission to reproduce figure was obtained 
from Nature through RightsLink® - licence number 2822050758022.46 
 
 
 
Lipid recognition by the T cell receptor occurs through the exposed polar head 
group of α-GalCer. Contacts with the glycolipid are mediated by the CDR1α and 
CDR3α loops of the TCR. The invariant TCR α-chain forms three hydrogen bonds 
with the 2‟, 3‟ and 4‟ hydroxyl groups of the galactose ring: the 2‟ and 4‟ hydroxyl 
groups of the galactose are H-bonded to Gly96 and Phe29, respectively, whilst on 
the main chain, the 3‟ hydroxyl forms a hydrogen bond with the side-chain OH in 
Ser30 (Figure 1.14).  
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Figure 1.14.   α-GalCer-mediated interactions with iNKT T cell receptor.  
 Figure adapted from ref 46. Permission to reproduce figure was obtained 
from Nature through RightsLink® - licence number 2812180982041.46.  
 
 
The formation of these three hydrogen bonds appears to be important for the 
recognition of the glycolipid-antigen-presenting complex and activation of iNKT 
cells. Moreover these observations explain why α-mannosylceramide (α-ManCer) 
does not activate iNKT cells.47 The 2‟ and 4‟ hydroxyl groups in mannose have a 
different (2‟-axial and 4‟-equatorial) orientations when compared with galactose, 
which results in the loss of two key hydrogen bonds with the TCR. Thus whilst it is 
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likely that α-ManCer binds to CD1d, the resulting complex is not recognised by the 
TCR and so does not lead to iNKT cell activation. 
The α-glycosidic linkage is also important for TCR recognition. The corresponding 
β-anomer, β-galactosylceramide, was recently shown to activate iNKT cells in vivo 
and in a CD1d-dependent manner;48 however it is a siginificantly less potent 
agonist than α-GalCer. It has been postulated that the β-GalCer binds in a more 
perpendicular orientation, which disrupts contacts with the α-chain.  
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1.7  Other agonists of CD1d 
 
Since the discovery of α-GalCer and subsequent detailed evaluation of its 
biological activity, a large number of natural and other synthetic agonists of CD1d 
have been examined. It has become clear that the immune responses that these 
analogues can trigger differ from those elicited by α-GalCer, not only quantitatively 
but also qualitatively. These observations have had a profound impact on our 
understanding of the biology of iNKT cells, which is crucial for developing effective 
iNKT-cell-based therapies. 
 
 
1.7.1  Natural self-lipids presented by CD1d 
 
A number of CD1d antigens have been found among endogenous self 
phospholipids and self glycosphingolipids. These are able to activate both mouse 
and human iNKT cells. Their autoreactivity occurs through the recognition of 
cellular lipids associated with CD1d proteins within cells.  
 
A representative example of a natural agonist is the glycosphingolipid 
isoglobotrihexosylceramide 9 (iGb3) (Figure 1.15).49 iGb3, which is generated in 
lysosomal compartments, was found to activate human and murine iNKT cells in 
vitro; however when compared with the most potent synthetic CD1d agonist (α-
GalCer), it is at least 5 orders of magnitude less active.49 Recognition of the much 
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larger trisaccharide head group by the TCR is possible thanks to its peripherally 
located CDR3β loop, which provides plasticity to accommodate different 
antigens.46 Interestingly, it was shown that iNKT cells are not stimulated by Gb3 
(the iGb3 analogue with an α1-4-linked terminal galactose), which suggests that 
the specific orientation of the terminal sugar is crucial for the formation of the 
CD1d-glycolipid-TCR ternary complex.46 It remains unclear whether or not iGb3 
can serve as a physiologically relevant ligand in vivo. To be stimulated, human 
iNKT cells require lysosomal processing of self antigens.50,51 Moreover, in contrast 
to mouse, iGb3 is not found in humans, owing to the lack of functional genes for 
iGb3 synthase, which is required for its biosynthesis.52  
 
 
 
 
Figure 1.15.  Structure of the natural self-lipid, isoglobotrihexosylceramide (iGB3). 
 
Self phospholipid antigens form another group of natural lipid ligands for CD1d. 
Among these are phosphatidylinositol (PI), phosphatidylglycerol (PG), 
phosphatidylethanolamine (PE) and phosphatidylcholine (PC) (Figure 1.16). Whilst 
these polar lipids were also found to bind murine CD1d, they displayed limited 
capability to activate murine iNKT hybridoma cells.53-57 In another study58 of the 
cellular ligands of hCD1d such as PE 10, PC 11 also showed little or no 
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antigenicity, although it was suggested that lipids found in cell membranes may 
play an important role in the folding and stabilisation of CD1 molecules and hence 
modulate the ability of other more antigenic lipids to load on to CD1d molecules.58  
 
 
 
 
 
 
 
 
 
 
Figure 1.16.  Structure of natural phospholipids, phosphatidylethanolamine (PE) and 
phosphatidylcholine (PC). 
 
A recent study of lysophosphatidylcholine (LPC) shows that this monoacyl form of 
PC also serves as a natural phospholipid ligand for NKT cells. LPC was found 
among lipids extracted from the plasma of multiple myeloma patients and proved 
to bind CD1d dimers and activate type II NKT cells (Vα24-Vβ11-) present in human 
blood. 
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Figure 1.17.  Structure of monoacyl self-phospholipid, lysophsphatidylcholine (LPC). 
 
This self phospholipid is postulated to be an endogenous signal for cellular stress 
or damage, as higher levels of LPC are detected in asthma, allergic and 
autoimmune inflammation and human cancers such as multiple myeloma.59 LPC 
has consequently gained an increased interest and a recent study of Fox et al.58  
also suggests that NKT cells might be stimulated by physiological lipid signalling 
pathways to carry out their homeostatic immunoregulatory functions. 
 
 
1.7.2  Synthetic analogues of α-galactosylceramide 
 
Even though α-GalCer is the most potent agonist of iNKT cells, it may not be an 
optimal ligand for generating an antitumour or immunomodulatory effect. The iNKT 
cell activation by α-GalCer leads to the release of both Th1- and Th2-type 
cytokines. A number of different modifications have been applied to the KRN7000 
structure resulting in significant changes in the profiles of cytokine production 
following iNKT cell activation. Finding the right balance in the Th1 versus Th2 
cytokine profile is very important as these two types of cytokine result in two 
different immune responses. 
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1.7.2.1 Sphingosine base derivatives 
Analogues of α-GalCer with modifications in the phytosphingosine base have been 
extensively studied and provided researchers with a set of useful SAR (structure-
activity relationship) information long before the crystal structure of CD1d with 
bound α-GalCer was disclosed.  
 
Phytosphingosine is structurally similar to naturally occurring sphingosine: both 
molecules have C18 hydrocarbon chains; however sphingosine lacks the hydroxyl 
group at C4 and bears a trans double bond between C4 and C5 instead of the fully 
saturated backbone found in phytosphingosine. The importance of the two 
hydroxyl groups, at C3 and C4 in the phytosphingosine base in α-GalCer structure 
has been confirmed.60 Kronenberg and co-workers reported that 4-deoxy α-GalCer 
binds to murine CD1d but is not recognised by human CD1d.61 3,4-Dideoxy-α-
GalCer was not antigenic in both mouse and human models.61 These findings 
were later rationalised, when it was shown that the 3-OH group forms a hydrogen 
bond to Asp80 in both mouse and human CD1d, whilst the OH group at the 4 
position participates in hydrogen bond formation only in mCD1d.45   
 
OCH 13 is an analogue of α-GalCer, which induces a Th2 bias of NKT cells 
through the predominant production of IL-4 cytokines. In this CD1d agonist, the 
sphingosine base is truncated from 18 to 9 carbons and the acyl chain is reduced 
to 24 instead of 26 carbons (Figure 1.18).62 OCH is five- to tenfold less active in 
inducing cell proliferation and produces less IFNγ but more IL-4 in vitro, when 
compared with α-GalCer. These observations have been confirmed in experiments 
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in vivo where IL-4 levels in serum remained unaffected for both agonists, but the 
amount of IFNγ detected for the OCH analogue was much lower. Even when 
much lower doses of α-GalCer are administered, the ratios of IL-4 / IFNγ remains 
almost unchanged, proving that the distinct cytokine polarising effect of OCH 
cannot be obtained by simply lowering the amount of α-GalCer. Despite being a 
less active agonist in inducing NKT cell proliferation, OCH displays a different type 
of activity to α-GalCer. OCH is now commonly used as a control in biological 
assays for IL-4 production, when compared with new agonists. Other analogues 
with a truncated phytosphingosine chain ranging from 9 to 15 carbons have been 
reported and were also found to increase the release of IL-4 in both murine and 
human iNKT cells.63 These Th2-biasing analogues may find a future application in 
the treatment of different autoimmune diseases.  
 
The origin of the Th2 bias for OCH and related analogues remains unclear. 
However, it has been postulated that the shorter sphingosine length destabilises 
the CD1d-glycolipid complex. As the release of IFNγ by iNKT cells needs a longer 
exposure to the CD1d-glycolipid complex (usually measured after 18 hours), lower 
levels of IFNγ are observed when compared with α-GalCer.  
 
Attaching an aromatic ring to the end of a truncated sphingosine chain has been 
shown to result in a potent iNKT cell activator that induces a more Th1-biased 
cytokine response (Figure 1.18).64 It is suggested that C13 14 binds to CD1d with 
higher affinity thanks to the added aromatic substituent in the phytosphingosine 
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chain, which increases the time that C13 is in contact with CD1d resulting in higher 
levels of IFNγ upon iNKT cell activation. 
 
 
 
 
 
 
 
 
 
 
Figure 1.18.  Structure of OCH 13 and C13, 14 analogues of α-GalCer. 
 
 
  
1.7.2.2 N-acyl chain derivatives 
 
 
The length and degree of unsaturation in the N-acyl chain of α-GalCer was 
another point of focus in the search of new agonists of CD1d protein. C10:0 15 
(Figure 1.19) is an analogue with significantly shorter N-acyl chain, bearing 10 
instead of 26 carbons in the chain. This modification in the agonist‟s structure was 
found to bias Th2 type response and weaken the activation of iNKT cells.65  
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α-GalCer-C20:2 19 has two double bonds in the acyl chain at carbon 11 and 14 
(Figure 1.19) and like compound 15 preferentially induces IL-4 production being 
another example of Th2 type agonist of CD1d.66 However, in contrary to α-GalCer, 
it does not require endosomal localisation of CD1d for efficient loading and 
presentation.67  
 
Other modifications in the N-acyl chain involved incorporation of the C20 
prostaglandin B1 chain (α-GalCer-PGB1 16), aromatic rings (α-GalCer-C11Ph 17), 
4-fluorophenylacetate group (α-GalCer-4FPA 18) or arachidonic acid (α-GalCer-
C20:4 20) (Figure 1.19). These analogues also showed Th2-skewing of the 
cytokine profile generated by iNKT cell activation and are less dependent on 
endosomal loading for presentation by CD1d when compared with α-GalCer which 
produces mixed Th1 and Th2 cytokine profile. 
 
It is suggested that the polarised iNKT cell cytokine production biased towards 
Th2-type response is an effect of direct loading of these agoniststs into CD1d 
molecules at the cell surface of APC.  
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Figure 1.19.  Structures of representative N-acyl chain analogues of α-GalCer. 
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1.7.2.3  Carbohydrate modifications 
 
 
α-GalCer analogues with modified sugar unit are an important group of new 
agonists of CD1d. The activity of α-glucosylceramide (α-GlcCer) 21 in mouse 
spleen iNKT cell activation assay was found to be similar to that of α-GalCer 8 
(Figure 1.20). Only configuration of 4-hydroxyl group (equatorial) in α-GlcCer 21 
varies from structure of α-GalCer 8 (axial), this indicated that the 4-hydroxyl 
configuration of the sugar was not essential for bioactivity. However, α-
mannosylceramide (α-ManCer) 22 (Figure 1.20) with the 2-hydroxyl group in an 
axial configuration as compared to an equatorial orientation in α-GalCer 8 or α-
GlcCer 21, was found to be inactive. The configuration of the 2-hydroxyl group on 
the sugar moiety proved to be crucial to activate iNKT cells.68 These observations 
were later explained by determining the crystal structures of mouse and human 
CD1d-α-GalCer-TCR ternary complexes, which revealed that the equatorial 
position of the galactose 2‟-OH in α-GalCer forms a hydrogen bond with the side-
chain of Asp151 in hCD1d (Asp153 in mCD1d) and the resulting adopted 
orientation of the sugar is crucial for the recognition by the iNKT TCR.  
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Trappeniers et al. reported few analogues of α-GalCer with modifications at the 
galactose 6‟-position.69 The crystal structure analysis of human and mouse CD1d-
α-GalCer complexes showed that the 6‟-hydroxyl group of the galactose in α-
GalCer does not take part in a hydrogen bond formation between α-GalCer and 
CD1d. Analogue 23 (Figure 1.20) in which 1-naphtyl group attached to 6‟ureido-
6‟deoxy-α-GalCer, was found to stimulate a Th1-cytokine biased response with 
production of IFNγ cytokine similar to α-GalCer. 
 
 
The threitolceramide ThrCer 24 (Figure 1.20) is a truncated non-glycosidic 
analogue of α-GalCer. In this compound the labile α-glycosidic linkage is replaced 
with an ether bond to gain metabolic stability in vivo. A galactose ring has been 
replaced with an acyclic sugar but with retained relative and absolute 
stereochemistry. ThrCer 24 proved to be a less potent agonist of CD1d when 
compared with α-GalCer, however it does not cause the lysis of dendritic cells.70 
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Figure 1.20.  Representative carbohydrate derivatives of α-GalCer. 
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1.7.2.4  Glycosidic bond derivatives 
 
The C-glycosyl derivative, α-C-GalCer 25 (Figure 1.21), was found to be a more 
potent agonist than α-GalCer in mouse model of malaria and melastatic 
melanoma, but also showed induced Th1-biased cytokine production.71 In this 
analogue the oxygen atom of the α-GalCer glycosidic bond (a polar hydrogen 
acceptor) has been replaced with a non-polar CH2, which cannot participate in 
hydrogen bonding. This modification has been proposed to cause the glycolipid to 
sit differently in the CD1d groove thereby changing the structure of the complex 
and its affinity for the iNKT TCR, and may also allow for free rotation of the 
“glycoside” bond connecting the galactose and ceramide portions of the 
molecule.71,72 Greater levels of IFN-γ production might be also a result of higher 
stability of this analogue in vivo, as C-glycosidic linkage has increased resistance 
to enzymatic degradation. 
 
Recently, the same research group (R. W. Franck and co-workers) reported a 
series of α-C-GalCer analogues and found E-alkene-linked C-glycoside analogues 
e.g. GK 109 26 (Figure 1.21) were potent human iNKT-cell stimulants that also 
induce Th1-biased cytokine production relative to α-GalCer.73 It was proposed that 
replacement of the CH2 glycosidic linkage with the E-alkene linker may result in 
fixed orientation of the polar head group that is beneficial for iNKT cell TCR 
recognition.73  
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These findings highlight the flexibility of the iNKT cell TCR, which in spite of its 
relatively limited diversity appears to be capable of different modes of recognition 
that enable responses to a wide range of CD1d-presented ligands. 
 
 
 
 
 
 
Figure 1.21.  Representative glycosidic bond derivatives of α-GalCer. 
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1.8  Aims and objectives 
 
Recent years have shown a growing interest in understanding the biology of iNKT 
cells that in turn could translate into successful immune therapies. Numerous α-
GalCer analogues have been synthesised and tested in order to find a potent iNKT 
cell agonist that could selectively induce beneficial cytokine profile. 
 
To date, very few alterations around the amide bond of α-GalCer have been 
explored. To investigate its importance in iNKT cell stimulation, we decided to 
synthesise a range of α-GalCer and ThrCer analogues, in which the amide group 
in our lead has been replaced with different carbonyl functional groups. These 
compounds would then be tested for iNKT cell induction and in particular their 
Th1/Th2 response, which in turn would determine their therapeutic potential.  
 
The second part of the project will focus on additional modifications and the 
synthesis of labelled derivatives, which will find application in intracellular 
trafficking studies. 
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2. Amide Analogues of α-Galactosylceramide and Threitol Ceramide 
 
2.1.  Interactions between the amide moiety of α-GalCer and amino acid 
residues of the iNKT TCR and CD1d protein in the human      h  1d  α-
GalCer ternary complex 
 
The first crystal structures of the hCD1d–α-GalCer complex,45 and the TCR–
hCD1d–α-GalCer ternary complex,46 discussed in the Introduction (Sections 1.5 
and 1.6), did not reveal any direct hydrogen bonds between the amide group of α-
GalCer and amino acid residues of CD1d or the iNKT cell TCR. Recently however, 
Pellici et al.74 reported a crystal structure of the human NKT cell TCR–hCD1d–α-
GalCer complex at improved (2.5 Å) resolution (Borg et al. reported the crystal 
structure of the NKT cell TCR–hCD1d–α-GalCer complex at 3.2 Å resolution). 
From this better-resolved structure, the carbonyl group of the amide functionality in 
α-GalCer was found to form a hydrogen bond with a water molecule, which in turn, 
formed a hydrogen bond with the backbone carbonyl of isoleucine-69 (Ile69) in the 
CD1d molecule. 
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Figure 2.1.   Cartoon representation of polar contacts in the iNKT cell TCR–hCD1d–
α-GalCer complex (α-GalCer – green sticks, CD1d – blue cartoon). 
Figure generated from 3HUJ.74 
 
 
The structural analyses made by Pellici et al. also identified a direct hydrogen 
bond between the N-H of the amide group of α-GalCer and the hydroxyl group in 
the side-chain of the threonine-154 (Thr154) residue located on the α-2 helix of the 
human CD1d molecule (Thr156 in mouse CD1d). We postulated that this 
interaction might play an important role in positioning α-GalCer in the right 
conformation for subsequent recognition by the iNKT cell TCR receptor. 
 
 
 
2.5 Å 3.1 Å 
2.9 Å 
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Figure 2.2.   Cartoon representation of the hydrogen bond interaction between the –
NH of α-GalCer (pink sticks), and the Thr154 residue of hCD1d (green 
cartoon). Figure generated from 3HUJ.74 
 
 
 
 
 
 
 
Figure 2.3.  Interactions between the amide moiety of α-GalCer and amino acid 
residues of hCD1d in the iNKT cell TCR–hCD1d–α-GalCer ternary 
complex revealed by the crystal structure determined at 2.5 Å 
resolution.74 
2.9 Å 
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2.2.   eported analogues of α-GalCer with variations around the amide 
group 
To date, only a few analogues of α-GalCer have been synthesised, in which the 
amide group has been replaced by other functional groups. Lee et al.75 replaced 
the amide moiety in α-GalCer with a 1,2,3-triazole. They reported a series of 
analogues containing this heteroaromatic unit and possessing different lengths of 
the lipid chain ranging from 6 to 26 carbon atoms 27-32 (Figure 2.4).  
 
 
Figure 2.4.  A series of 1,2,3-triazole-containing analogues of α-GalCer 27-32. 
 
The 1,2,3-triazole functionality exhibits structural similarities to the ubiquitous 
amide moiety found in natural systems;76 however in contrast to amides, triazoles 
are much more stable to hydrolysis, as well as to oxidising and reducing conditions 
in vivo.77 In a similar fashion to the amide group, a 1,4-disubstituted 1,2,3-triazole 
can also participate in hydrogen bond formation (Figure 2.5). However, whilst 
primary and secondary amides can function as hydrogen bond donors and 
acceptors, two of three nitrogen atoms of 1,2,3-triazoles can only ever serve as 
hydrogen bond acceptors.   
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A                                                    B 
 
 
Figure 2.5.   Hydrogen bond formation and dipole-dipole interactions between amides 
(A) and 1,2,3-triazoles (B) and a hydroxyl group. 
 
The bioisosteric replacement of the amide moiety of α-GalCer with a 1,2,3-triazole 
unit is potentially interesting as the resulting modified glycolipids should survive a 
wider range of conditions in vivo and therefore last longer. Activation of iNKT cells 
with the C-glycosyl analogue of α-GalCer (discussed in the Introduction in Chapter 
1.7.2.4), results in greater production of IFNγ (Th1 - type) and lower amounts of IL-
4 (Th2 - type). Since IFNγ requires a longer release time than IL-4, it has been 
postulated that the longer exposure time of the CD1d-glycolipid complex to iNKT 
cell TCR might account for this Th1-biased cytokine response.  
 
Biological evaluation of glycolipids 27-32 in vitro (with the use of mouse 
splenocytes), however, showed a Th2 bias for all analogues. Analogue 31 in 
particular, which bears a saturated 24-carbon alkyl chain, produced higher levels 
of IL-4 and less IFNγ when compared with α-GalCer. Subsequent in vivo studies 
confirmed the in vitro observations for triazoles 30-32, which all possess longer 
alkyl chains (n = 21, 22, 23); however those analogues with short- and medium-
chain lengths were unable to stimulate iNKT cells in vivo. 
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Recently, Mori and co-workers investigated the replacement of the amide bond in 
α-GalCer with ether 33 and ester groups 34.78 In both cases, the formation of the 
hydrogen bond with the Thr154 residue of human CD1d (and Thr156 for mouse 
CD1d) may still be possible in these analogues with relatively little structural 
reorganisation; the oxygen atom of the ether or ester group, which replaced the N-
H of the amide group of α-GalCer, might now act as a hydrogen bond acceptor to 
the hydrogen of the hydroxyl group in the side-chain of Thr154. 
 
 
Figure 2.6.   α-GalCer analogues where ether and ester groups have been 
introduced in place of the amide linkage found in α-GalCer. 
 
The ether analogues, which lacked both the N-H and the carbonyl oxygen of the 
amide in α-GalCer were unable to activate iNKT cells. Glycolipids with an ester 
group, however, were able to activate iNKT cells although with significantly 
reduced activity compared to α-GalCer: IFNγ production was 10% of that shown 
by α-GalCer; IL-4 production was one-third to two-thirds of that shown by α-
GalCer. These results further support the importance of the amide N-H in α-
GalCer, and its ability to act as a hydrogen bond donor to the Thr154 residue of 
hCD1d, for iNKT cell activation. 
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2.3. Target compounds and the rationale for replacing the amide bond 
We were also interested in investigating further modifications around the amide 
bond. In light of the apparent importance of the amide N-H in CD1d binding, and in 
contrast to other studies, we decided to retain the NH in the structure, and replace 
the amide moiety with related functional groups, namely a thioamide, urea and 
carbamate. Our target molecules are shown below in Figure 2.7. 
 
  
 
 
 
 
 
Figure 2.7.   Target molecules, α-GalCer and three analogues in which the amide has 
been replaced with other functional groups. 
 
We also decided to make similar changes to ThrCer, the non-glycosidic analogue 
of α-GalCer (see Introduction Chapter 1.7.2.3) and the four target molecules 
based on this scaffold are presented in Figure 2.8. 
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Figure 2.8.   Non-glycosidic glycolipid, ThrCer and thioamide, urea and carbamate  
analogues. 
 
We postulated that these changes would be interesting for a number of reasons. 
First, the applied modifications could result in increased metabolic stability, as 
these functional groups should survive a wider range of conditions in vivo, being 
less prone to enzyme-mediated hydrolysis.79-81 Second, the introduction of 
different heteroatoms could alter the hydrogen bonding network. The pKa values of 
the N-H in a urea, amide, carbamate and thioamide are summarised in Figure 2.9. 
The urea has the highest pKa value and is less acidic than an amide, whereas the 
N-H in a carbamate and thioamide is more acidic and should be a better hydrogen 
donor.82,83 
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Figure 2.9.   Comparison of pKa values (in DMSO) for amide, carbamate, urea and 
thioamide.82,83  
 
The formation of additional hydrogen bonds is possible for the carbamate 
analogue, where the additional oxygen atom is a potential hydrogen bond 
acceptor. Likewise, the urea analogue possesses an additional N-H which could 
serve as another hydrogen bond donor. In the case of the thioamide analogue, we 
postulated that the larger*, lipophilic sulfur atom might also change the rate of 
glycolipid loading / deloading from CD1d and increase the stability of the CD1d-
glycolipid-TCR complex, since  this more hydrophobic analogue of α-GalCer, 
might be buried “deeper” in the hydrophobic binding groove of CD1d, leading to a 
more stable CD1d-glycolipid-TCR complex. 
 
 
 
                                               
* The atomic volume of a sulfur atom is 1.66 times larger (24.4/14.7=1.66) than oxygen (van der 
Waals radius of a sulfur atom rW = 1.80 Ǻ, for oxygen rW = 1.52 Ǻ, hydrogen rW = 1.20 Ǻ) 
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A                                                                     B            
        
 
                    
                      rW = 1.52 Ǻ                                                rW = 1.80 Ǻ 
          
 
  
 
rW - van der Waals radius 
 
Figure 2.10.   Sphere representation of the primary amide N-methyl-acetamide (A) and 
N-methyl-thioacetamide (B), indicating a difference in atomic volume 
between the carbonyl oxygen and sulfur atoms. (oxygen – red, sulfur – 
yellow, nitrogen – blue, carbon – grey, hydrogen – white). 
 
These modifications have not been applied to glycosyl ceramide structures, 
although similar modifications to the amide bond in a ceramide lipid were recently 
reported84-87 after this synthetic work had been completed. In this study, De Libero 
and co-workers prepared a range of sphingolipids and ceramides with different 
carbonyl functions (Figure 2.11). Compounds 41-45 were tested for iNKT cell 
activation, but none showed significant activity. A competition assay was designed 
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to test the ability of these ceramides to compete with α-GalCer for binding to CD1d 
and prevent T cell activation. Only compound 43 bearing a 1,2,3-triazole and 
thioamide function was found to compete with α-GalCer in in vitro studies, albeit 
only at 15-fold molar excess over α-GalCer; the same result was not replicated in 
in vivo assays, even when a large excess of this ceramide was used. In light of the 
structural differences, principally the absence of a sugar residue, further 
comparisons of these ceramide analogues with our α-GalCer and ThrCer 
derivatives are difficult. 
 
 
 
Figure 2.11.  Modification of the amide group of 7-oxaceramides.81 
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2.4.  Retrosynthetic analysis 
The retrosynthesis of α-GalCer 8 and its three analogues 35, 36 and 37 is outlined 
in Scheme 2.1. In our approach we wanted to prepare a common precursor, 
namely amine 46, which could be functionalised at a late stage of the synthesis 
with acyl chloride 47, isocyanate 48 and mixed carbonate 49, to provide three of 
our target molecules after deprotection. We identified β-galactose pentaacetate 53 
and phytosphingosine 54 as the starting materials for our synthesis; these could 
be readily converted into the two reacting partners required for the glycosylation 
reaction, which would unite the two fragments. Galactose 51 would then serve as 
the glycosyl donor and phytosphingosine 52 as the acceptor. Reduction of the 
azide in the resulting glycoside product 50 would afford our common precursor, 
amine 46.   
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Scheme 2.1.   Retrosynthetic analysis of α-GalCer 8 and thioamide 35, urea 36 and 
carbamate 37.  
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2.5.  First-Generation Synthesis of α-GalCer 
 
We first decided to prepare α-GalCer, as this compound would be needed as the 
control against which our new analogues 35, 36 and 37 would be compared in the 
biological assays. Moreover, this first synthesis would help us to identify any 
limitations (low-yielding reactions, poor choice of reagents and protecting groups) 
in our planned approach towards advanced intermediate amine 46, as well as the 
final deprotection step, before embarking on the synthesis of the new analogues. 
 
The synthesis of 2,3,4,6-tetra-O-benzyl-D-galactose 51 began with commercially 
available β-galactose pentaacetate, which, on activation with BF3·OEt2 at 0 °C in 
the presence of PhSH, afforded thioglycoside 55 in excellent yield as an 
inconsequential 1:1 mixture of anomers (Scheme 2.2).88 The acetate groups in 55 
were then removed under Zemplén conditions to afford the fully deprotected 
thioglycoside 56. This deprotection method allowed a simple work-up, which 
consisted of neutralising the reaction mixture with an acidic Dowex ion exchange 
resin followed by filtration of the resin and removal of the solvent under reduced 
pressure. The very polar tetraol 56 was collected as a white foam without any 
need for further purification.89 Subsequent re-protection of the alcohols in 56 as 
benzyl ethers provided thioglycoside 57, which was then hydrolysed with N-
iodosuccinimide in an acetone/water mixture (10:1) to yield the hemiacetal 51 as 
our sugar donor precursor as a 1:1 mixture of diastereoisomers.89 The product 
was characterised by HRMS, and the 1:1 ratio of diastereoisomers was evidenced 
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in the 1H NMR spectrum by integrating the OH proton resonances for the two 
anomers, which appeared at 2.93 ppm and 3.15 ppm. The IR spectrum also 
showed an OH stretch as further evidence for the thioglycoside hydrolysis. 
 
 
Scheme 2.2.  Synthesis of 2,3,4,6-tetra-O-benzyl-D-galactose 51. 
 
Phytosphingosine 54 served as the starting material for the glycosyl acceptor 52 
whose synthesis is summarised in Scheme 2.3. This commercially available amine 
54 was first converted into the corresponding azide 58 in a diazo transfer 
reaction.90 Imidazole-1-sulfonyl azide hydrochloride90 was used as the “diazo 
donor” in this copper(II)-catalysed reaction, which proceeded in excellent yield. 
This reaction had been carried out previously in our group using 
trifluoromethanesulfonyl azide (TfN3)
91-93 as the “diazo donor”. However, 
disadvantages of using TfN3 as a reagent include the explosive nature of neat 
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TfN3, and its poor shelf-life, which necessitates its preparation immediately prior to 
use.94 Moreover, the preparation of TfN3 involves the use of expensive 
trifluoromethanesulfonic anhydride and the removal of 
trifluoromethanesulfonamide from the reaction mixture, which complicates the 
work-up procedure.95 In contrast, imidazole-1-sulfonyl azide hydrochloride is 
cheap to prepare, more robust, easy to store (in its crystalline form) and provides a 
much safer alternative to TfN3.  
 
 
 
 
 
 
 
 
Scheme 2.3.  Synthesis of azido alcohol 52. 
 
Selective tritylation of the less hindered primary alcohol in 58 afforded trityl ether 
59 in 60% yield. The low yield of this reaction was a result of by-product formation. 
MS and NMR spectroscopic analysis of the side-products, isolated from the crude 
reaction mixture by flash column chromatography, showed that a major side-
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product was a di-trityl ether, in which the primary and one of the secondary 
alcohols had reacted with the trityl chloride. Diol 59 was then treated with sodium 
hydride to provide the corresponding di-alkoxide, which was reacted with 2.2 equiv 
of benzyl bromide to give the dibenzylated derivative 60 in 80% yield. The desired 
glycosyl acceptor 5296-98 was finally obtained after selective deprotection of the 
trityl ether with p-TsOH. 
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A key challenge in our synthesis was the selective formation of the α-glycosidic 
bond in our target galactosides. To this end, we chose to employ the halide ion-
catalysed α-glycosylation methodology developed originally by Lemieux and co-
workers,97-99  and shown to be a useful entry into -galactosides by Kobayashi and 
co-workers.100,101 Scheme 2.4 illustrates the mechanism of this interesting α-
glycosylation reaction.  
In the first step, a 2-O-benzyl-1-hydroxy sugar† reacts with CBr4 and Ph3P, the so-
called Appel reagents,102,103 to generate a glycosyl bromide. Under the reaction 
conditions, and in the presence of an excess of nucleophilic bromide anions 
(Bu4NBr) and N,N-tetramethyl urea (TMU), the more stable α-glycosyl bromide 
equilibrates with the highly reactive β-anomer. The acceptor alcohol (R-OH) then 
reacts preferentially with the more reactive β-glycosyl bromide in an SN2 fashion to 
provide the α-glycoside product. TMU and bromide anions play a critical role in the 
glycosylation, in ensuring the isomerisation of the α- and β-glycosyl bromides is 
much faster than their reaction with the glycosyl acceptor.  
The labile β-glycosyl bromide will also react with adventitious water to generate 
the starting 2-O-benzyl-1-hydroxy sugar. However, CBr4 and Ph3P are employed 
in excess to ensure any hydrolysed donor is recycled. The Appel reagents also 
capture any adventitious water. Kobayashi and co-workers100 found that 3 molar 
equivalents of CBr4 and Ph3P were optimal. Under these conditions, in situ 
formation of the glycosyl bromide and glycosylation proceeded without having to 
                                               
†
 The key requirement for the glycosyl donor in this α-selective glycosylation is a non-participating 
protecting group on the C-2 position.  
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pay special attention to carrying out the reaction under strictly anhydrous 
conditions. 
 
 
Scheme 2.4.  Overview of one-pot dehydrative α-glycosylation with Appel agents. 
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In our hands, when glycosyl donor 51 (2,3,4,6-tetra-O-benzyl-D-galactose) was 
treated with CBr4 and PPh3 at r.t., the formation of the glycosyl bromide, as 
monitored by TLC analysis, was complete within three hours. In the next step, the 
acceptor 52, TMU and Bu4NBr were added to the reaction mixture. Work-up after 
72 hours provided the desired α-galactoside 50 as a single anomer. 
 
 
Scheme 2.5.  Synthesis of α-galactoside 50. 
 
In our first attempt at glycosylation, the reported procedure was followed 
closely,104 with three equivalents of acceptor 52 being employed as directed. 
However, instead of leaving the reaction for 8 days, the reaction mixture was 
worked-up after only 3 days, as TLC analysis showed no further consumption of 
the starting materials after that time. Unfortunately, it proved difficult to separate 
the α-glycosyl product from the starting materials (bromide of the donor 51 and the 
acceptor 52), which compromised the isolated yield (42%) of -galactoside 50. 
Table 2.1 summarises the modifications we applied in order to improve matters. 
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entry acceptor 52 
[equiv] 
scale     
[mmol of 51] 
3 Å 
MS 
used 
recovery 
of                          
52        
[%] 
isolated 
yield of 50    
α-glycoside 
[%] 
1 3.0 0.37 no 43 42 
2 1.5 0.37 yes 44 64 
3 1.5 1.85 yes 45 62 
4 1.5 3.50 yes 41 64 
 
Table 2.1.   Summary of modifications applied to the literature Kobayashi α-
glycosylation. 
 
First, to facilitate the chromatographic separation of the α-glycosyl product 50 from 
the starting acceptor, we decreased the amount of alcohol 52 from 3.0 to 1.5 
equivalents and were pleased to observe that this modification did not result in a 
lower isolated yield, nor in a longer reaction time. Under these conditions, 
chromatographic purification of 50 was now possible.‡ The inclusion of molecular 
sieves also helped matters. In combination, these changes led to a significantly 
improved isolated yield (64%) without affecting the reaction time (72 h). Moreover, 
it was now possible to perform the reaction on larger scale (3.50 mmol) without 
observing any deleterious effect on either the isolated yield or the stereoselectivity. 
With these modifications, we were able to access significant quantities of 
glycoside 50 for further study. 
                                               
‡
 45% of the unreacted acceptor 52 was also recovered. 
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The stereochemistry of the glycosidic linkage was unambiguously assigned by 
NMR spectroscopic analysis. The easiest signal to find in the 13C NMR spectrum 
of 50 is the anomeric carbon, which appears at δ 98.6 ppm. From this, the 
attached H-1‟ proton was then identified by 2-D chemical shift-correlated 
spectroscopy (HSQC). Measuring the coupling constant of this anomeric proton 
from the 1H NMR spectrum [δ 4.91 ppm (1H, d, J1,2  3.5 Hz, H-1‟)], confirmed the 
assignment as the α-glycoside. The β-anomer would be expected to show a larger 
coupling constant in the range 8-12 Hz, associated with trans diaxial axial-axial 
coupling (Figure 2.12). An axial-equatorial coupling constant is much smaller, 
usually in the range 2-5 Hz. 
 
 
 
Figure 2.12.   J1,2 coupling constants for α- and β-glycosyl products. 
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The azido group in glycoside 50 was next reduced with trimethylphosphine in a 
Staudinger reaction105,106 to give amine 46 in 72% yield (Scheme 2.6). In the first 
step of the proposed mechanism of this Staudinger reaction (Scheme 2.7),107 a 
phosphine, usually Ph3P, reacts with the azide function to form a phosphazide 
intermediate, which then liberates nitrogen gas in the formation of an 
iminophosphorane. 
 
 
 
 
Scheme 2.6.  Synthesis of common precursor amine 46. 
 
In the presence of water (wet solvent or aqueous work-up) the iminophosphorane 
is hydrolysed to give the desired amine and a phosphine oxide by-product. 
Although triphenylphosphine is a stable and easy-to-handle reagent, the resulting 
by-product, triphenylphosphine oxide, can be difficult to remove in the work-up. 
We therefore chose to use trimethylphosphine instead as this reacts with azides in 
the same fashion;94 however, the trimethylphosphine oxide by-product is a volatile 
solid, which can be removed from the crude product under reduced pressure.108 
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Scheme 2.7.  The general mechanism of the Staudinger reaction. 
 
Amine 46 was next reacted with hexacosanoyl chloride 47 in the presence of NEt3 
to give protected α-GalCer 62 in 85% yield (Scheme 2.8). The acid chloride was 
freshly prepared from hexacosanoic acid with oxalyl chloride in the absence of 
solvent, and could be used without purification.  
 
Scheme 2.8.  Synthesis of amide 62. 
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Finally, hydrogenolysis of the benzyl groups in the presence of palladium over 
charcoal afforded the desired product 8 in 68% yield (Scheme 2.9). We modified 
the literature conditions of this debenzylation reaction,104 with THF being used as 
the solvent instead of the reported CH2Cl2/EtOH. Reaction in THF led to a much 
faster reaction, which was usually complete within 24 hours. In contrast, reaction 
in CH2Cl2/EtOH was very slow, with benzylated material still present even after 72 
hours. Moreover, with this solvent system, the reaction mixture required repeated 
filtration followed by addition of “fresh” catalyst to achieve complete removal of the 
benzyl protecting groups. 
 
 
Scheme 2.9.  Hydrogenolysis of 62 led to target compound 8. 
 
Having prepared the advanced intermediate, amine 46, and successfully used it to 
synthesise our first target compound – α-GalCer 8, we were ready to move on to 
our target α-GalCer analogues. Although we had not encountered any major 
problems in the synthesis of α-GalCer, we felt further improvements might still be 
made, particularly to the final deprotection step in the synthesis. 
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2.6.  Thioamide analogue 
With α-GalCer 8 in hand, three steps were required to access the desired 
thioamide 35 (Scheme 2.12). The key step in this synthesis would involve 
thionation of the amide and we chose to investigate Lawesson‟s reagent 63 as a 
thionating agent in the first instance. Lawesson‟s reagent109 is widely used for 
converting carbonyl compounds such as amides, ketones, lactams and lactones 
into their thiocarbonyl analogues.110,111 The reaction proceeds under mild 
conditions and is now generally preferred over the use of phosphorus pentasulfide 
(P2S5), which requires boiling toluene, pyridine or xylene as solvent, a large 
excess of the thionating agent and long reaction times.109,112 
The mechanism of the thionation reaction using Lawesson‟s reagent 63 is 
depicted in Scheme 2.10. Lawesson‟s reagent is in equilibrium with a highly 
reactive dithiophosphine ylide, which reacts with a carbonyl-containing compound 
to form a thiaoxaphosphetane.110 The driving force for the reaction involves the 
formation of a stable P=O bond in the final cycloreversion step, which is similar to 
the Wittig reaction.  
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Scheme 2.10.  Mechanism of the thionation reaction using Lawesson‟s reagent. 
 
There are very few examples of direct thionation of amides in the presence of free 
hydroxyl groups. Nishio et al. investigated the thionation of β-, δ-, and -hydroxy 
amides 64, 67 and 70, respectively, with Lawesson‟s reagent.113-115 Various 
products were formed in all three cases, including α-β-unsaturated thioamide 65, 
mercaptoamide 66, thiopheneimine 68 and thiones 69 and 71 (Scheme 2.11). 
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Scheme 2.11.  Reaction of β-, γ- and κ-hydroxy amides with Lawesson‟s reagent. 
 
In light of these results, we were not surprised to observe that performing the 
thionation of α-GalCer 8 without protecting the hydroxyl groups, resulted in the 
formation of a range of products. A large amount of unreacted starting material 
was also present in the reaction mixture, probably owing to the low solubility of the 
starting material in toluene. Moreover, separating the small amounts of the desired 
thioamide 35 from the excess of unreacted 8 proved to be difficult owing to their 
similar behaviour on silica.  
 
A more effective synthesis of thioamide 35 is outlined in Scheme 2.12. We first 
decided to protect the hydroxyl groups in 8 as acetates, expecting only the amide 
Chapter 2            Amide Analogues of α-Galactosylceramide and Threitol Ceramide 
 
71 
 
group would react with the Lawesson‟s reagent at 80 ºC in toluene. Thionation of 
esters is possible using Lawesson‟s reagent, but the reaction is usually performed 
in xylene at 140 ºC.116 Peracetylation of α-GalCer afforded 72 in 94% yield. We 
were pleased to observe that reaction of 72 with one equivalent of Lawesson‟s 
reagent in toluene at 80 ºC for four hours afforded thioamide 73 in 85% yield. 
Deprotection of the acetyl groups under Zemplén conditions afforded thioamide 35 
in 90% yield. 
 
  
 
 
 
 
 
 
 
 
 
Scheme 2.12.  Synthesis of thioamide analogue 35. 
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2.7.  Synthesis of urea analogue of α-GalCer 
 
Formation of the urea analogue 36 from amine 46 required the synthesis of an 
appropriate isocyanate. We envisaged this would be accessed by a Curtius 
rearrangement on the corresponding acid azide.117,118 Use of hexacosanoic acid 
61 as the starting point would lead to a urea product containing 27 atoms (26 
carbons and one nitrogen) in the acyl chain. Since CD1d does not readily 
accommodate acyl chain lengths longer than the C26 chain found in α-GalCer,119 
we chose to start with tetracosanoic acid 74 as this would be processed through to 
a urea product containing 25 atoms in the acyl chain (24 carbons and one 
nitrogen). Since the α-GalCer analogue containing a C24 acyl chain displays 
similar biological activity to α-GalCer 8,68 we expected any differences in biological 
activity between a urea analogue containing 25 atoms in the acyl chain (i.e. 36), 
and α-GalCer 8, would be attributable to an amide-urea switch and not a result of 
the slightly truncated acyl chain.   
 
The preparation of isocyanate 48 and urea analogue 36 is summarised in Scheme 
2.13. Conversion of the starting tetracosanoic acid 74 to the corresponding acid 
chloride 75 using the (COCl)2 procedure,
120 followed by treatment with NaN3 led to 
the acid azide 76,121 which underwent Curtius rearrangement121 on heating in 
toluene at reflux for four hours to provide the desired isocyanate 48. These three 
steps were performed as a sequence on the same day, without purification of any 
intermediates to minimise their possible decomposition. Crude isocyanate 48 was 
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reacted with amine 46 to provide urea 77 in 68% yield (Scheme 2.13). The product 
was characterised by HRMS and the quaternary resonance corresponding to the 
carbonyl C=O of the urea was observed at δ 158.8 ppm in the 13C NMR spectrum. 
The IR spectrum also showed a C=O stretch at 1670 cm-1, providing further 
evidence of successful functionalisation of amine 77. Hydrogenolysis of the benzyl 
groups in urea 77 under our standard conditions, effected global deprotection and 
afforded our next target, urea 36.  
 
 
Scheme 2.13.  Synthesis of urea analogue 36. 
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2.8.  Second-Generation Synthesis of α-GalCer 
 
Whilst benzyl ethers are very commonly employed as protecting groups, 
particularly in carbohydrate chemistry, conformational effects can mean that some 
groups are particularly stubborn to remove under hydrogenolysis conditions. 
Indeed, this proved to be the case with one of the benzyl ethers in the 
phytosphingosine unit of amide 62 and urea 77. Debenzylation was often slow, 
and frequently required filtration of the reaction mixture and addition of fresh 
catalyst to effect complete removal of all benzyl protecting groups.  
We envisaged that we could facilitate the hydrogenolysis step in our synthesis by 
finding alternative protecting groups for the two secondary alcohols in the 
phytosphingosine acceptor. To this end, we chose to investigate a modified 
phytosphingosine acceptor 78 in our glycosylation. Whilst the use of an acetal to 
protect the internal 1,2-diol in our phytosphingosine acceptor would likely 
necessitate a two-step deprotection post glycosylation, we expected the 
debenzylation step would be easier, and no problems with a late-stage acetal 
hydrolysis.  Moreover, this additional deprotection step would be mitigated by a 
more straightforward two-step synthesis of acceptor 78 from phytosphingosine 58 
(Scheme 2.14),55,90 compared with the three-step synthesis required to access 
dibenzyl ether 52.96  
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Scheme. 2.14.  Synthesis of modified acceptor 78. 
 
Although the choice of donor/acceptor pairs can impact on the stereoselectivity of 
glycosylation reactions, we were pleased to observe that galactoside 79 could be 
accessed in similarly good yield and once again with complete α-stereoselectivity 
under our optimised conditions (Scheme 2.15). As an unexpected bonus, 
purification of 79 proved to be less laborious than for 50, and probably goes some 
way to accounting for the slightly higher (71%) isolated yield of the product. The 
product was confirmed by HRMS and the characteristic α-anomeric proton in the 
1H NMR spectrum at 4.93 ppm, which appeared as a doublet with a small coupling 
constant (1H, d, J1,2 3.6 Hz, H-1‟). The characteristic α-anomeric carbon 
resonance at 98.8 ppm in the 13C NMR spectrum provided further diagnostic data.  
 
 
Scheme 2.15.  Synthesis of galactoside 79 with modified acceptor 78. 
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Staudinger reduction provided amine 80, which was acylated, as before, to provide 
amide 81 (Scheme 2.16). In the next step, the acetal protecting group was 
hydrolysed with TFA and after evaporation of the volatiles from the reaction 
mixture, the crude diol product was debenzylated to provide α-GalCer 8. As 
expected, hydrogenolysis of four instead of six benzyl ether groups proved to be 
much faster, taking eight hours instead of the 22 hours required to debenzylate 62. 
 
 
 
 
 
 
 
 
 
 
Scheme 2.16.  Second-generation synthesis of α-GalCer 8. 
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2.9.  Synthesis of carbamate analogue of α-GalCer 
 
Carbamates are traditionally prepared either by functionalisation of an alcohol with 
an isocyanate, or by reacting an amine with a chloroformate or synthetic 
equivalent. Chloroformates are moisture-sensitive, and their preparation requires 
reaction of an alcohol with difficult-to-handle and highly toxic phosgene or slightly 
less dangerous triphosgene. We therefore chose to investigate an alternative 
approach reported by Ghosh et al.122 In this report, Ghosh showed that alcohols 
react with commercially available N,N‟-disuccinimidyl carbonate in the presence of 
triethylamine to afford stable and easy-to-handle mixed carbonates, which can 
then be reacted with an amine to provide the corresponding carbamate.   
 
 
 
 
 
 
 
Scheme 2.17.  Retrosynthetic analysis for carbamate. 
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Scheme 2.18.  Retrosynthetic analysis of 37, the carbamate analogue of α-GalCer. 
 
Our next target was the carbamate analogue of α-GalCer 37 (Scheme 2.18). To 
maintain the optimum length of 26 atoms in the lipid tail, our carbamate analogue 
required a 24-carbon alkyl chain. We therefore started from tetracosanoic acid 74, 
which was reduced to alcohol 82 with LiAlH4 in THF at reflux (Scheme 2.19). 
Reaction of 1-tetracosanol with 1.5 equivalents of N,N‟-disuccinimidyl carbonate 
83 in the presence of 2.5 equivalents of triethylamine afforded mixed carbonate 49 
in almost quantitative yield. The product was characterised by HRMS. Further 
evidence came from the 13C NMR spectrum, which showed a quaternary carbon 
resonance characteristic for the carbonate carbonyl group at δ 151.6 ppm in 
addition to a resonance at δ 168.7 ppm corresponding to the imide carbonyls. 
Mixed carbonate 49 was then reacted with amine 80, to provide carbamate 84 in 
very good yield (Scheme 2.19). Formation of the product was confirmed by HRMS 
and by the chemical shift of the quaternary carbon in the 13C NMR spectrum, 
which appeared at δ 159.9 ppm. The IR spectrum also showed a C=O stretch at 
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1689 cm-1 as further evidence of carbamate formation. Finally, the protecting 
groups in carbamate 84 were removed uneventfully in a two-step acetal hydrolysis 
/ debenzylation sequence to provide our final target 37 (Scheme 2.19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.19.  Synthesis of carbamate 37. 
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2.10.  Synthesis of Threitol Ceramide 
 
Threitol ceramide (ThrCer) 24 is a non-glycosidic analogue of α-GalCer (described 
previously in Chapter 1.7.2.3). Like α-GalCer, it does not display a biased Th1/Th2 
cytokine response and compared with α-GalCer, it is a less potent agonist of 
CD1d; however it successfully activates iNKT cells without causing their 
overstimulation, thereby overcoming the problematic iNKT cell activation-induced 
anergy associated with α-GalCer.123   
The synthesis of ThrCer 24 has been recently reported by Reddy et al.70  and by 
our research group.124 The protecting group strategy employed in both these 
approaches is slightly different to the synthetic route we chose to follow. We 
envisaged ThrCer and its three analogues would again be accessed from a 
common precursor amine 85, which could then be functionalised in the same 
fashion as for the α-GalCer series (Scheme 2.20). Amine 85 would be accessed 
from the corresponding azide 86, which can be further disconnected to the 
previously prepared primary alcohol 78 (the acceptor in our improved second-
generation glycosylation reaction) and commercially available (+)-2,3-O-
isopropylidene-L-threitol 88. 
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Scheme 2.20.  Retrosynthetic analysis of ThrCer 24 and its analogues, thioamide 38, 
urea 39 and carbamate 40. 
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The protecting groups in the azide 86 were carefully selected to provide an 
intermediate suitable for the synthesis of ThrCer and its three analogues. Reddy et 
al.70 used a similar azide 89 in their synthesis of ThrCer, only the primary alcohol 
on the threitol moiety was protected as a benzyl ether, whilst in our previous 
report, the same primary alcohol was protected with a bulky TBDPS silyl ether, 
and the internal 1,2-diol of the threitol unit as a benzylidene acetal 90. 
 
 
 
Scheme 2.21.   Comparison of protecting group strategy employed in the synthesis of  
ThrCer. 
 
In our approach, deprotection of all five hydroxyl groups was envisaged as the last 
step of the synthesis. We wanted to avoid benzyl ethers as these usually require a 
hydrogenolysis deprotection step, which would prevent us from incorporating 
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unsaturated acyl chains. We also wanted to protect the two 1,2-diols as 
isopropylidene acetals and avoid a benzylidene acetal, as this introduces an 
additional stereocentre, which would render characterisation of the resulting 
products more difficult. We first considered protecting the primary alcohol of 
threitol as its tetrahydropyranyl ether 91, as this would allow us to perform a 
deprotection of all five hydroxyl groups in a single step; however, like for the 
benzylidene acetal, the THP-protected derivatives would likely result in 
diastereoisomeric mixtures. We therefore opted for a bulky TBDPS silyl ether in 
azide 86. Whilst this protecting group would entail a two-step deprotection 
sequence, it might be advantageous to employ an orthogonal protecting group, 
should we wish to selectively functionalise the primary alcohol of the threitol 
moiety at a later date.  
 
The synthesis of our precursor amine 85 is summarised in Scheme 2.22.  Starting 
from commercially available (+)-2,3-O-isopropylidene-L-threitol 88, reaction with 
equimolar quantities of tBuPh2SiCl afforded the corresponding mono-silyl ether 
92, which was further reacted with triflic anhydride in pyridine to provide triflate 87.  
This intermediate served as our electrophilic coupling partner for an etherification 
with nucleophilic coupling partner 78, which was the acceptor we had employed 
previously in our second-generation glycosylation reaction (see Section 2.9 of this 
Chapter). 
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Scheme 2.22.  Synthesis of the advanced intermediate amine 85. 
 
Treatment of alcohol 78 with NaH afforded the corresponding sodium alkoxide 93, 
which underwent smooth reaction with triflate 87 to provide the desired ether 86 in 
80% yield.124 Staudinger reduction of the resulting azide using PMe3
94 provided 
amine 85 (Scheme 2.22), and thence straightforward access to ThrCer and its 
three analogues, using the same approaches that were developed for the 
thioamide 35, urea 36 and carbamate 37 analogues of α-GalCer.  
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The synthesis of ThrCer 24 is summarised in Scheme 2.23. Amine 85 was first N-
acylated with hexacosanoyl chloride 47 to provide amide 94. The product 94 was 
confirmed by HRMS. Key spectroscopic signals included the amide carbonyl 
stretch in the IR spectrum at 1646 cm-1. The amide functionality was further 
evidenced in the 13C NMR spectrum, which showed the characteristic quaternary 
carbon environment of a carbonyl at δ 172.4 ppm. In the next steps, silyl ether 
deprotection with TBAF, followed by acid-catalysed hydrolysis of the acetals 
provided our target molecule ThrCer 24 as confirmed by HRMS. Analysis of the 
1H- and 13C NMR spectra also confirmed the successful removal of the TBDPS 
silyl ether and two acetals. The IR spectrum showed the OH stretch as further 
evidence of hydroxyl groups. 
 
Scheme 2.23.  Synthesis of ThrCer 24. 
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2.11.  Synthesis of thioamide analogue of ThrCer 
 
Scheme 2.24 presents the synthesis of the thioamide 38 analogue of ThrCer, 
which was prepared in the same fashion as the thioamide analogue of α-GalCer 
35 (Chapter 2.6). ThrCer 24 was first peracetylated to give 95, which underwent 
thionation, using Lawesson‟s reagent, to provide thioamide 96 in good yield. 
Acetate deprotection with sodium methoxide in methanol provided our target 
compound 38. 
 
 
Scheme 2.24.  Synthesis of the thioamide analogue of ThrCer 38. 
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We also wanted to investigate an alternative approach to thioamide 38, and 
perform thionation on the early-stage intermediate amide 94 to minimise handling 
of the fully deprotected ThrCer 24. Our alternative approach is summarised in 
Scheme 2.25. We were pleased to observe that thionation of amide 94 proceeded 
uneventfully. The product 97 was confirmed by HRMS and spectroscopic data, 
which provided evidence for the thiocarbonyl C=S group in the 13C NMR spectrum 
at δ 205.5 ppm. Silyl ether deprotection, followed by hydrolysis of the two 
isopropylidene acetals, provided the final product 38. 
 
 
 
Scheme 2.25.  Alternative synthesis of thioamide analogue of ThrCer 38 starting from 
amide 94. 
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2.12.  Synthesis of urea analogue of ThrCer 
Reaction of amine 85 with tricosanyl isocyanate 48 (prepared as previously 
discussed in Chapter 2.7) in toluene at 80 ºC furnished urea 98, which underwent 
our standard two-step deprotection sequence to afford urea analogue 39 in a 
satisfactory yield. This final compound was insoluble at r.t. in the chloroform / 
methanol mixture normally used to solubilise these glycolipids for NMR 
spectroscopic analysis. Fortunately, running the spectra at 40 ºC prevented 
product precipitation and allowed us to obtain good quality data 
 
  
Scheme 2.26.  Synthesis of 39, the urea analogue of ThrCer. 
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2.13.  Synthesis of carbamate analogue of ThrCer 
 
 
Scheme 2.27.  Synthesis of carbamate analogue of ThrCer, 40. 
 
Treatment of amine 85 with the mixed carbonate 49 derived from the reaction of 
tetracosanoyl alcohol with N,N′-disuccinimidyl carbonate (discussed in Chapter 
2.9), provided carbamate 99. After aqueous work-up and silica column 
chromatography, the product was confirmed by HRMS. Formation of the 
carbamate function was further evidenced in the 13C NMR spectrum, which 
revealed a quaternary carbon resonance at 156.0 ppm and a C=O stretch at 1687 
cm-1 in the IR spectrum. Our standard two-step deprotection sequence provided 
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carbamate analogue 40. Carbamate 40 was also found to precipitate from a 2:1 
chloroform / methanol mixture at r.t. and 1H- and 13C NMR experiments were 
performed at 40 ºC in order to obtain good quality data.   
 
Having prepared our target compounds 8, 24, 35-40, these were next submitted 
for biological testing which was carried out in the group of Prof. Vincenzo 
Cerundolo by Dr John-Paul Jukes and Dr Hemza Ghadbane at the Weatherall 
Institute of Molecular Medicine in Oxford, UK. 
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2.14.  Biological evaluation of glycolipid antigens: thioamide, urea and 
carbamate analogues of α-GalCer and ThrCer 
 
In a preliminary screen, our newly synthesised α-GalCer and ThrCer thioamide, 
urea and carbamate analogues were tested for their ability to stimulate the iNKT 
cell hybridoma DN32§, following pulsing of C1R-mCD1d** cells with various 
concentrations of ligands. The concentration of interleukin-2 (IL-2) in the 
supernatant, released after iNKT cell activation, was measured using an enzyme-
linked immunosorbent assay (ELISA) (Figure 2.13 A, B).  
 
Encouragingly, the results of these experiments demonstrated that ThrCer 
thioamide 38 and ThrCer carbamate 40 induced increased activation compared 
with ThrCer 24; however the ThrCer urea analogue 39 led to weak stimulation 
(Figure 2.13 A). A similar hierarchy was observed for the α-GalCer analogues 
(Figures 2.13 B), although the differences, particularly at high concentration, were 
less pronounced (Figure  2.13 B). 
 
 
 
 
 
                                               
§
 DN32 - the Vα14
+
 NKT cell hybridoma cell lines. 
**
 C1R-mCD1d - mouse CD1d-expressing C1R cells. 
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      A                                                        B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13.   Activation of murine iNKT cells using thioamide, urea and 
carbamate analogues of ThrCer and α-GalCer. C1R-mCD1d cells 
were pulsed with various concentrations of ThrCer analogues (A) and α-
GalCer analogues (B) as indicated and used to stimulate the DN32 
hybridoma in vitro. The supernatants were tested for the presence of 
IL-2. 
 
 
To confirm these findings, human iNKT cells were co-cultured for 40 hours with 
C1R-hCD1d cells that had been pulsed with 100 ng/ml, 10 ng/ml or 1 ng/ml 
vehicle, ThrCer 24, ThrCer thioamide 38, ThrCer urea 39, ThrCer carbamate 40 
(Figure 2.14 A) and α-GalCer 8, α-GalCer thioamide 35, α-GalCer urea 36, α-
GalCer carbamate 37 (Figure 2. 14 B). Cytokine production was again determined 
by ELISA. The ThrCer analogues stimulated human iNKT cells and in agreement 
with murine iNKT cell data, the weakest ligand at 100 ng/ml was ThrCer urea 39, 
although in this experiment, both the ThrCer thioamide 38 and ThrCer carbamate 
24, ThrCer                                                          
38, ThrCer thioamide                    
39, ThrCer urea                                          
40, ThrCer carbamate    
Vehicle 
 
         
 8,   α-GalCer                                                          
35,  α-GalCer thioamide                    
36,  α-GalCer urea                                          
37,  α-GalCer carbamate    
Vehicle 
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40 analogues were comparable to ThrCer 24 (Figure 2.14 A). All the α-GalCer 
analogues stimulated human iNKT cells showing almost the same activity at 100 
ng/ml when compared with α-GalCer, while at 10 ng/ml they stimulated iNKT cells 
stronger than α-GalCer. Interestingly at that concentration α-GalCer thioamide 
analogue 35 was found to be 2-fold more potent than α-GalCer 8. Unlike the 
ThrCer analogues, all three α-GalCer analogues 35, 36 and 37 were active even 
at low concentrations (Figures 2.14 A, B). 
 
        A                                                        B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14.    Activation of human iNKT cells using thioamide, urea and 
carbamate analogues of ThrCer and α-GalCer. C1R-hCD1d cells 
were pulsed with various concentrations of ThrCer analogues (A) and α-
GalCer analogues (B) as indicated and used to stimulate human iNKT 
cells in vitro. The supernatants were tested for IFNγ. 
 
 
24, ThrCer                                                          
38, ThrCer thioamide                    
39, ThrCer urea                                          
40, ThrCer carbamate    
Vehicle 
 
         
 8,   α-GalCer                                                          
35,  α-GalCer thioamide                    
36,  α-GalCer urea                                          
37,  α-GalCer carbamate    
Vehicle 
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Since the two urea derivatives 36 and 39 displayed the weakest activity in our in 
vitro experiments, further studies focused solely on the thioamide and carbamate 
derivatives of ThrCer and α-GalCer.  These analogues were further investigated in 
vivo, alongside the parent compounds and Th2-biasing molecule OCH 13,62,125 
specifically to assess their ability to effect DC maturation as well as their Th1/Th2 
cytokine response profile. To this end, 1 μg lipid was injected intravenously into 
mice.  After 2 h, the mice were tail-bled and IL-4 levels in the serum measured by 
ELISA (Figure 2.15).  At 18 h, the mice were sacrificed and blood serum levels of 
IFNγ were measured by ELISA (Figure 2.15).   
The in vivo experiments for the α-GalCer analogues show that the thioamide and 
carbamate derivatives, 35 and 37, respectively, both display a slightly more Th1-
biasing cytokine response than α-GalCer 8, resulting from a reduction in IL-4 
production relative to the parent α-GalCer 8, rather than an increase in IFNγ 
production, which was similar to that generated by α-GalCer 8. Results for the 
ThrCer derivatives were more interesting in that these displayed a similar but more 
pronounced trend. Compared with α-GalCer 8, ThrCer 24 is a weaker activator of 
iNKT cells, although it displays a similar Th1-Th2 cytokine profile.70,123 Very 
interestingly ThrCer thioamide 38 and ThrCer carbamate 40 displayed no IL-4 
production, when assayed at 2 h; however they showed levels of IFNγ production 
at 18 h that were higher than those shown for ThrCer 24 and only four times lower 
than that displayed by α-GalCer 8. Thus ThrCer analogues 38 and 40 appear to be 
promising Th1-biasing glycolipids. 
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             A                       B           
 
 
                                          
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15.   IL-4 and IFN levels in blood serum taken at the indicated times after 
injection of mice with glycolipid.  
 
 8,   α-GalCer                                                          
35,  α-GalCer thioamide                                                         
37,  α-GalCer carbamate    
13,  OCH 
 
         
24,  ThrCer                                                          
38,  ThrCer thioamide                                                         
40,  ThrCer carbamate    
13,  OCH 
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Finally, bacterially-expressed hCD1d and beta-2-microglobulin (β2m) molecules 
were refolded with the thioamide, and carbamate analogues of both α-GalCer and 
ThrCer by oxidative refolding chromatography, and then biotinylated as described 
previously for use in surface plasmon resonance (SPR) experiments (BIAcore 
3000 instrument).36,126 The urea analogues of α-GalCer and ThrCer could not be 
refolded, so no SPR data are available for these analogues.  
Soluble human iNKT TCR was prepared as described by McCarthy et al.36 SPR 
experiments were used to measure the affinity and kinetics of human iNKT cell 
TCRs for hCD1d loaded with α-GalCer, ThrCer, and their thioamide and 
carbamate analogues (Figure 2.16). To this end, increasing concentrations of TCR 
were injected for 5 seconds over the indicated complex immobilised on the 
BIAcore chip until the specific binding reached its plateau. Kd and Bmax were 
calculated by fitting the data using a non-linear regression binding kinetics model 
(GraphPad Prism) (Figure 2.16). Kinetic measurements for the koff were calculated 
using BIAevaluation software kit; kon values were calculated from the experimental 
koff and Kd (Figure 2.16 C). 
In terms of binding affinity of the TCR for glycolipid-loaded hCD1d, Kd values for 
the TCR–carbamate–hCD1d complexes in both series were comparable to those 
measured for the parent compounds. The iNKT TCR exhibited slightly lower 
binding affinity for hCD1d loaded with α-GalCer-thioamide 35 compared with 
hCD1d/ α-GalCer, whilst binding affinity for hCD1d loaded with ThrCer-thioamide 
38 was interestingly an order of magnitude lower than that for hCD1d/ThrCer 24. 
The binding kinetics experiment showed that these lower binding affinities are a 
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consequence of a faster off rate and a slower on rate of the TCR–thioamide–
hCD1d complex compared to CD1d complexes with the parent molecules (Figure 
2.16 C). This observation is comparable to the kinetics displayed by the Th2-
biasing α-GalCer analogue, OCH 13.127 These iNKT cell TCR binding affinity data 
for the CD1d/glycolipid complexes do not show a clear correlation with the 
observed cytokine response. 
      
 
C     
Lipid on 
CD1d 
Experimental 
Kd (μM) 
Experimental 
koff (s
-1) 
Calculated kon 
(M-1 s-1) 
A B 
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   ThrCer, 24 4.57 ± 0.12 1.18 ± 0.034 2.58 Χ 105 ± 0.010 Χ 105 
ThrCer 
thioamide, 38 
36.06 ± 0.96 1.88 ± 0.045 5.2 Χ 105 ± 0.26 Χ 104 
ThrCer 
carbamate, 40 
4.60 ± 0.13 1.19 ± 0.072 2.59 Χ 105 ± 0.017 Χ 105 
α-GalCer, 8 2.19 ± 0.07 0.565 ± 0.008 2.58 Χ 105 ± 0.009 Χ 105 
α-GalCer 
thioamide, 35 
4.20 ± 0.15 0.537 ± 0.011 1.28 Χ 105 ± 0.05 Χ 105 
α-GalCer 
carbamate, 37 
1.72 ± 0.10 0.919 ± 0.035 5.34 Χ 105 ± 0.37 Χ 105 
 
Figure 2.16.   Binding affinities (left) and kinetics (right) of the iNKT TCR for hCD1d 
molecules loaded with α-GalCer and ThrCer analogues measured using 
surface plasmon resonance (SPR). ThrCer analogues (A) and α-GalCer 
analogues (B).  
 
A recent study by Sullivan et al. made a direct comparison between the Th2-
biasing OCH glycolipid 13 and the Th1-biasing C-glycosyl analogue of α-GalCer 
25.127 The group showed that both OCH and the C-glycosyl analogue of α-GalCer 
displayed weaker interactions than α-GalCer with iNKT cell TCRs.  The authors 
attributed differences in cytokine response profiles to other factors including their 
differing pharmacokinetics properties, and their ability to transactivate other 
cytokine-releasing T-lymphocytes such as NK cells.  When such transactivation 
requires prolonged lifetime after initial injection, metabolically more stable 
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glycolipid analogues should function better.  A similar observation was made by 
Taniguchi and co-workers with the neoglycolipid α-carba-GalCer, which also 
induces a Th1-biased cytokine response profile upon iNKT cell activation.128 
Having replaced the amide residue with metabolically more stable functionality, we 
expected all three structural analogues, and in particular the non-glycosidic threitol 
derivatives 38, 39 and 40, which are not susceptible to glycosidase-mediated 
hydrolysis, would exhibit prolonged lifetimes in vivo, and for this reason, tentatively 
postulated that this might lead to Th1-biasing antigens.  This hypothesis appears 
to have been borne out, at least in part, in the ThrCer series with the thioamide 
and carbamate analogues displaying a cytokine profile that is biased towards Th1. 
In both α-Gal and Thr series, the urea analogues displayed poor activity and we 
were unable to obtain binding and kinetics data for these two substrates, which 
may suggest that the additional NH incorporated into the acyl chain disrupts 
glycolipid binding and subsequent presentation. 
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2.15.  Conclusion and Future Work 
 
We have designed and synthesised two advanced intermediate amines 46 and 78, 
which provided us with easy access to α-GalCer 8 and ThrCer 24 and their 
thioamide, urea and carbamate analogues.   
All of the analogues were found to stimulate iNKT cells by CD1d-mediated 
presentation to varying degrees; however, the thioamide and carbamate 
analogues of ThrCer were of particular interest in that they elicted a strongly 
polarised in vivo Th1 response in mice.   
ThrCer thioamide 38 may be useful for future investigation since it has the ability 
to activate both murine and human iNKT cells and elicted a strongly polarised in 
vivo Th1 response in mice. Its low binding affinity for CD1d is analogous to the 
truncated form of α-GalCer, OCH which has been shown to be rapidly presented 
on CD1d molecules, compared to α-GalCer.127 The analysis of the crystal structure 
of the iNKT TCR-hCD1d–α-GalCer ternary complex suggests that whilst NH in 
ThrCer thioamide 38 should be able to partake in a strong hydrogen bond with the 
side-chain hydroxyl of Thr156 in mCD1d (and Thr154 in hCD1d), we expected any 
hydrogen bonding with a bridging water molecule would be weaker. It is also 
possible that one of the water molecules might be displaced due to the increased 
size of the sulfur atom. Attempts are currently on-going to crystallise CD1d with 
ThrCer 26 and ThrCer thioamide 38 with to understand the mechanism by which 
the addition of thioamide influences CD1d-TCR interactions. 
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It would be interesting to investigate further why the urea analogues of α-GalCer 
and ThrCer showed very weak iNKT cell stimulation. One possibility is that the 
additional N-H present in the urea can form a hydrogen bond with one of the 
amino acid residues of CD1d and change the conformation of the glycolipid-CD1d 
complex which is no longer recognised by iNKT TCR. To test this hypothesis the 
N-methyl urea analogue of α-GalCer and ThrCer should be prepared (Figure 
2.17).  
 
Our findings might suggest that increased metabolic stability of the glycolipid is 
important for favouring a Th1-biased cytokine response. For that reason we also 
considered moving away from the carboxylic acid derivatives and introducing 
aromatic and heterocyclic rings into the glycolipid structure that could mimic amide 
functionality. These amide derivatives would be less conformationally flexible and 
also more stable in vivo. We also envisage the preparation of the thioamide 
analogue of the C-glycosyl α-GalCer derivative, which stimulates a Th1-biased 
cytokine response (see Chapter 1.7.2.4), would be worthwhile. Direct comparison 
of the altered biological activity of this analogue with our ThrCer thioamide 38 
could provide us with more information on the relation between glycolipid structure 
and Th1/Th2 bias.  
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Figure 2.17.  Possible future targets.
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Synthesis and Functional Activity of Labelled α-GalCer, 
ThrCer and Their Unsaturated Analogues 
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3.  Synthesis and functional activity of labelled α-GalCer, ThrCer and 
their unsaturated analogues 
 
3.1.  Target compounds  
 
The mechanisms leading to stimulation of biased Th1/Th2 responses by α-GalCer 
analogues remain poorly understood. As discussed earlier (see Chapter 1.7.2.1), 
one hypothesis states that for Th2 type agonists, like OCH 13, low levels of IFNγ 
are observed due to the low affinity of the CD1d-OCH complex for the iNKT cell 
TCR.36,66 However, another Th2-biasing agonist, α-GalCer(C20:2) 19, when 
complexed with mCD1d or hCD1d, has been shown to have high binding affinity 
for the iNKT cell TCR, similar to that displayed by the most potent CD1d agonist α-
GalCer 8, a molecule which does not show significant skewing in its cytokine 
profile.129 
Another hypothesis points at differences in uptake and presentation of various 
glycolipids. Studies carried out by van den Elzen and co-workers revealed that α-
GalCer loading into CD1d occurs mainly in endosomes and requires uptake by 
endocytosis through a process that is facilitated by extracellular lipid carrying 
proteins such as apolipoprotein E (ApoE).130 Further studies50,131,132 showed that 
α-GalCer loading and presentation is also facilitated by lipid transfer proteins 
(LTPs) such as saposins and GM2 activator protein and requires acidic pH. Yu 
and co-workers67 demonstrated that Th2-biasing α-GalCer(C20:2) 19 loads 
directly into cell-surface CD1d and does not require intracellular loading, which 
leads to much faster presentation. Figure 3.1 outlines the proposed mechanism 
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leading to stimulation of biased cytokine responses by α-GalCer and its 
analogues. 
 
                       α-GalCer                                             α-GalCer(C20:2) 
 
 
 
                                                                                                
 
 
 
 
 
 
Figure 3.1.   Proposed mechanism leading to stimulation of Th2-biased cytokine 
responses by α-GalCer and its analogues. α-GalCer requires 
intracellular processing and loading into CD1d protein in late 
endosomes. α-GalCer(C20:2), on the contrary, binds to CD1d at the cell 
surface without endosomal processing and activates iNKT cells resulting 
in Th2 type response.  
 Figure adapted from ref 3.  Permission to reproduce figure was obtained 
from Elsevier through RightsLink® - licence number 2812141231176. 
 3.  
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To further study intracellular trafficking of exogenous glycolipids and to better 
understand the relationship between the cytokine profile of iNKT agonists and their 
differences in loading and presentation, we desired a series of labelled derivatives 
of α-GalCer, ThrCer and their unsaturated C20:2 analogues (Figure 3.2). Our first 
target was biotinylated ThrCer 106. The synthesis and biological evaluation of this 
molecule would first confirm that the location of the label and linker did not impact 
on functional activity, as it is important that labelled analogues mimic the 
unlabelled glycolipids closely to provide useful information.  
 
Having confirmed the biotin label did not significantly modify functional activity of 
ThrCer, we would then prepare α-GalCer derivative 108 and α-GalCer(C20:2) 
derivative 109, each bearing differently coloured fluorescent labels. The same 
modifications would be applied in the ThrCer series. A green label would be 
attached to α-GalCer and ThrCer, and a red label to their unsaturated analogues 
α-GalCer(C20:2) and ThrCer(C20:2). Incubating cell lines with a pair of differently 
fluorescent α-GalCer derivatives, and separately with similar ThrCer analogues, 
would allow us to use multicolour fluorescence detection. The resulting cellular 
images should reveal the location and distribution of the different CD1d bound 
glycolipids and allow their direct comparison. For example, we would expect to see 
red colouration at the cell surface where the presentation of α-GalCer(C20:2) 
occurs and green areas in the intracellular compartments and at the cell surface, 
since α-GalCer(C26) needs to be first internalised before presentation to iNKT 
TCR can take place. 
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Figure 3.2.   Target molecules: biotinylated ThrCer 106, ThrCer Alexa 488 107,         
α-GalCer Alexa 488 108, α-GalCer Alexa 594 109, ThrCer 594 110. 
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Alexa Fluor® dyes, although very expensive, are now frequently used for 
conjugates with histological applications, providing the high fluorescence quantum 
yield and high photostability required to detect biological structures with excellent 
selectivity and sensitivity.133 Figure 3.3 outlines alternative dyes commonly used in 
fluorescence microscopy, flow cytometry, and nucleic acid-based detection: 
cyanine dye Cy3 111, Oregon Green® 112 from the rhodamine class and a boron-
dipyrromethane example, namely BODIPY TR 113. However Alexa Fluor® dyes 
and their bioconjugates have more desirable properties including resistance to 
photobleaching, aqueous solubility, relative insensitivity to pH changes, high molar 
extinction coefficients and favourable quantum yields.134  
 
 
Figure 3.3.  Examples of commonly used fluorescent dyes: cyanine Cy3 111, 
rhodamine Oregon Green 112 and BODIPY TR 113. 
 
We first had to identify a label attachment point which would be common for all our 
target molecules. Chemical labelling studies of α-GalCer 8 have previously 
introduced the label at either the terminus of the N-acyl chain135-137 or at the 
C(6)OH of the galactose residue,138,139 both of which were deemed unsuitable for 
our purposes. We argued that a ThrCer analogue possessing a biotin label (and 
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any other for that matter) at the terminus of the N-acyl chain would result in the 
label being buried deep inside the A‟ pocket of the protein molecule (assuming 
such an analogue still binds in a similar conformation to ThrCer) and therefore 
unavailable for streptavidin or anti-biotin Ab recognition. Appending a label to the 
sugar residue in ThrCer was also rejected since all three alcohol groups in this 
truncated sugar unit are important for TCR recognition. We therefore considered 
alternative sites in the glycolipid, which would preserve binding and at the same 
time allow the biotin label to be recognised by some type of reporter group.  
Although an X-ray structure of the ThrCer-CD1d complex has so far eluded us, our 
working hypothesis assumes that ThrCer 24 adopts a similar bound conformation 
as does α-GalCer 8 in the CD1d molecule;45,46,74 thus the N-acyl chain of ThrCer 
occupies the hydrophobic A‟ pocket of the protein and the ceramide base the less 
voluminous F‟ pocket, leaving the polar sugar residue surface-exposed for TCR 
recognition.  An examination of the available X-ray structures of α-GalCer45 and 
various other glycolipids bound to CD1d44,127,140,141 and the related iNKT cell TCR 
ternary complexes,46,74,142 encouraged us to consider the α-methylene unit in the 
N-acyl chain as a potential derivatisation site.  Moreover, of the first set of 
glycolipid CD1d agonists, which were isolated from the marine sponge Agelas 
mauritianus,34 AGL-548 is a potent synthetic analogue.143 This glycolipid is 
structurally identical to α-GalCer apart from it possessing a hydroxyl group in the 
α-position (S configuration) of the N-acyl chain. Early studies had shown that 
deleting this hydroxyl functionality (which generates α-GalCer 8) has no significant 
impact on activity.143 Analysis of the X-ray structures of the α-GalCer-CD1d 
complex45 and the α-GalCer-CD1d-TCR complex46,74 revealed this site in the 
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glycolipid lies close to the surface of the CD1d molecule in the glycolipid-protein-
TCR complex. Based on this analysis, we decided to introduce our labels into the 
α-position of the N-acyl chain of all our glycolipids.   
  
 A                                                 B 
 
 
 
 
C 
 
 
 
 
 
 
Figure 3.4.    Chosen label attachment point (pointed with white arrow) at the α-
position of the acyl chain of α-GalCer, showing that this part of the 
molecule is not buried inside the CD1d protein in the α-GalCer-CD1d 
complex (A) and is also exposed in the iNKT TCR  α-GalCer  CD1d 
ternary complex (B, C). Surfaces: grey – CD1d, purple – iNKT TCR, 
cyan – β2m. (A - generated from 1ZT4,
45 B, C – generated from 2PO646 
with Pymol). 
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We chose not to couple our labels directly to the glycolipid (junction of three 
components of the α-GalCer-CD1d-TCR complex), and instead attach these 
through a linker to minimise their impact on binding to CD1d protein, and 
recognition by the iNKT TCR. Owing to its widespread use elsewhere for similar 
purposes an oligo(ethylene glycol) spacer group was chosen to separate the biotin 
label from the „active‟ ThrCer portion of the molecule.144-146 Such a linker would 
also impart favourable solubility properties on the late-stage products in a range of 
organic solvents.147,148 A triethylene glycol spacer unit was deemed to be of 
sufficient length to ensure the label in our targets would extend away from the 
TCR recognition site so as not to interrupt antigen presentation, and allow its own 
uninhibited recognition by streptavidin (in the case of biotin). 
Chapter 3           Synthesis and Functional Activity of Labelled α-GalCer, ThrCer and 
Their Unsaturated Analogues 
112 
 
3.2.  Retrosynthetic analysis 
 
The general retrosynthetic analysis of labelled glycolipids 106, 107, 108, 109 and 
110 is outlined in Scheme 3.1. Considering the very high unit cost of the 
fluorescent labels and to minimise difficult-to-handle, water-soluble labelled 
products, we decided to install the label of choice in the final step of the synthesis. 
We identified α-azido fatty acid chlorides and the previously prepared precursor 
amine 85 and modified (PMB protecting groups instead of Bn in galactose ring) 
amine 80 (see Chapter 2) as the starting materials for all of our syntheses. The 
resulting α-azido amide would then be reacted with the alkyne-terminated 
oligoethylene glycol linker 114 in a “click” reaction to provide the desired 1,2,3-
triazole, which after global deprotection, would provide the primary amine ready to 
be coupled with a commercially available, amine-reactive biotin or fluorophore 
derivative leading to our target compounds.  
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Scheme 3.1.   Retrosynthetic analysis of biotinylated ThrCer 106, ThrCer and α-GalCer 
derivatives 107 and 108 labelled with green Alexa 488 fluorescent label; 
and α-GalCer(C20:2) and ThrCer(C20:2) derivatives 109, 110 labelled 
with red Alexa 594. 
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3.3.  Synthesis of biotinylated ThrCer 
 
Biotinylation of ThrCer had been performed before in our research group;149 
however, we wanted to refine the previous synthesis of 106 to provide a late-stage 
intermediate amine 122, which could be coupled with any amine-reactive label 
such as the N-succinimidyl ester of biotin 123 or an activated ester of a fluorescent 
label such as Alexa Fluor ®.  
We first had to prepare α-azido hexacosanoic acid 116, which would also be used 
in the synthesis of our target labelled molecules 107 and 108.  
 
 
 
Scheme 3.2.  Synthesis of α-azido hexacosanoyl chloride 117. 
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α-Azido hexacosanoic acid 116 was prepared in two steps from hexacosanoic acid 
61 (Scheme 3.2). Thus treatment of acid 61 with bromine in the presence of red 
phosphorus provided the corresponding α-bromo acid bromide, and then α-bromo 
acid 115 after aqueous work up,150 which was converted into α-azido acid 116 by 
reaction with NaN3 in DMF.
151 Treatment of acid 116 with oxalyl chloride generated 
the corresponding acid chloride 117, which was reacted directly with amine 118 to 
provide the desired amide 119 as an inseparable 1:1 mixture of epimers (Scheme 
3.3).   
 
Scheme 3.3.  Synthesis of amide 119. 
 
Linker 114 was prepared in four steps starting from commercially available 2-[2-(2- 
chloroethoxy)ethoxy]ethanol 120, which was first reacted with NaN3 to provide the 
corresponding azide, in which the hydroxyl group was then treated with NaH and 
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reacted directly with propargyl bromide to give alkyne 121 in 70% overall yield 
(Scheme 3.3). The product was characterised by HRMS and the quaternary 
resonance corresponding to the alkynyl C≡CH was observed at δ 158.8 ppm in the 
13C NMR spectrum. The IR spectrum showed a strong N3 stretch at 2099 cm
-1 
providing further evidence of successful formation of the product 121. Staudinger 
reduction of the azido group under our standard conditions provided the 
corresponding amine, which was next N-Boc-protected to give linker 114 in 82% 
yield after two steps. The product 114 was confirmed by HRMS. Key 
spectroscopic signals included the carbamate carbonyl stretch in the IR spectrum 
at 1706 cm-1. The carbamate functionality was further evidenced in the 13C NMR 
spectrum, which showed the characteristic quaternary carbon environment of a 
carbonyl at δ 154.2 ppm. 
 
 
Scheme 3.6.  Synthesis of linker 114. 
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Click reaction152,153 of azide 119 with alkyne 114 proceeded uneventfully and with 
complete regioselectivity to afford the desired 1,4-disubstituted 1,2,3-triazole 121, 
which was isolated as a 1:1 mixture of epimers. At this stage we were able to 
observe two epimers by TLC analysis; however, their chromatographic separation 
was not possible. Formation of the product was confirmed by HRMS. Further 
evidence came from the 13C NMR spectrum, which showed a quaternary carbon 
resonance at δ 145.4 ppm and a CH resonance at δ 122.3 ppm characteristic for 
the 1,4-disubstituted 1,2,3-triazole. From this, the proton of the triazole ring H-1‟‟‟‟ 
was then identified by 2-D chemical shift-correlated spectroscopy (HSQC) and 
appeared as two broad singlets in the 1H NMR spectrum in the region of 7.71-7.75 
ppm for one epimer and in the region of 7.76-7.82 ppm for second epimer. Final 
global deprotection with trifluoroacetic acid provided the corresponding amine 122, 
which underwent smooth coupling with the N-hydroxysuccinimide activated ester 
of biotin 123 to provide our target,154 biotinylated ThrCer 106 as a 1:1 epimeric 
mixture (Scheme 3.7). Both epimers were now separable by careful column 
chromatography on silica, which provided us with 5 mg of the less polar epimer 
(epimer A) and 4 mg of the more polar epimer (epimer B).  
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Scheme 3.7.  Synthesis of biotinylated ThrCer 106. 
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The epimeric mixture 106 and the single epimers A and B were submitted for 
biological testing, which was carried out in the group of Prof. Vincenzo Cerundolo 
by Dr John-Paul Jukes and Dr Hemza Ghadbane at the Weatherall Institute of 
Molecular Medicine in Oxford, UK. 
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3.4.  Biological evaluation of biotinylated ThrCer 
 
The epimeric mixture and single epimers of biotinylated ThrCer 106 were next 
tested separately for their ability to be loaded on to hCD1d or mCD1d molecules 
as detected by the binding of tetrameric iNKT cell TCR (Figure 3.3 A) or the 
stimulation of murine iNKT cells (Figure 3.3 B). Whilst the mixture of epimers 
behaved similarly to ThrCer 24, when tested separately, it was apparent that the 
two epimers displayed different activity: iNKT cell TCR recognition of the CD1d  
single epimer complex was noticeably weaker when the less polar (on silica) 
epimer (epimer A) was employed (Figure 3.3 A).  These results were confirmed 
using mCD1d C1R cells and murine iNKT cell hybridomas (DN32) where the 
differences between epimer A and B became even more apparent (Figure 3.3 B). 
As a consequence of the difference in functional activity between the two epimers, 
the biological results using the 1:1 mixture were similar to those using purified 
epimer B, and for this reason, all subsequent experiments described below were 
performed with the more readily accessed epimeric mixture of 106. 
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Figure 3.3.   iNKT cell recognition of ThrCer 24 and biotinylated ThrCer 106, epimer 
A, epimer B and 1:1 mixture of epimers A+B.  (A) The recognition of 24 
and 106 by human iNKT TCR tetramer was assessed by FACS following 
co-incubation of fluorescent human iNKT cell TCR and hCD1d C1R cells 
loaded with indicated lipids. (B) The activation of iNKT cells (DN32) was 
examined following overnight culture with mCD1d C1R cells pulsed with 
24 and 106. IL-2 production in supernatant was measured by ELISA 
after 24 h.   
ThrCer 24                         
Biotinylated ThrCer 106 Epimer A                  
Biotinylated ThrCer 106 Epimer B                  
Biotinylated ThrCer 106 (A+B) 
Background 
ThrCer 24                         
Biotinylated ThrCer 106 Epimer A                  
Biotinylated ThrCer 106 Epimer B                  
Biotinylated ThrCer 106 (A+B) 
Background 
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Functional experiments were next performed with both ThrCer 24 and biotinylated 
ThrCer 106 to assess whether or not the presence of the biotin moiety linked to 
ThrCer alters optimal loading on to CD1d molecules and presentation to human 
iNKT cells.  To this end, we first analysed the ability of CD1d+ target cells pulsed 
with both compounds to be recognised by human iNKT cells.70 The results of 
these experiments are summarised in Figure 3.4 and demonstrate that both 
ThrCer 24 and the active epimer of biotinylated ThrCer 106 are capable of 
sensitising iNKT cells to a similar level, as defined by IFNγ secretion (analysed 
after 36 h by ELISA70 (Figure 3.3)).  We extended these results by employing a 
second protocol based on the use of a soluble human iNKT cell TCR tetramer,36 
which was used as a staining reagent for CD1d+ target cells pulsed with a range of 
concentrations of biotinylated ThrCer 106 (Figure 3.3). These results again 
indicate that the biotin label and linker in the active epimer of 106 do not alter 
optimal loading on to CD1d molecules, since the biotin moiety remains available 
for binding to streptavidin and anti-biotin (Figure 3.3 A/B), and still allows iNKT 
TCR tetramer binding (Figure 3.4). Significantly, it is possible to co-localise the 
iNKT TCR tetramer and biotin moiety using streptavidin (Figure 3.5).   
 
 
 
 
Chapter 3           Synthesis and Functional Activity of Labelled α-GalCer, ThrCer and 
Their Unsaturated Analogues 
123 
 
 
 
Figure 3.4.   Biotinylated ThrCer 106 activates human iNKT cells in vitro. A human 
iNKT cell line was incubated with C1R hCD1d cells pulsed with ThrCer 
24 (black squares) or biotinylated ThrCer 106 (1:1 epimeric mixture) 
(open squares) at various concentrations. IFNγ secretion was analysed 
after 36 h by ELISA. 
 
ThrCer 24                    
Biotinylated ThrCer 106 
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Figure 3.5.  Detection of biotinylated ThrCer 106 (1:1 epimeric mixture) on the 
surface of APCs.  C1R hCD1d cells were pulsed with the indicated 
concentrations of biotinylated ThrCer for 16 h and then stained with a) 
fluorescent streptavidin (APC), b) anti-biotin Ab (FITC), c) soluble iNKT 
TCR tetramer (APC). Panels a, b and c depict histogram overlays of the 
indicated fluorescence intensities. The dot plot shown in panel d depicts 
a double staining with the soluble iNKT TCR (APC) and anti-biotin Ab 
(FITC). 
 
At this stage of the study, we did not know the absolute stereochemistry at the 
triazole tethering site of the more active epimer although our previous analysis of 
the crystal structure of the α-GalCer-CD1d-TCR ternary complex46,74 suggested 
that substituting the pro-S hydrogen in the α-methylene unit would exert fewer 
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conformational changes on the iNKT cell TCR-CD1d-glycolipid complex and also 
allow the biotin label to protrude away from this complex to allow its recognition.   
  
A 
 
 
 
B 
 
 
 
 
 
 
Figure 3.6.  (A) Representation of the pro-S hydrogen and pro-R hydrogens in the α-
GalCer structure. (B) Pro-S hydrogen in the α-position of the N-acyl 
chain of α-GalCer pointing away from the interior of the CD1d protein in 
the crystal structure of the iNKT TCR  α-GalCer  hCD1d ternary 
complex. Cartoon representation was obtained with PyMol from 2PO6.46 
 
 
pro-S hydrogen 
pro-S hydrogen 
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In summary, we have shown that attaching a biotin label through a tri(ethylene 
glycol) spacer to the α-position of the N-acyl chain in ThrCer 24 generates a 
functionally active labelled analogue 106. Whilst introducing a label at this site 
necessarily introduces a new stereogenic centre into the molecule, and therefore a 
mixture of diastereoisomers when racemic azido acid 116 is employed, these two 
epimers can be separated by chromatography. Although the two epimers display 
different functional behaviour, the relatively large difference between the two 
means that the more active epimer 106 B dominates the behaviour of the epimeric 
mixture, and obviates the need to use the diastereoisomerically pure active epimer 
for biological studies.  
More generally, this study has shown that the α-site of the N-acyl chain should be 
a viable location for introducing labels into other ceramide-based CD1d agonists 
(and potentially other bioactive glycolipids). Furthermore, whilst this study involved 
the introduction of a biotin label, our synthetic strategy has been designed to allow 
the late-stage incorporation of other labels (e.g. fluorophores, lumophores) and we 
were now ready to prepare Alexa-labelled derivatives of ThrCer and α-GalCer. 
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3.5.  Synthesis of ThrCer(C26:0) labelled with Alexa 488 
 
With advanced intermediate amine 122 in hand we were also ready to perform a 
coupling reaction with an amine-reactive fluorescent label. To prepare Alexa 488 
labelled ThrCer 107 we chose to use the commercially available Alexa Fluor® 488 
carboxylic acid, 2,3,5,6-tetrafluorophenyl ester 124, which unfortunately comes 
with a high cost of £230 per 1 mg. Our biggest challenge would be to perform the 
coupling reaction efficiently on small scale; however we knew that providing 0.5-1 
mg of labelled compound would be sufficient for our collaborators to carry out 
many biological assays.  
Amine 122 was reacted with Alexa 488 active ester 124 in the presence of NEt3 in 
DMF to provide the final product 107 in 73% yield (1.2 mg of isolated product). 
Owing to the small amount of isolated material, its high molecular mass (Figure 
3.2), the charged nature of the material and the fact that it was an epimeric 
mixture, analysis of the 1H NMR spectra proved to be very difficult. TLC analysis 
however showed two bright fluorescent products that were not contaminated with 
any of the starting materials and gave a positive test for glycolipids with Molisch‟s 
reagent (α-naphtol solution 10 wt. % in ethanol) and lipid stain (phosphomolybdic 
acid solution 5 wt. % in ethanol).  
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Scheme 3.8.  Synthesis of Alexa 488-labelled ThrCer 107. 
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3.6.   Synthesis of α-GalCer(C26:0) labelled with Alexa 488 
To access the corresponding α-GalCer derivative labelled with Alexa 488 108, we 
first considered using our previously prepared amine 80 (See Chapter 2.8), which 
could be coupled with α-azido hexacosanoyl chloride and then processed as 
before after removal of the protecting groups. However, the intermediate amine 80 
bears four benzyl ether groups whose removal would likely cause a problem in our 
next target 109, which incorporates a skipped diene in the acyl chain. We 
therefore decided to further optimise our glycosylation reaction, and investigate the 
use of a new galactosyl donor containing PMB protecting groups, which we 
envisaged could be removed selectively under acidic conditions. 
p-Methoxybenzyl (PMB) ethers have been used widely in carbohydrate 
chemistry.155 These electron-rich ethers can be selectively removed by oxidation 
with, for example, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), without 
affecting alkenes, acetals, epoxides and silyl ethers.156 They can also be cleaved 
with trifluoroacetic acid (TFA) without affecting azido groups, acetates and O-
glycosidic linkages in oligosaccharides.157 For our purposes, the employment of 
PMB groups in the glycosyl donor would result in a potentially more efficient 
approach to amine 131. In analogy with amine 122, a final deprotection step with 
TFA would remove four PMB groups, the isopropylidene acetal and the Boc group.  
 
Our new donor precursor, 2,3,4,6-tetra-O-p-methoxybenzyl-galactose 126, was 
prepared in two steps (Scheme 3.9). Previously prepared tetraol 56 (see Chapter 
2.2) was first treated with NaH and the resulting alkoxide was reacted with p-
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methoxybenzyl chloride to afford thioglycoside 125 in 90% yield. This step 
required the reaction temperature to be raised to 60 ºC for the reaction to go to 
completion, whereas with benzyl bromide, r.t. had been sufficient to generate the 
tetra benzyl ether in almost quantitative yield. The thioglycoside 125 was then 
hydrolysed with N-bromosuccinimide in an acetone/water mixture (10:1) to yield 
the hemiacetal 126 as a 1:1 mixture of diastereoisomers.158  
We were pleased to find that the glycosylation reaction of donor precursor 126 
with acceptor 78 under our standard conditions resulted in glycoside 127 with 
complete α-selectivity and in 70% yield (Scheme 3.9). The product was confirmed 
by HRMS and the characteristic α-anomeric proton in the 1H NMR spectrum at δ 
4.93 ppm, which appeared as a doublet with a small coupling constant (1H, d, J1,2 
3.6 Hz, H-1‟). The 13C NMR spectrum also showed the diagnostic α-anomeric 
carbon resonance at δ 98.8 ppm.  
 
  
 
 
 
 
 
Scheme 3.9.  Synthesis of galactoside 127 using new donor 126. 
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The next steps involved a Staudinger reaction to afford amine 128, which was 
acylated with acid chloride 117 to provide amide 129 as a 1:1 mixture of epimers 
(Scheme 3.10). Formation of the product 129 was evidenced by HRMS and in the 
13C NMR spectrum, two characteristic amide C=O quaternary resonances were 
observed for both epimers at δ 168.6 and δ 168.9 ppm. From this, the H-2‟‟ 
protons were identified by 2-D chemical shift-correlated spectroscopy (HMBC) and 
the resonances for the corresponding C(2‟‟) carbons for both epimers at δ 64.2 
and δ 64.5 ppm (by HSQC). The IR spectrum showed a characteristic azido 
stretch at 2100 cm-1, and a carbonyl amide C=O stretch at 1720 cm-1 provided 
further evidence of successful functionalisation of amine 128 with α-azido-
hexacosanoyl chloride 117. Click reaction performed on azide 129 with linker 114 
resulted in the desired 1,2,3-triazole 130 as a 1:1 mixture of epimers.  
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Scheme 3.10. Synthesis of 1,4-disubstituted 1,2,3-triazole 130. 
 
Scheme 3.11 outlines the synthesis of target molecule 108. Treatment of 130 with 
TFA afforded amine 131, which was purified by chromatography and confirmed by 
HRMS. Amine 131 was next reacted with the 2,3,5,6-tetrafluorophenyl ester of 
Alexa Fluor® 488 124 in the presence of NEt3 in DMF. This reaction was 
performed, as previously, on 1 mg (Alexa Fluor® 488) scale. The product 108 was 
purified from the starting materials by flash column chromatography using a 
cartridge pre-packed with 100 mg of silica. Working on such small scale and with a 
mixture of epimers prevented us from obtaining full characterisation data of the 
product; however, we were able to confirm the formation of the product by HRMS.  
Chapter 3           Synthesis and Functional Activity of Labelled α-GalCer, ThrCer and 
Their Unsaturated Analogues 
133 
 
 
Scheme 3.11.  Synthesis of target molecule α-GalCer derivative labelled with Alexa 488 
108. 
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To summarise, we further optimised our glycosylation reaction by introducing 
2,3,4,6-tetra-O-p-methoxybenzyl-galactose 126 as a new donor precursor.  Since 
all the protecting groups in the glycoside product can be removed (in a single step) 
under acidic conditions, this modification opened up the possibility of coupling 
unsaturated carboxylic acids, which forms the subject of the next Section.  
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3.7.  Synthesis of α-GalCer(C20:2) labelled with Alexa 594 
 
With amine 128 in hand we could now focus on the preparation of α-azido-
eicosadienoic carboxylic acid. The high cost of cis-11,14-eicosadienoic acid (circa 
£100 / 100 mg, SIGMA-ALDRICH) encouraged us to develop a synthesis of α-
azido-eicosadienoic acid from the much cheaper linoleic acid (£43 / 5 g, SIGMA-
ALDRICH). For convenience, the α-azido acid would be synthesised in racemic 
form in the first instance, which would necessarily generate a final product as a 
mixture of a diastereoisomers. If necessary, an enantioselective route would be 
investigated at a later stage. 
The retrosynthetic analysis of (Z,Z)-2-azido-eicosa-11,14-dienoic acid 132 is 
outlined in Scheme 3.12. Starting from inexpensive cis-9,12-linoleic acid 138 
requires the addition of two carbons to the 18-carbon alkyl chain. These would be 
introduced sequentially, proceeding via aldehyde 135 (19-carbons in length), 
which would undergo a Strecker reaction to provide the corresponding α-amino-
nitrile 134 (20 carbons in total) and after subsequent hydrolysis, α-amino-
eicosadienoic acid 133. The final step in our approach would require an amine-
azide conversion in a diazo transfer reaction.90 Goddard-Borger et al. optimised 
this reaction for the preparation of α-azido acids from natural α-amino acids and 
therefore, we presumed it would also work as a final step in our synthesis of 132. 
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Scheme 3.12.  Retrosynthetic analysis of (Z,Z)-2-azido-eicosa-11,14-dienoic acid 132. 
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The Strecker reaction159,160  is a well-known method for preparing α-amino nitriles, 
from which the corresponding α-amino acids can be obtained by hydrolysis of the 
nitrile. Furthermore enantioselective variants of the reaction, employing chiral 
auxiliaries161,162 or asymmetric catalysts;163,164 opens up the possibility of rendering 
our route to 132 enantioselective at a later stage.  
 
Our synthesis of α-azido acid 132, began with the conversion of linoleic acid 138 
into its methyl ester, which was then reduced with LiAlH4 to the corresponding 
alcohol 139.165 In the next step, 139 was reacted with the Appel reagents (CBr4, 
PPh3) to provide bromide 137,
165 which, upon treatment with NaCN in DMSO,166 
afforded nitrile 136. DIBAL-H reduction, and subsequent hydrolysis of the 
intermediate imine, afforded aldehyde 135.167 The product was confirmed by 
HRMS and further evidenced by the 13C NMR spectrum, which showed the 
characteristic C=O resonance of an aldehyde at δ 202.8 ppm, and by the 1H NMR 
spectrum, in which the aldehyde proton appeared as a triplet [δ 9.77 ppm (1H, t, J 
1.9, CHO)]. IR analysis revealed an aldehyde C=O stretch at 1742 cm-1. 
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Scheme 3.13.  Synthesis of (Z,Z)-2-azido-eicosa-11,14-dienoic acid 132. 
 
In the next step, aldehyde 135 was converted to α-aminonitrile 134 using the 
Strecker reaction. The general mechanism of this transformation is summarised in 
Scheme 3.14. The first steps involve in situ generation of HCN from the cyanide 
salt and ammonium chloride and acid-catalysed imine formation. Cyanide anions 
react more rapidly with the iminium species than with the starting aldehyde, to 
generate an α-aminonitrile, which can then be hydrolysed to the corresponding α-
amino acid.  
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Scheme 3.14.  The general mechanism of the Strecker reaction. 
 
Aldehyde 135 underwent a one-pot Strecker reaction168 to afford racemic α-
aminonitrile 134 in a satisfactory 75% yield. The product was confirmed by HRMS. 
The 13C NMR spectrum of 134 showed a quaternary carbon resonance for the 
nitrile group at δ 122.2 ppm and only one CH resonance in the alkyl region at δ 
43.4 ppm. The product was further evidenced in the IR spectrum with a 
characteristic CN stretch at 2246 cm-1 and a broad amine stretch at 3343 cm-1. 
Nitrile 134 was then hydrolysed under basic conditions169 by heating with 40% 
aqueous potassium hydroxide solution for 8 hours, followed by work-up with 10% 
aqueous HCl solution, to provide crude α-amino acid 133, which was used in the 
next step without further purification. The final step involved conversion of 133 into 
the corresponding α-azido acid 132,90 which was evidenced by HRMS and 
confirmed by 13C NMR spectroscopic analysis, where the quaternary carbon 
resonance for the carboxylic acid group appeared at δ 176.1 ppm and the CH 
resonance for the α-carbon at δ 61.7 ppm. The IR spectrum showed a C=O stretch 
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at 1719 cm-1, a characteristic azide stretch at 2108 cm-1 and a very broad stretch 
for the O-H group in the range of 3400-2500 cm-1, providing further evidence of 
successful formation of target molecule 132. The two cis double bonds remained 
unchanged throughout the synthesis, and always appeared in the 13C NMR 
spectra as four CH resonances in the region of δ 128-130 ppm. 
 
We next converted carboxylic acid 132 into the corresponding acid chloride 140 
under mild reaction conditions (Scheme 3.15). Here we wanted to avoid heating 
the acid in neat oxalyl chloride††, conditions which might affect the skipped diene 
present in the acyl chain. Acid 132 was therefore reacted with two equivalents of 
oxalyl chloride in the presence of catalytic amount of DMF in dichloromethane at 0 
ºC.170   
 
 
 
Scheme 3.15.  Synthesis of acid chloride 140. 
 
                                               
††
 We had employed these conditions for the conversion of hexacosanoic acid 61 and α-azido-
hexacosanoic acid 132 into the corresponding acid chlorides. 
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Previously prepared intermediate amine 128 was successfully acylated with the 
resulting acyl chloride 140, affording amide 141 in 85% yield as a 1:1 mixture of 
epimers. Formation of the product 141 was evidenced by HRMS and in the 13C 
NMR spectrum by two characteristic amide C=O quaternary resonances for both 
epimers at δ 168.8 and δ 168.9 ppm. From this, the H-2‟‟ protons were identified 
by 2-D chemical shift-correlated spectroscopy (HMBC) and the resonances for the 
corresponding C(2‟‟) carbons for both epimers at δ 64.3 and δ 64.6 ppm (by 
HSQC). Four CH resonances for the two double bonds were identified in the 13C 
NMR spectrum at δ 127.9, 128.8, 130.0, 130.2 ppm. The IR spectrum showed a 
characteristic azido stretch at 2103 cm-1 and a carbonyl amide C=O stretch at 
1683 cm-1, providing further evidence of successful functionalisation of amine 128 
with α-azido acid chloride 140. Azide 141 underwent click reaction with linker 114, 
to afford the desired 1,2,3-triazole 142 as a 1:1 mixture of epimers.  
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Scheme 3.15.  Synthesis of advanced intermediate amine 143. 
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Treatment of 142 with TFA and purification by chromatography resulted in amine 
143, as confirmed by HRMS, which was reacted with the succinimidyl ester of 
Alexa Fluor® 594 carboxylic acid 144 in the presence of NEt3 in DMF. This reaction 
was performed as previously on 1 mg (1.2 μmol of Alexa Fluor® 594) scale. The 
amide product 109 was purified from the starting materials by flash column 
chromatography using a cartridge prepacked with 100 mg of silica. As was the 
case for 107 and 108, the small scale of this reaction, working with a mixture of 
epimers and now regioisomers‡‡ prevented us from obtaining full characterisation 
data of the product 109; however in the preliminary biological experiment this 
labelled glycolipid was found to activate iNKT cells in a similar way as its 
unlabelled derivative. 
                                               
‡‡
 Alexa Fluor
®
 594 succinimidyl ester is only available as a mixture of 5- and 6-regioisomers, 
which after reaction with our amine 143 results in formation of four possible products adding even 
more complexity to the spectroscopic data. 
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Scheme 3.16.  Synthesis of α-GalCer(C20:2) derivative 109 labelled with Alexa 594. 
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3.8.  Synthesis of ThrCer(C20:2) labelled with Alexa 594 
 
Our last target molecule ThrCer(C20:2) labelled with Alexa 594 110 was prepared 
in four steps as for α-GalCer derivative 109. The synthesis of 110 is outlined in 
Schemes 3.17 and 3.18. Amine 118 was first N-acylated with acid chloride 140 to 
provide amide 145 as a 1:1 mixture of epimers. The product 145 was confirmed by 
HRMS. Key spectroscopic signals included the amide carbonyl stretch in the IR 
spectrum at 1660 cm-1 and a characteristic azido stretch at 2100 cm-1. The amide 
functionality was further evidenced in the 13C NMR spectrum, which showed two 
characteristic quaternary carbon environments of a carbonyl for both epimers at δ 
168.9 ppm and at 168.9 ppm. Click reaction of azide 145 and previously prepared 
alkyne 114 proceeded uneventfully and with complete regioselectivity to afford the 
desired 1,4-disubstituted triazole 146 as a 1:1 mixture of epimers. Treatment of 
146 with TFA afforded amine 147, which was purified by chromatography and 
confirmed by HRMS. 
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Scheme 3.17.  Synthesis of ThrCer(C20:2) derivative 110 labelled with Alexa 594. 
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Amine 147 was then reacted with the succinimidyl ester of Alexa Fluor® 594 
carboxylic acid 144 in the presence of NEt3 in DMF. This reaction was again 
performed on 1 mg (Alexa Fluor® 594) scale. The amide product 110 was purified 
from the starting materials by flash column chromatography using a cartridge pre-
packed with 100 mg of silica. As was the case for 107, the small scale of this 
reaction, working with a mixture of epimers and regioisomers prevented us from 
obtaining full characterisation data of the product 110; however in the preliminary 
biological experiment this labelled glycolipid was also found to activate iNKT cells 
in a similar way as its unlabelled derivative ThrCer(C20:2). 
 
Alexa labelled glycolipids 107, 108, 109 and 110 were submitted for biological 
testing, which was carried out in the group of Prof. Vincenzo Cerundolo by Dr 
John-Paul Jukes and Dr Hemza Ghadbane at the Weatherall Institute of Molecular 
Medicine in Oxford, UK. 
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3.9.  Biological evaluation of Alexa-labelled glycolipids  
 
The Alexa-conjugated α-GalCer and ThrCer (C26 and C20:2) compounds 107-110 
were tested for their ability to stimulate iNKT cells. Splenocytes from C57 BL/6 
mice were pulsed with various concentrations of ligands. The concentration of 
IFNγ in the supernatant released after iNKT cell activation was measured using 
ELISA. The results of these experiments demonstrated that Alexa-conjugated α-
GalCer activated iNKT cells, although this was considerably weaker then the 
parent compound (Figure 3.7 A). Moreover, the Alexa-conjugated ThrCer were 
found to be inactive when cultured with C57 BL/6 splenocytes (Figure 3.7 A).  
In parallel, the Alexa-conjugated α-GalCer and ThrCer (C26 and C20:2) 
compounds 107-110 were further tested for their ability to bind to biotinylated 
tetramerised human iNKT TCR, as previously described by McCarthy et al.36 Thus, 
C1R-hCD1d cells were pulsed with lipids to determine the binding affinity of iNKT 
TCR tetramer (as determined by MFI) by FACS.  
 
The Alexa 594-labelled α-GalCer(C20:2) 109 was shown to bind as well as the 
parent compound 19 although the Alexa 488-conjugated α-GalCer(C26) 108 
bound considerably weaker than its parent compound α-GalCer 8 (Figure 3.7 B). 
Although the Alexa-conjugated ThrCer derivatives were found to be inactive when 
cultured with C57 BL/6 splenocytes (Figure 3.7 A), the binding assay showed only 
moderate binding with the Alexa 594-labelled ThrCer(C20:2) 110, and this was 
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considerably weaker for the Alexa 488-conjugated ThrCer(C26) 107, when 
compared to the parent compound (Figure 3.6 B).  
 
 
A  B  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.  Testing the activation of murine iNKT cells using Alexa-labelled α-
GalCer. Splenocytes from C57BL/6 mice were cultured for 48 hours in 
the presence of vehicle, α-GalCer(C26) 8, α-GalCer(C26) Alexa 488 
108, α-GalCer(C20:2) 19 and α-GalCer(C20:2) Alexa 594 109 in vitro 
(A). The supernatants were analysed for the presence of IFNγ by ELISA. 
C1R-hCD1d cells were pulsed with vehicle, α-GalCer(C26) 8, α-
GalCer(C26) Alexa 488 108, α-GalCer(C20:2) 19 and α-GalCer(C20:2) 
Alexa 594 109 to determine the binding affinity using biotinylated 
tetramerised iNKT TCR. Mean fluorescent intensity (MFI) as determined 
by fluorescence-activated cell sorting (FACS).  
 
    8,   α-GalCer                                                        
108,   α-GalCer(C26:0) Alexa 488                                                                                                                                  
s19,   α-GalCer(C20:2)                                
109,   α-GalCer(C20:2) Alexa 594         
Vehicle 
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A   B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8.   Testing the activation of murine iNKT cells using Alexa-labelled 
ThrCer. Splenocytes from C57BL/6 mice were cultured for 48 hours in 
the presence of vehicle, ThrCer (C26), ThrCer-Alexa 488 (C26), ThrCer 
(C20:2) and ThrCer-Alexa 594 (C20:2) in vitro (A). The supernatants 
were analysed for the presence of IFN-γ by ELISA. C1R-hCD1d cells 
were pulsed with vehicle, ThrCer (C26), ThrCer-Alexa 488 (C26), ThrCer 
(C20:2) and ThrCer-Alexa 594 (C20:2) to determine the binding affinity 
using biotinylated tetramerised iNKT TCR. Mean fluorescent intensity 
(MFI) as determined by FACS (B).  
 
 
Alexa-594-conjugated α-GalCer(C20:2) 109 showed comparable binding to hCD1d 
as the parent compound (C20:2) and was able to stimulate murine iNKT cells. 
However, the Alexa-594-conjugated ThrCer, despite binding in a cell-free system 
to hCD1d was inactive when tested with murine iNKT cells. Both Alexa-488-
conjugated α-GalCer and ThrCer were either significantly weaker (α-GalCer) or 
 24, ThrCer                                                          
107, ThrCer(C26:0) Alexa 488                    
ThrCer(C20:2)                                          
110, ThrCer(C20:2) Alexa 594    
Vehicle 
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inactive (ThrCer) in comparison to their corresponding parent compound in both 
assays.  
At this stage it is not clear why saturated derivatives 107 and 108 failed to activate 
iNKT cells whilst their unsaturated analogues showed activity and binding similar 
(or better) than the parent unlabelled compounds. It is unclear whether the Alexa-
488-conjugated analogues compromised binding and hence activation of iNKT 
cells or whether these compounds require C20:2 ceramides for binding and 
activity. Future work will assess the choice of the label and its effect on the 
solubility of the resulting conjugates. It was previously reported by Moqbel and co-
workers171 that in some cases the negative charge of fluorophores may cause a 
non-specific electrostatic interaction with positively charged cell structures. In 
these few cases, conventional neutral dyes, such as BODIPY FL, rhodamine, or 
Texas Red, may be better alternatives.133 Alexa 488 is doubly negative charged 
with diethylammonium counter ions, while Alexa 596 comes as a zwitterion. Based 
on the information provided in the introduction of this Chapter, it may be that the 
Alexa 594-labelled glycolipids are more easily presented to iNKT TCR at the 
surface of the cell, while Alexa 488-labelled glycolipids, like α-GalCer 8, require 
additional intracellular processing, which proves to be difficult for labelled 
compounds.  
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3.10.  Conclusions and future work 
 
We successfully synthesised biotinylated ThrCer 106 and showed that attaching a 
biotin label through a tri(ethylene glycol) spacer to the α-position of the N-acyl 
chain in ThrCer 24 generates a functionally active labelled analogue 106.  Whilst 
introducing a label at this site necessarily introduces a new stereogenic centre into 
the molecule, and therefore a mixture of diastereoisomers when racemic azido 
acid 116 is employed, these two epimers can be separated by careful 
chromatography.  
Continuation of this work in our group has since led to an enantioselective 
synthesis of (S)-2-azido-hexacosanoic acid, which provided biotinylated ThrCer 
106 as a single epimer of known configuration, allowing us to confirm the identity 
of the more active epimer B. Gratifyingly, this more active diastereoisomer 
corresponded to the more polar epimer prepared using racemic α-azido acid 116, 
which is in complete agreement with our predictions that this epimer should better 
orient the label away from the TCR and therefore have minimal impact on iNKT 
cell activity. 
The synthesis of ThrCer and α-GalCer analogues containing Alexa fluorescent 
labels proved to be challenging in respect to the small scale of the final step. 
However, we were able to provide two labelled derivatives that showed activity 
towards iNKT cells and which might be useful for in vivo imaging. The labelled 
derivatives of α-GalCer and ThrCer need to be further optimised and alternative 
labels will probably need to be examined. Ongoing work in the group involves 
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labelling α-GalCer and ThrCer with red Alexa 594, which should allow us to test 
whether or not the green Alexa 488 was the problem with α-GalCer 108 and 
ThrCer 107. 
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Synthesis and biological activity of Galp-α-(1→2)-ThrCer 
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4.  Synthesis and biological activity of Galp-α-(1→2)-ThrCer 
4.1.  Introduction to Galp-α-(1→2)-ThrCer  
 
Among the numerous analogues of α-GalCer, Galp-α-(1→2)-Galp-α-1-Cer 148 
(Figure 4.1) has proven to be a valuable tool for studying iNKT cell-mediated 
immunity. Galp-α-(1→2)-Galp-α-1-Cer 148 is a derivative of α-GalCer 8, in which 
the 2‟O-position of the galactose moiety is α-glycosylated with a second D-
galactose unit. Determination of the crystal structure of the iNKT TCR  hCD1d  α-
GalCer complex46 revealed an important role for the free hydroxyl group in the C-
2‟-position of α-GalCer (see Chapter 1.6), as this forms a hydrogen bond to the 
side-chain carboxylate of Asp151, which is crucial for the antigenicity of α-GalCer.   
 
 
Figure  4.1.  Structure of Galp-α-(1→2)-Galp-α-1-Cer 148. 
 
Although some disaccharide glycosphingolipid antigens can be recognised by 
iNKT TCR without prior processing, the responses to Galp-α-(1→2)-Galp-α-1-Cer 
148 require removal of the terminal galactose to permit interaction with the TCR.172 
In this case, a lysosomal enzyme, α-galactosidase A, is responsible for 
hydrolysing the terminal glycoside and generating the antigenic α-GalCer 8. 
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As it requires intracellular processing, Galp-α-(1→2)-Galp-α-1-Cer 148 has proven 
to be a very useful tool to assess the lipid antigen presentating capacity of 
professional antigen presenting cells, like dendritic cells.130 Indeed, it has been 
shown that cells bearing mutations in enzymes involved in glycosphingolipid 
processing have altered processing capacity of Galp-α-(1→2)-Galp-α-1-Cer 148 
because of engulfment and lysosomal storage.173 We have observed that 
presentation of Galp-α-(1→2)-Galp-α-1-Cer requires lipid transfer proteins 
belonging to the family of saposins.174 THP1 cells in which prosaposin has been 
inactivated by lentiviral transduction of shRNA sequences, are impaired in 
presentation of Galp-α-(1→2)-Galp-α-1-Cer 148 and partly of α-GalCer 8 but not of 
α-GalCer(C20:2) 19, which is efficiently loaded from the extracellular milieux.67 To 
further investigate the role of saposins in CD1d-mediated lipid antigen 
presentation, THP1 prosaposin deficient cells were pulsed with the non-glycosidic 
α-GalCer analogue ThrCer 24.123 In addition to being sensitive to cellular fixation, 
these experiments showed that this lipid is also dependent on saposin activity. We 
wished to extend these results using a galactosylated derivative of ThrCer. 
 
The synthesis of Galp-α-(1→2)-Galp-α-1-Cer 148 has been recently reported.175 
We decided to prepare the analogous Galp-α-(1→2)-ThrCer 149 (Figure 4.2), 
which we hoped would provide a similarly useful molecular tool for studying the 
biological pathways of this important non-glycosidic analogue of α-GalCer. In 
particular, this glycosylated ThrCer analogue would be useful for studying the 
kinetics and cellular site of glycolipid loading, which is known to play a critical role 
in dictating the outcome of iNKT cell activation.129   
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Figure 4.2.  Structure of target molecule Galp-α-(1→2)-ThrCer 149. 
 
 
Chapter 4                             Synthesis and biological activity of Galp-α-(1→2)-ThrCer 
158 
 
4.2.  Retrosynthetic analysis 
 
The retrosynthesis of Galp-α-(1→2)-ThrCer 149 is summarised in Scheme 4.1. We 
envisaged that the first step in the synthesis of our target molecule would involve 
formation of the disaccharide 153, which would be obtained from commercially 
available methyl 3,4-O-isopropylidene-L-threonate 154 and 2,3,4,6-tetra-O-p-
methoxybenzyl-D-galactose 126. The key challenge in this step would involve the 
stereoselective synthesis of the α-glycosidic linkage using a relatively hindered 
secondary alcohol as the glycosyl acceptor. Reduction of the ester to the primary 
alcohol in the resulting disaccharide, and formation of the corresponding triflate 
152 would then allow a Williamson etherification with a suitably protected 
phytosphingosine base 78. Unmasking the amine 150 and acylation with 
hexacosanoyl chloride 47 would complete the assembly of the four fragments, 
leaving a one-step global deprotection of the four PMB ether protecting groups 
and two acetals to deliver our target molecule 149. 
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Scheme 4.1.  Retrosynthetic analysis of Galp-α-(1→2)-ThrCer 149. 
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4.3.  Synthesis of Galp-α-(1→2)-ThrCer 
 
In Chapter 3.2 we demonstrated that PMB-protected galactose 126 worked well as 
the donor in a highly α-stereoselective glycosylation. Reaction of PMB-protected 
galactose 126 with methyl 3,4-O-isopropylidene-L-threonate 154 under our 
standard glycosylation conditions also provided the desired α-glycoside product 
155.  Unfortunately a second α-linked§§ disaccharide, with the same molecular 
weight, was also observed in the crude reaction mixture. Although we were unable 
to separate the two compounds by flash column chromatography, very careful 
analysis of the NMR spectra of the mixture revealed this second disaccharide 
product to be α-galactoside 156. Whilst this compound was the minor product 
when the reaction was performed on small scale (e.g. 0.5 mmol, ratio 155:156, 
3:2), it predominated when the glycosylation was scaled up (e.g. 1.85 mmol scale, 
ratio 155:156, 1:3).   
 
 
 
 
 
 
 
 
                                               
§§
  The small vicinal coupling constant between H-1‟ and H-2‟ in this disaccharide by-product 
allowed assignment of the α-configuration [δH 5.09 ppm (1H, d, J1,2  3.7 Hz, H-1‟)]. 
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Scheme 4.2.  Synthesis of disaccharide 155. 
 
The easiest resonance to assign in the 13C NMR spectrum of glycosides is the 
anomeric carbon (C-1‟), which usually appears in the region 90-110 ppm. We 
found two resonances in that region when we analysed a 1:3 mixture of 
disaccharides 155 and 156: one resonance for the minor product appeared at δ 
96.0 ppm, and a second at δ 98.2 ppm for the major component of the mixture. 
From this, the corresponding anomeric protons [δ 5.09 ppm (1H, d, J 3.7, H-1‟) 
and δ 4.91 ppm (1H, d, J1,2  3.5 Hz, H-1‟), respectively] were then identified by 2-D 
chemical shift-correlated spectroscopy (HSQC). Both doublet resonances have 
small J1,2 coupling constants confirming an α-glycosidic linkage in both products. 
An HMBC experiment revealed strong cross-peaks of 3JC-H coupling for both 
anomeric carbons, which correlated to two different proton environments in the 
threitol portion of the molecule (Figure 4.3). The anomeric carbon at δ 98.2 
correlated to a proton resonance in the 1H NMR spectrum [δ 3.65 ppm (1H, dd, J 
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11.6, 5.0)], which was assigned by HSQC and COSY experiments as C(4)HaHb of 
the undesired 156 disaccharide. In the same way, the resonance at δ 96.1 ppm 
correlated to the H2 resonance [δ 4.27 ppm (1H, d, J 7.0)]. Thus the major product 
in this mixture was the undesired disaccharide 156. 
 
 
 
 
 
 
Figure 4.3.   HMBC was crucial for assigning the minor 155 and major 156 
disaccharides in the mixture. 
 
Aside from generating the reactive glycosyl bromide in situ, the Appel agents 
(PPh3 and CBr4) in the glycosylation reaction serve two other useful roles: they 
function as a scavenger for adventitious water, and when used in excess, are 
capable of re-generating the active donor from any product that is trapped initially 
by water rather than the acceptor. However, one of the by-products from this 
dehydrative glycosylation pathway is HBr, which in our case, presumably 
catalyses the translational isomerisation of the isopropylidene acetal in 154 from 
the terminal to the internal 1,2-diol, allowing the remaining primary alcohol to 
function as a (more reactive) second glycosyl acceptor (Scheme 4.3). Fortunately, 
we were able to suppress completely this undesirable side-reaction by including 
Hünig‟s base as an acid scavenger in the glycosylation reaction mixture.99 Under 
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these modified conditions, the desired disaccharide 155 was isolated in a 
satisfactory 45% yield as a single -stereoisomer.  
 
Scheme 4.3.   Proposed mechanism of the acid-catalysed isopropylidene acetal 
migration in 154. 
 
With disaccharide 155 in hand, reduction of the ester with LiAlH4 afforded primary 
alcohol 153 in 92% yield. We next decided to combine disaccharide 153 with a 
phytosphingosine coupling partner using a Williamson etherification. Applying the 
same method as had been used successfully in the synthesis of ThrCer 24 (see 
Chapter 2.7), we envisaged converting the primary alcohol of the disaccharide 153 
into the corresponding triflate and reacting this with the alkoxide of 
phytosphingosine 78 would deliver our desired product. 
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Scheme 4.4.  Unsuccessful attempt at triflate formation using alcohol 153. 
 
Unfortunately the corresponding triflate 152 proved to be unstable (Scheme 4.4) 
and we were unable to effect Williamson ether formation. The colour of the 
reaction mixture turned from colourless to black immediately after adding an 
equimolar amount of triflic anhydride to the solution of 153 and 2 equivalents of 
acid scavenger, 2,6-di-tert-butyl-4-methylpyridine (DTBMP), at 0 ºC in 
dichloromethane. TLC analysis of the resulting reaction mixture revealed the 
formation of more than four by-products, which were difficult to separate. The 1H 
NMR spectrum of the crude reaction mixture was also too complicated to assign 
any of the by-products; however, a significant reduction of resonances in the 
aromatic proton region, when compared with the 1H NMR spectrum of the starting 
material 153, suggested partial deprotection of the PMB groups. 
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We next wanted to check whether or not the etherification step would work if the 
triflate were formed on the phytosphingosine instead. Applying the same reaction 
conditions as before, but this time using alcohol 78, TLC analysis of the reaction 
mixture showed the formation of a less polar product, suggesting that triflate 
formation had been successful. However, its reaction with the sodium alkoxide of 
the alcohol in disaccharide 153 provided none of the desired etherification product. 
 
 
Scheme 4.5.   Reversing the electrophile and nucleophile coupling partners failed to 
provide the desired ether product. 
  
At this juncture, whilst a range of other coupling partners could have been 
investigated, we had concurrently been investigating the glycosylation reaction 
using 2,3,4,6-tetra-O-benzyl-D-galactose 51 as the latent glycosyl donor. Under 
our optimised reaction conditions, where Hünig‟s base was employed as an acid 
scavenger to prevent acetal migration in the threonate acceptor, the desired 
disaccharide 157 was obtained in a moderate 45% yield, again as a single α-
anomer (Scheme 4.6). We were not surprised that the isolated yield was lower 
than for the α-selective glycosylation reaction employed in the synthesis of α-
GalCer (64%, see Chapter 2.3) as the sterically hindered secondary alcohol of 
acceptor 154 is less reactive than the primary alcohol of phytosphingosine 78. 
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Moreover, separating the product 157 from the unreacted starting materials proved 
to be difficult, and prevented us from using an excess of the acceptor, which could 
also account for the observed lower yield.  
LiAlH4 effected reduction of the ester in 157 to provide alcohol 158 in 95% yield, 
which was converted into triflate 159 by treatment with Tf2O in the presence of the 
acid scavenger, 2,6-di-tert-butyl-4-methylpyridine (DTBMP). As expected, triflate 
159 proved to be more stable than its analogue containing PMB protecting groups; 
however it was still used directly and without purification in the etherification step 
with the sodium alkoxide of alcohol 78 (Scheme 4.7).124  
 
 
 
Scheme 4.6.  Synthesis of triflate 159. 
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Using this pairing, the desired ether 160 was isolated in 72% over the two steps 
from alcohol 78. Further processing to the target was straightforward: Staudinger 
reduction105,124 of the azide in 160 provided the corresponding amine 161 in 86% 
yield, which was acylated with hexacosanoyl chloride 47, prepared as before, from 
the reaction of hexacosanoic acid with oxalyl chloride,120 to provide amide 162 in 
85% yield.  A two-step deprotection involving acetal hydrolysis with aqueous 
trifluoroacetic acid, followed by hydrogenolysis of the remaining benzyl ethers, 
delivered our target Galp-α-(1→2)-ThrCer 149 in 75% yield over the two steps 
(Scheme 4.7). 
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Scheme 4.7.  Synthesis of Galp-α-(1→2)-ThrCer 149. 
 
Our target compound Galp-α-(1→2)-ThrCer 149, was submitted for biological 
testing. This work was carried out in the group of Prof. Vincenzo Cerundolo by Dr 
Mariolina Salio at the Weatherall Institute of Molecular Medicine in Oxford, UK. 
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4.4.  Biological evaluation of Galp-α-(1→2)-ThrCer 
Human monocyte-derived dendritic cells (DC) (50000/well) were pulsed with the 
indicated concentrations of lipids and then a human iNKT cell line was added 
(30000 cell/well). Supernatants were harvested after 36 hours and assayed for 
human IFNγ by ELISA. 
 
 
 
Figure 4.4.   Activation of human iNKT cells using Galp-α-(1→2)-Galp-α-1-Cer, 
Galp-α-(1→2)- hr er,  hr er, α-GalCer.  C1R-hCD1d cells were 
pulsed with various concentrations of Galp-α-(1→2)-Galp-α-1-Cer 148, 
Galp-α-(1→2)-ThrCer 149, ThrCer 24, α-GalCer 8 as indicated and used 
to stimulate human iNKT cells in vitro. The supernatants were tested for 
IFNγ . 
 
 
Unpulsed         148            148             149              149          ThrCer        ThrCer       α-GalCer  
                      1 μg/ml       0.2 μg/ml      3 μg/ml      1 μg/ml       1 μg/ml        0.3 μg/ml       50 ng/ml 
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These results demonstrate that Galp-α-(1→2)-ThrCer is presented by DC, albeit 
weakly, and recognised by iNKT cells. 
In another experiment, DC were differentiated from bone marrow precursors of 
wild type and CD1d/NKT deficient mice for 4 days in 1 ng/ml GM-CSF. DC 
(33000/well) were pulsed for 16 hours with 20 ng/ml α-GalCer, 200 ng/ml Galp-α-
(1→2)-Galp-α-1-Cer, 200 ng/ml ThrCer, 1 µg/ml Galp-α-(1→2)-ThrCer in the 
presence or absence of 1mM 1-deoxygalactonojirimycin (DGJ) to inhibit α-
galactosidase A activity. The cells were extensively washed and incubated with 
the iNKT hybridoma DN32 (30000 cell/well). Supernatants were harvested after 36 
hours and IL-2 secretion measured by ELISA. 
 
 
Figure 4.5.  Activation of murine iNKT cells using Galp-α-(1→2)-Galp-α-1-Cer, 
Galp-α-(1→2)- hr er,  hr er, α-GalCer. C1R-mCD1d cells were 
pulsed with various concentrations of Galp-α-(1→2)-Galp-α-1-Cer 148, 
Galp-α-(1→2)-ThrCer 149, ThrCer 24, α-GalCer 8 as indicated and used 
to stimulate the DN32 hybridoma in vitro. The supernatants were tested 
for the presence of IL-2. 
 
Unpulsed     α-GalCer           148              149               ThrCer             
                      20 ng/ml       200 ng/ml     1 μg/ml           200 ng/ml       
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These results demonstrate that Galp-α-(1→2)-ThrCer is processed in a α-
galactosidase A-dependent manner, as presentation is abrogated by treatment 
with DGJ mice (which are deficient in α-galactosidase A). 
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4.5.  Conclusions and future work 
 
We have successfully completed a stereoselective synthesis of the target 
molecule Galp-α-(1→2)-ThrCer 149. In the key step in our synthesis, namely the 
α-glycosylation, we found that incorporation of an acid scavenger was important to 
prevent acetal migration in the acceptor 154. 
 
Preliminary immunological assays have shown that this compound is active and 
requires intracellular processing by an α-galactosidase enzyme, which requires as 
cofactor lipid transfer proteins belonging to the saposin family. 
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5.  Experimental Section 
5.1     General Experimental 
Optical rotations were measured using an Optical Activity PolAAr2001 automatic 
polarimeter. Melting points were determined using open capillaries on a 
Gallenkamp MPD350 melting point apparatus and are uncorrected. Infrared 
spectra were recorded either neat as thin films between NaCl discs, on a Perkin 
Elmer 1600 FTIR spectrometer, or neat on a Perkin Elmer Spectrum 100 fitted 
with a universal ATR accessory. The intensity of each band is described as s 
(strong), m (medium) or w (weak), and with the prefix v (very) and suffix br (broad) 
where appropriate. 1H-NMR spectra were recorded at 500 MHz, 400 MHz, or 300 
MHz, using Bruker DRX 500, Bruker AMX 400, Bruker AV 400, Bruker AV 300 and 
Bruker AC 300 spectrometers. 13C-NMR spectra were recorded at 125 MHz, 100 
MHz, or 75 MHz, respectively, using Bruker DRX 500, Bruker AMX 400, Bruker AV 
400, Bruker AV 300 and Bruker AC 300 spectrometers. Chemical shifts are 
reported as values (ppm) referenced to the following solvent signals: CHCl3, H 
7.26; CDCl3, C 77.0; CH3OH, H 3.34; CD3OD, C 49.9. The term "stack" is used 
to describe a region where resonances arising from non-equivalent nuclei are 
coincident, and multiplet, m, to describe a region where resonances arising from a 
single nucleus (or equivalent nuclei) are coincident but coupling constants cannot 
be readily assigned. Mass spectra were recorded on a Micromass LCT 
spectrometer utilising electrospray ionisation (and a MeOH mobile phase), and are 
reported as (m/z (%)). HRMS were recorded on a Micromass LCT spectrometer 
using a lock mass incorporated into the mobile phase. 
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All reagents were obtained from commercial sources and used without further 
purification unless stated otherwise. Anhydrous solvents were purchased from 
Sigma-Aldrich UK, stored over 4 Å molecular sieves and under an Ar atmosphere. 
All solutions are aqueous and saturated unless stated otherwise. 
Reactions were monitored by TLC using pre-coated aluminium-backed ICN silica 
plates (60A F254) and visualised by UV detection (at 254 nm) and staining with 5% 
phosphomolybdic acid in EtOH (MPA spray). Column chromatography was 
performed on Merck silica gel (particle size 40-63 m mesh) or Fluka 60 (40-60 m 
mesh) silica gel.  
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(2S,3S,4R)-2-Azido-octadecane-1,3,4-triol (58) 
 
 
Amine 54 (5.00 g, 15.6 mmol), CuSO4·5H2O (40 mg, 0.16 mmol), and K2CO3 (3.23 
g, 23.4 mmol) were dissolved in H2O (50 mL) and the mixture stirred for 10 min at 
r.t.  A solution of imidazole-1-sulfonyl azide hydrochloride90 (6.00 g, 28.1 mmol, 
CAUTION: potential explosion risk during purification of this reagent) in CH2Cl2 (50 
mL) was then added with vigorous stirring.  CH3OH (150 mL) was then added over 
30 min through a dropping funnel. After 20 min, the resulting slurry became a 
transparent pale blue solution, which was stirred vigorously at r.t. for a further 18 
h. The mixture was then diluted with CHCl3 (400 mL). The phases were separated 
and the organic phase was extracted with H2O (2  350 mL). The combined 
organic phases were dried with Na2SO4 and the volatiles were removed under 
reduced pressure. The crude azide product was re-dissolved in a CHCl3 / CH2Cl2 
mixture (5:1, 16 mL) and filtered through a silica plug, washing with EtOAc / 
acetone (9:1) until complete elution of the product.  Removal of the solvent under 
reduced pressure afforded azide 58 as a white solid (4.95 g, 91%): Rf = 0.7 
(eluent: EtOAc); mp 92 – 94 C, (lit. mp 90 C);176 []D
22 + 9.6 (c = 1.0, CHCl3) (lit. 
[]D
25 + 10 (c = 1, CHCl3);
177 max(film) / cm
-1 3261 br (OH), 2916s, 2847s, 2096s 
(N3), 1590w, 1461m, 1248m, 1099w, 1058s, 1008m, 923w, 857m, 723s; H(300 
MHz, CDCl3/CD3OD, 2:1) 0.66 (t, J 6.5, 3H, CH3CH2), 0.95-1.22 (stack, 24H, CH2), 
1.37-1.42 (stack, 2H, CH(OH)CH2CH2), 3.34-3.39 (stack, 3H), 3.58 (dd, J  6.1, 5.7, 
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1H), 3.72 (dd, J  3.9, 3.7, 1H); C(75 MHz, CDCl3/CD3OD, 2:1) 14.4 (CH3, 
CH2CH3), 23.7 (CH2), 26.7 (CH2), 30.5 (CH2), 30.7 (CH2), 30.8 (CH2), 33.1 (CH2), 
33.9 (CH2), 62.5 (CH2, CH2OH), 66.6 (CH, CHN3), 72.9 (CH, CHOH), 76.0 (CH, 
CHOH), some overlap in the methylene resonances; MS (TOF ES+) m/z 366.2 ([M 
+ Na]+, 100%); HRMS (TOF ES+) calcd for C18H37N3O3Na [M + Na]
+ 366.2733, 
found 366.2728. 
 
Data were in agreement with those reported in the literature.124,176 
 
 
(2S,3S,4R)-2-Azido-1-O-trityl-octadecane-1,3,4-triol (59) 
 
 
 
TrCl (4.43 g, 15.9 mmol) was added to a solution of alcohol 58 (5.20 g, 15.5 mmol) 
in pyridine (30 mL) at r.t. The reaction mixture was stirred for 21 h at r.t. and then 
the solvent was removed under reduced pressure to provide the crude product. 
Purification by flash column chromatography (15% EtOAc in hexane) afforded trityl 
ether 59 as a pale yellow oil (5.45 g, 60%): Rf = 0.3 (15% EtOAc in hexane); []D
18 
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= +10.5 (c = 1.0, CHCl3) (lit. []D
20 = +8.9 (c = 1, CHCl3);
96 max(film)/cm
-1 3291 (br 
OH), 2915s, 2848s, 2096m (N3), 1463m, 1447m, 1249m, 1216w, 1152w, 1099w, 
1071m, 1059w, 1010w, 929w, 909w, 757s, 723m, 700s, 667w; H(300 MHz, 
CDCl3) 0.88 (t, J 7.0, 3H, CH3CH2), 1.18-1.34 (stack, 23H), 1.36-1.57 (stack, 3H), 
1.81 (d, J 5.7, 1H, OH), 2.35 (d, J 5.0, 1H, OH), 3.38-3.45 (m, 1H), 3.49-3.59 
(stack, 2H), 3.60-3.69 (stack, 2H), 7.20-7.37 (stack, 9H, Ph), 7.40-7.51 (stack, 6H, 
Ph); C(75 MHz, CDCl3) 14.1 (CH3, CH3CH2), 22.7 (CH2), 25.6 (CH2), [29.4, 29.6, 
29.7 (CH2, resonance overlap)], 31.7 (CH2), 31.9 (CH2), 62.3 (CH, CHN3), 63.5 
(CH2, CH2OTr), 72.2 (CH, CHOH), 74.2 (CH, CHOH), 87.8 (C, CPh3), 127.3, 
128.0, 128.5, (CH, Ph)], 137.4 (C, ipso Ph); MS (TOF ES+) m/z 608.5 ([M + Na]+, 
100%); HRMS (TOF ES+) calcd for C37H51N3O3Na [M + Na]
+ 608.3828, found 
608.3836. 
 
Data were in agreement with those reported in the literature.96 
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(2S,3S,4R)-2-Azido-3,4-di-O-benzyl-1-O-trityl-octadecane-1,3,4-triol (60) 
 
 
 
NaH (1.095 g of a 60 wt % suspension in mineral oil, 18.24 mmol) was added to a 
solution of alcohol 59 (4.45 g, 7.60 mmol) in DMF (38 mL) at r.t.  The reaction 
mixture was stirred for 30 min and then cooled to 0 °C.  BnBr (1.99 mL, 16.7 
mmol) was added dropwise over 3 min and the reaction mixture was stirred for 15 
h at r.t.  H2O (40 mL) was then added and the mixture was extracted with Et2O (2 
 20 mL) and then dried over Na2SO4. The drying agent was removed by filtration 
and the filtrate concentrated under reduced pressure. Purification of the residue by 
flash column chromatography (5% EtOAc in hexane) afforded dibenzyl ether 60 as 
a yellow oil (4.66 g, 80%): Rf = 0.3 (5% EtOAc in hexane); []D
18 = +4.9 (c = 1, 
CHCl3) (lit. []D
20 = +6.4 (c = 1, CHCl3));
96 max(film)/cm
-1 2923s, 2853s, 2095s 
(N3), 1491m, 1449m, 1315w, 1265w, 1209w, 1065s, 899w, 744m, 696s, 632m; 
H(300 MHz, CDCl3) 0.88 (t, J 6.9, 3H, CH3CH2), 1.14-1.34 (stack, 23H), 1.35-1.62 
(stack, 3H), 3.32-3.41 (stack, 2H), 3.43-3.57 (stack, 3H), 4.37-4.60 (stack, 4H, 
CH2Ph), 7.04-7.11 (stack, 3H, Ph), 7.14-7.32 (stack, 15H, Ph), 7.35-7.47 (stack, 
7H, Ph); C(75 MHz, CDCl3) 14.1 (CH3, CH3CH2), 22.7 (CH2), 25.3 (CH2), [29.4, 
29.7 (CH2, resonance overlap)], 31.9 (CH2), 63.2 (CH, CHN3), 64.3 (CH2, 
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CH2OTr), 72.0 (CH2, CH2Ph), 73.5 (CH2, CH2Ph), 79.2 (CH, CHOBn), 79.4 (CH, 
CHOBn), 87.2 (C, CPh3), 127.0, 127.5, 127.6, 127.8, 128.2, 128.3, 128.7 (CH, 
Ph, resonance overlap)], 137.9 (C, ipso Ph), 138.3 (C, ipso Ph,), 143.7 (C, ipso 
Ph); MS (TOF ES+) m/z 788.5 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for 
C51H63N3O3Na [M + Na]
+ 788.4767, found 788.4774. 
 
Data were in agreement with those reported in the literature.96 
 
 
 
(2S,3S,4R)-2-Azido-3,4-di-O-benzyl-octadecane-1,3,4-triol (52) 
 
 
 
A solution of trityl ether 60 (4.61 g, 6.02 mmol) and p-TsOH (170 mg, 0.90 mmol) 
in CH2Cl2 / MeOH (60 mL, 3:1) was stirred for 16 h at r.t.  The reaction mixture 
was then washed with NaHCO3 solution (20 mL).  The phases were separated and 
the aqueous phase was extracted with EtOAc (2  20 mL) and dried over Na2SO4. 
The drying agent was removed by filtration and the filtrate concentrated under 
reduced pressure. Purification of the residue by flash column chromatography 
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(10% EtOAc in hexane) afforded alcohol 52 as a colourless oil (84%, 2.65 g): Rf = 
0.2 (10% EtOAc in hexane); []D
17
 = + 5.5 (c 1, CHCl3) (lit. []D
20 = + 5.7 (c = 1, 
CHCl3));
96 max(film)/cm
-1 3428m (br, OH), 3088w, 3063m, 3030m, 2603, 2532w, 
2496w, 2366w, 2335w, 2099s (N3), 1944w, 1887w, 1810w, 1741w, 1682w, 1644w, 
1606w, 1496m, 1454s, 1326m, 1264m, 1208m, 1071s, 1028s, 912w, 844w, 735s, 
697s, 608m; H(300 MHz, CDCl3) 0.89 (t, J 6.4, 3H, CH3), 1.18-1.48 (stack, 24H, 
alkyl chain), 1.50-1.62 (m, 1H), 1.63-1.75 (m, 1H), 2.55 (app t, J 6.6, 1H, OH), 
3.61-3.74 (stack, 3H), 3.75-3.84 (m, 1H), 3.86-3.95 (m, 1H), 4.55-4.65 (stack, 2H,  
OCH2Ph), 4.66-4.74 (stack, 2H, OCH2Ph), 7.31-7.37 (stack, 10H, Ph); C(75 MHz, 
CDCl3) 14.1 (CH3, CH2CH3), 22.6, 25.4, 29.3, 29.6, 30.1, 31.9 (CH2, alkyl chain, 
resonance overlap), 62.1 (CH2, CH2OH), 63.1 (CH, CHN3), 72.3 (CH2, CH2Ph), 
73.5 (CH2, CH2Ph), 78.9 (CH, CHOBn), 80.1 (CH, CHOBn), 127.7, 127.9, 128.0, 
128.3, 128.4 (CH, Ph, resonance overlap)], 137.4 (C, ipso Ph), 137.9 (C, ipso Ph); 
MS (TOF ES+) m/z 546.3 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for 
C32H49N3O3Na [M + Na]
+ 546.3672, found 546.3657. 
 
Data were in agreement with those reported in the literature.96  
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(2S,3S,4R)-2-Azido-3,4-O-isopropylidene-octadecane-1,3,4-triol (78) 
 
 
 
98% H2SO4 (200 µL) was added dropwise over 2 min to a solution of triol 58 (509 
mg, 1.49 mmol) in dry acetone (10 mL) at 0 °C.  After 30 min, the reaction mixture 
was carefully poured into saturated NaOH solution (1 mL), and then evaporated to 
dryness under reduced pressure.  The residue was extracted with EtOAc (15 mL).  
The organic phase was washed with brine (3 mL), and then dried over Na2SO4.  
Concentration of the filtrate under reduced pressure and purification of the residue 
by flash column chromatography afforded acetal 78 as a white, low-melting point, 
amorphous solid (412 mg, 72%): Rf = 0.3 (25% EtOAc in hexane); []D
21 = +27.5 (c 
= 1.0, CHCl3) (lit. []D
22 +23 (c = 1.0, CHCl3);
124 max(film) / cm
-1 3414 br (OH), 
2919s, 2850s, 2095s (N3), 1471m, 1382m, 1370m, 1261m, 1208m, 1102m, 1019s, 
883m, 826w, 718m; H(300 MHz, CDCl3) 0.88 (t, J 6.0, 3H, CH2CH3), 1.26-1.30 
(stack, 23H), 1.34 (s, 3H, 1  C(CH3)2), 1.43 (s, 3H, 1  C(CH3)2), 1.50-1.63 (stack, 
3H), 2.08 (app. t, J 6.0, 1H, CH2OH), 3.44-3.50 (m, 1H), 3.83-3.91 (m, 1H), 3.94-
4.03 (stack, 2H), 4.15-4.21 (m, 1H); C(75 MHz, CDCl3) 14.1 (CH3, CH2CH3), 25.5 
(CH3, 1  C(CH3)2), 26.5 (CH2), 28.0 (CH3, 1  C(CH3)2), 29.35 (CH2), 29.41 (CH2), 
29.53 (CH2), 29.58 (CH2), 29.59 (CH2), 29.65 (CH2), 29.68 (CH2), 29.69 (CH2), 
31.9 (CH2), 61.2 (CH, CHN3), 63.9 (CH2, CH2OH), 76.6 (CH, CHO), 77.7 (CH, 
CHO), 108 (C, C(CH3)2), some overlap in the methylene resonances; MS (TOF 
Chapter 5         Experimental Section 
183 
 
ES+) m/z 406.2 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for C21H41N3O3Na [M 
+ Na]+ 406.3046, found 406.3033. 
 
Data were in agreement with those reported in the literature.124  
 
 
(2S,3R,4R)-2-Azido-3,4-di-O-benzyl-1-O-(2’,3’,4’,6’-tetra-O-benzyl-α-D-
galactopyranosyl)octadecane-1,3,4-triol (50) 
 
 
 
Ph3P (1.46 g, 5.55 mmol) and CBr4 (1.84 g, 5.55 mmol) were added sequentially to 
a solution of 2,3,4,6-tetra-O-benzyl-D-galactose 51 (1.00 g, 1.85 mmol) in CH2Cl2 
(10 mL) at r.t. The reaction mixture was stirred for 3 h.  In separate flasks, a 
solution of tetramethyl urea (TMU) (1.2 mL) and Bu4NBr (1.79 g, 5.55 mmol) in 
CH2Cl2 (5 mL), and a solution of azide 52 (1.46 g, 2.78 mmol) in CH2Cl2 (5 mL), 
were stirred over activated 3 Å MS for 30 min, after which time, these solutions 
were added dropwise (15 min) via syringe sequentially (TMU/Bu4NBr solution first) 
to the solution containing the glycosyl donor. The reaction mixture was stirred at 
r.t. for 3 d until the donor was no longer being consumed (as judged by TLC). The 
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reaction mixture was then filtered through a silica plug, washed with CH2Cl2 (1.2 L) 
and concentrated under reduced pressure to provide the crude product. 
Purification of the residue by flash column chromatography (8% EtOAc in hexane) 
afforded glycoside 50 as a colourless oil (1.21 g, 62%, -anomer only):  Rf = 0.3 
(8% EtOAc in hexane); []D
18 + 22 (c 1.4, CH2Cl2) (lit []D
20
 = + 26 (c 1.4, 
CH2Cl2));
178 max(film)/cm
-1 2988s, 2972s, 2923s, 2854m, 2097m (N3), 1721m, 
1704m, 1602w, 1585w, 1496w, 1454m, 1405m, 1394m, 1380m, 1314m, 1262s, 
1155m, 1066s, 1056s, 1027s, 904m, 805m, 734s, 711s; H(500 MHz, CDCl3) 0.90 
(3H, t, J 6.9, CH2CH3), 1.20-1.35 (23H, stack, alkyl chain methylenes), 1.35-1.45 
(m, 1H, alkyl chain CHaHb), 1.50-1.58 (m, 1H, C(5)HaHb), 1.63-1.71 (m, 1H, 
C(5)HaHb), 3.47-3.54 (stack, 2H, C(6‟)HaHb), 3.60-3.63 (m, 1H, H-4), 3.71-3.76 
(stack, 3H, C(1)HaHb, H-2, H-3), 3.94-3.98 (stack, 2H, H-4‟, H-5‟), 3.98-4.04 (stack, 
2H, H-3‟, C(1)HaHb), 4.08 (dd, J 10.0, 3.5, 1H, H-2‟), 4.37 (A of AB, J 11.8, 1H, 
C(6‟)OCHaHbPh), 4.45 (B of AB, J 11.8, 1H, C(6‟)OCHaHbPh), 4.48 (A of AB, J 
11.6, 1H, C(4)OCHaHbPh), 4.57-4.59 (stack, 2H, C(4)OCHaHbPh, 
C(4‟)OCHaHbPh), 4.63 (A of AB, J 11.3, 1H, C(3)OCHaHbPh), 4.67 (B of AB, J 
11.3, 1H,  C(3)OCHaHbPh), 4.69 (A of AB, J 12.0, 1H, C(2‟)OCHaHbPh), 4.74 (A of 
AB, J 11.5, 1H, C(3‟)OCHaHbPh), 4.81 (B of AB, J 12.0, 1H, C(2‟)OCHaHbPh), 4.84 
(B of AB, J 11.5, 1H, C(3‟)OCHaHbPh), 4.91 (d, J 3.5, 1H, H-1‟), 4.95 (d, J 11.5, 
1H, C(4‟)OCHaHbPh), 7.22-7.40 (stack, 30H, 6  Ph); C(125 MHz, CDCl3) 14.1 
(CH3, CH2CH3), 22.6, 25.3, 29.3, 29.6, 29.9, 31.9 (CH2, alkyl chain, resonance 
overlap), 61.9 (CH, C-2), 68.4 (CH2, C-1), 68.9 (CH2, C-6‟), 69.6 (CH, C-5‟), 71.9 
(CH2, C(4)OCH2Ph), 73.0 (CH2, C(3‟)OCH2Ph), 73.1 (CH2, C(2‟)OCH2Ph), 73.3 
(CH2, C(6‟)OCH2Ph), 73.6 (CH2, C(3)OCH2Ph), 74.7 (CH2, C(4‟)OCH2Ph), 75.0 
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(CH, C(4‟)), 76.3 (CH, C(2‟)), 78.7 (CH, C(3‟)), 78.8 (CH, C(3)), 79.2 (CH, C(4)), 
98.6 (CH, C(1‟)), 127.3, 127.4, 127.56, 127.60, 127.7, 127.8, 128.1, 128.2 (CH, 
Ph, resonance overlap)], 137.9 (C, ipso Ph), 138.0 (C, ipso Ph), 138.3 (C, ipso 
Ph), 138.58 (C, ipso Ph), 138.63 (C, ipso Ph), 138.7 (C, ipso Ph); MS (TOF ES+) 
m/z 1068.8 ([M + Na]+, 100%); HRMS (TOF ES+) 1068.6063 [M + Na]+, 
C66H83N3O8Na requires 1068.6078; and then unreacted azide 52 was also 
recovered (445 mg, 45%). 
 
Data were in agreement with those reported in the literature for 50 prepared by a 
different route.178  
 
 
(2S,3S,4R)-2-Amino-3,4-di-O-benzyl-1-O-(2’,3’,4’,6’-tetra-O-benzyl-α-D-
galactopyranosyl)octadecane-1,3,4-triol (46) 
 
 
 
PMe3 (455 L of a 1.0 M soln in THF, 0.46 mmol) was added dropwise over 5 min 
to a solution of azide 50 (433 mg, 0.414 mmol) in THF (3.5 mL). The reaction 
mixture was stirred at r.t. for 4 h after which time, H2O (3 mL) was added. The 
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reaction mixture was stirred for 1 h and then concentrated under reduced 
pressure. The residual H2O was removed by co-evaporation with toluene (3  3 
mL) to provide the crude product. Purification of the residue by flash column 
chromatography (35% EtOAc in hexane) afforded amine 46 as a white solid (300 
mg, 72%), which was used directly without further purification. Selected data: Rf = 
0.3 (35% EtOAc in hexane); MS (TOF ES+) m/z 1020.5 ([M + H]+, 100%); HRMS 
(TOF ES+) calcd for C66H86NO8 [M + H]
+ 1020.6353, found 1020.6357. 
 
 
(2S,3S,4R)-3,4-Di-O-benzyl-1-O-(2’,3’,4’,6’-tetra-O-benzyl-α-D-galacto-
pyranosyl)-2-(hexacosanoylamino)octadecane-1,3,4-triol (62) 
 
 
 
A screw-capped glass tube containing a solution of hexacosanoic acid 61 (240 
mg, 0.580 mmol) in (COCl)2 (2.0 mL, 23 mmol) was closed tightly and heated at 70 
ºC for 2 h.  After 2 h, the volatiles were removed under a stream of N2 and the 
residual solvent removed on the vacuum line (1 h) to provide hexacosanoyl 
chloride 47 as a pale yellow oil, which was used directly in the next step without 
further purification (265 mg, quant.):  a solution of freshly prepared hexacosanoyl 
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chloride (265 mg, 0.58 mmol) in CH2Cl2 (1.5 mL) was added dropwise over 2 min 
to an ice-cooled solution of amine 46 (500 mg, 0.49 mmol) and NEt3 (136 L, 0.98 
mmol) in CH2Cl2 (3.5 mL) at 0 ºC.  The reaction mixture was stirred at r.t. for 8 h 
and then diluted with CH2Cl2 (20 mL), washed sequentially with NaHCO3 solution 
(20 mL), brine (4 mL) and then dried over Na2SO4.  The drying agent was removed 
by filtration and the filtrate concentrated under reduced pressure. Purification of 
the residue by flash column chromatography (12% EtOAc in hexane) afforded 
amide 62 as a white solid (582 mg, 85%): Rf = 0.3 (15% EtOAc in hexane); []D
20
 = 
+ 31.2 (c 1, CHCl3) (lit. []D
24
 = + 18.8 (c 0.9, CHCl3);
179 mp 75  76 ºC (lit. mp 74  
75 ºC);179 max(film)/cm
-1 2918s, 2850s, 1647m (C=O), 1531w, 1496w 1469m, 
1454m, 1349w, 1206w, 1115s, 1058s, 952m, 776w, 735s, 695s; H(300 
MHz, CDCl3) 0.88 (6H, t, J 6.9, 2  CH2CH3), 1.16-1.34 (69H, stack, alkyl chain 
methylenes), 1.37-1.57 (2H, stack), 1.58-1.72 (1H, m), 1.85-2.00 (2H, stack), 3.36-
3.43 (1H, m), 3.44-3.53 (2H, stack), 3.69-3.76 (1H, m), 3.83-3.96 (4H, stack), 3.99-
4.08 (2H, stack), 4.09-4.20 (1H, m), 4.32-4.47 (2H, stack), 4.48-4.67 (4H, stack), 
4.70-4.86 (6H, stack), 4.92 (1H, d, J 11.7), 6.12 (1H, d, J 8.7, NH), 7.20-7.37 (30H, 
stack); C(75 MHz, CDCl3) 14.1 (CH3), 14.7 (CH3), [22.7, 25.7, 26.1, 29.3, 29.4, 
29.7, 31.9, 36.7 (CH2, alkyl chain, resonance overlap), 50.3 (CH), 69.6 (CH2), 
69.96 (CH2), 70.05 (CH), 71.7 (CH2), 71.8 (CH2), 72.9 (CH2), 73.4 (CH2), 73.6 
(CH2), 73.7 (CH), 74.8 (CH2), 74.9 (CH), 78.6 (CH), 78.9 (CH), 80.1 (CH), 99.6 
(CH, C-1‟), [127.4, 127.6, 127.8, 128.2, 128.3 (CH, Ph, resonance overlap)], 
[137.5, 138.4, 138.5, 138.6 (C, ipso Ph, resonance overlap)], 172.8 (C, C=O); MS 
(TOF ES+) m/z 1421.6 ([M + Na]+, 100%). 
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Data were in agreement with those reported in the literature for 62 prepared by a 
different route.179    
 
 
General procedure for catalytic hydrogenolysis: Pd(OH)2/C or Pd/C (0.05 eq 
per benzyl group) was added to a solution of the benzylated compound in THF 
(0.01 M).  H2 gas was bubbled through the stirred suspension. The progress of the 
reaction was monitored by TLC. On completion, the reaction mixture was filtered 
through a plug of Celite, washed with THF and then CHCl3/MeOH (90/10, v/v), and 
concentrated under reduced pressure to provide the crude product, which was 
purified by flash column chromatography. 
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(2S,3S,4R)-1-O-(α-D-Galactopyranosyl)-2-(hexacosanoylamino)octadecane-
1,3,4-triol (α-GalCer, 8) 
 
 
Experimental details for the conversion of 62 to 8 
Amide 8 (GalCer) was prepared from perbenzylated amide 62 (180 mg, 0.129 
mmol) and Pd/C (85 mg, 10% wet) in THF (10 mL) according to the general 
procedure.  After 22 h, work-up and purification by flash column chromatography 
(8% MeOH in CHCl3) afforded amide 8 as an amorphous white solid (75 mg, 
68%).  
 
Experimental details for the conversion of 81 to 8 
TFA (150 L) was added dropwise over 1 min to a solution of acetal 81 (120 mg, 
0.095 mmol) in CH2Cl2 / H2O (10:1, 0.9 mL).  After stirring for 2 h at r.t., the 
reaction mixture was concentrated under reduced pressure and the residual TFA 
was removed by co-evaporation with Et2O (3  3 mL) to provide the crude acetal 
hydrolysis product as a white solid (116 mg, quant.), which was then treated with 
Pd(OH)2/C (30 mg, 10% wet) in THF (10 mL) according to the general 
hydrogenolysis procedure.  After 8 h, work-up and purification by flash column 
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chromatography (8% MeOH in CHCl3) afforded amide 8 as a white solid (61 mg, 
75%): Rf = 0.3 (10% MeOH in CHCl3); []D
20 = + 15.2 (c 1, 2:1 CHCl3/CH3OH) (lit. 
[]D
23 = + 43.6 (c 1, pyridine);143 mp 188 – 189 C (lit. mp 189 – 190 C);180 
max(film) / cm
-1 3313br (OH), 2918s, 2850s, 1642m (C=O), 1548w, 1468m, 
1261m, 1027s, 800s, 721m, 600w; H(400 MHz, 2:1 CDCl3/CD3OD) 0.83 (6H, t, J 
6.7, 2  CH2CH3), 1.16-1.40 (68H, stack, alkyl chain methylenes), 1.45-1.63 (4H, 
stack), 2.16 (2H, app. t, J 7.8), 3.46-3.57 (2H, stack), 3.60-3.79 (6H, stack), 3.80-
3.87 (1H, m), 3.90 (1H, d, J 2.5), 4.11-4.18 (1H, m), 4.86 (1H, d, J 3.7), OH and 
NH resonances not observed; C(100 MHz, 2:1 CDCl3/CD3OD) 14.3 (CH3, 2  
CH2CH3), 23.1 (CH2), 26.29 (CH2), 26.32 (CH2), [29.8, 29.9, 30.0, 30.09, 30.13, 
30.2 (CH2, alkyl chain, resonance overlap)], 32.4 (CH2), 32.9 (CH2), 36.9 (CH2), 
50.9 (CH), 62.3 (CH2), 67.8 (CH2), 69.4 (CH), 70.3 (CH), 70.8 (CH), 71.2 (CH), 
72.5 (CH), 75.1 (CH), 100.2 (CH), 175.1 (C, C=O); MS (TOF ES+) m/z 880.7 ([M + 
Na]+, 100%); HRMS (TOF ES+) calcd for C50H99NO9Na [M + Na]
+ 880.7218, found 
880.7198. 
 
Data were in agreement with those reported in the literature.180  
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(2S,3S,4R)-3,4-Di-O-acetyl-1-O-(2’,3’,4’,6’-tetra-O-acetyl-α-D-galactopyra-
nosyl)-2- (hexacosanoylamino)octadecane-1,3,4-triol (72) 
 
 
 
Ac2O (300 L, 3.2 mmol) was added dropwise over 1 min to a solution of -GalCer 
8 (90 mg, 0.11 mmol) in pyridine (2 mL) and the reaction mixture was stirred at r.t. 
for 10 h, after which time, the volatiles were removed under reduced pressure. The 
residue was diluted with CH2Cl2 (10 mL), washed sequentially with H2O (5 mL), 
NaHCO3 solution (10 mL), brine (3 mL) and then dried over Na2SO4. The drying 
agent was removed by filtration and the filtrate was concentrated under reduced 
pressure. The crude product was purified by flash column chromatography (25% 
EtOAc in hexane) to afford hexa-acetate 72 as a white solid (110 mg, 94%): Rf = 
0.3 (20% EtOAc in hexane); []20D = +8.4 (c 0.5, CHCl3); mp 43 – 44 C; max(film) / 
cm–1 1745s (C=O), 1683w (C=O); H(75 MHz, CDCl3) 0.87 (t, J 6.7, 6H, 2  
CH2CH3), 1.12-1.40 (stack, 68H, alkyl chain methylenes), 1.56-1.72 (stack, 4H), 
1.98 (s, 3H, C(O)CH3), 1.99 (s, 3H, C(O)CH3), 2.04 (s, 3H, C(O)CH3), 2.06 (s, 3H, 
C(O)CH3), 2.09 (s, 3H, C(O)CH3), 2.13 (s, 3H, C(O)CH3), 2.27 (t, J 7.4, 2H), 3.39 
(dd, J 10.6, 2.2, 1H), 3.64 (dd, J 10.7, 2.6, 1H), 3.97-4.14 (stack, 4H), 4.31-4.41 
(m, 1H), 4.90 (d, J 3.7, 1H), 5.13 (dd, J 10.8, 3.7, 1H), 5.25-5.36 (stack, 2H), 5.44 
(d, J 3.1, 1H), 6.39 (d, J 9.7, 1H); C(100 MHz, CDCl3) 14.1 (CH3, 2  CH2CH3), 
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[20.60, 20.66, 20.72, (CH3, C(O)CH3), resonance overlap], 20.1 (CH3, C(O)CH3), 
22.7 (CH2), 25.6 (CH2), 25.7 (CH2), 29.29, 29.35, 29.40, 29.7 (CH2, alkyl chain 
methylenes, resonance overlap), 31.9 (CH2), 36.7 (CH2), 47.8 (CH), 61.8 (CH2), 
66.7 (CH), 67.2 (CH2), 67.5 (CH), 67.9 (CH), 70.5 (CH), 73.4 (CH), 97.1 (CH), 
169.7 (C), 170.1 (C), 170.4 (C), 170.7 (C), 171.1 (C), 172.9 (C), some resonance 
overlap in C=O region; MS (TOF ES+) m/z 1132.8 ([M + Na]+, 100%); HRMS (TOF 
ES+) calcd for C62H111NO15Na [M + Na]
+ 1132.7851, found 1132.7860. 
 
 
 
(2S,3S,4R)-3,4-Di-O-acetyl-1-O-(2’,3’,4’,6’-tetra-O-acetyl-α-D-galactopyra-
nosyl)-2-(hexacosanethioylamino)octadecane-1,3,4-triol (73) 
 
 
 
 
Lawesson‟s reagent (60 mg, 0.15 mmol) was added to a solution of amide 72 (110 
mg, 0.10 mmol) in toluene (2 mL) at r.t. The reaction mixture was stirred at 80 ºC 
for 4 h and then the solvent was removed under reduced pressure. The residue 
was diluted with CH2Cl2 (10 mL), washed sequentially with H2O (5 mL), NaHCO3 
solution (10 mL), brine (2 mL) and then dried over Na2SO4. The drying agent was 
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removed by filtration and the filtrate was concentrated under reduced pressure. 
Purification of the residue by flash column chromatography (20% EtOAc in 
hexane) provided thioamide 73 as a pale yellow solid (96 mg, 85%): Rf = 0.3 (15% 
EtOAc in hexane); []20D = +46.0 (c 1, CHCl3); mp 47 – 48 C; max(film) / cm
–1 
1747s (C=O); H(500 MHz, CDCl3) 0.87 (t, J 6.8, 6H, 2  CH2CH3), 1.21-1.37 
(stack, 68H, alkyl chain methylenes), 1.58-1.69 (stack, 2H, H-5), 1.71-1.82 (stack, 
2H, H-3”), 1.99 (s, 3H, C(O)CH3), 2.00 (s, 3H, C(O)CH3), 2.03 (s, 3H, C(O)CH3), 
2.07 (s, 3H, C(O)CH3), 2.08 (s, 3H, C(O)CH3), 2.12 (s, 3H, C(O)CH3), 2.66-2.78 
(stack, 2H, H-2”), 3.40 (dd, J 10.7, 1.9, 1H, C(1)HaHb), 3.65 (dd, J 10.7, 2.7, 1H, 
C(1)HaHb), 3.97-4.07 (stack, 2H, C(6‟)HaHb, H-5‟), 4.08-4.14 (m, 1H, C(6‟)HaHb), 
4.75-4.81 (m, 1H, H-4), 4.93 (d, J 3.6, 1H, H-1‟), 5.08-5.16 (stack, 2H, (including 
5.10 (dd, J 10.8, 3.7, 1H, H-2‟)), H-2‟, H-2), 5.37 (dd, J 10.8, 3.4, 1H, H-3‟), 5.40-
5.42 (m, 1H, H-4‟), 5.49 (dd, J 10.0, 2.4, 1H, H-3), 8.66 (d, J 9.2, 1H, N-H); C(125 
MHz, CDCl3) 14.11 (CH3, 2  CH2CH3), [20.50, 20.54, 20.62, 20.66, 20.95 (CH3, 
C(O)CH3), resonance overlap], 22.6, 25.5, 27.5, 28.9, 29.2, 29.3, 29.4, 29.5, 29.7, 
31.9 (CH2, alkyl chain methylenes, resonance overlap), 47.0 (CH2, C-2”), 53.7 
(CH, C-2), 61.7 (CH2, C-6‟), 65.3 (CH2, C-1), 67.0 (CH, C-5‟), 67.3 (CH, C-3‟), 67.8 
(CH, C-2‟), 68.0 (CH, C-4‟), 69.8 (CH, C-3), 73.6 (CH, C-4), 96.8 (CH, C-1‟), 169.7 
(C, C(3)C=O), 170.0 (C, C(4‟)C=O), 170.3 (C, C(3‟)C=O), 170.4 (C, C(6‟)C=O), 
170.5 (C, C(2‟)C=O), 171.5 (C, C(4)C=O), 207.0 (C, C=S); MS (TOF ES+) m/z 
1148.9 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for C62H111NO14SNa [M + Na]
+ 
1148.7623, found 1148.7631. 
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(2S,3S,4R)-1-O-(α-D-Galactopyranosyl)-2-(hexacosanethioylamino)-
octadecane-1,3,4-triol (35) 
 
 
 
NaOMe (10 L of a 0.5 M soln in MeOH, 0.005 mmol) was added to a solution of 
hexa-acetate 73 (25 mg, 0.022 mmol) in MeOH (2.5 mL). After stirring at r.t. for 2 
h, the reaction mixture was neutralised by the addition of acidic ion-exchange resin 
(Dowex H CR-S, pre-washed with MeOH (100 mL) and CHCl3 (50 mL)). The 
solution was filtered and the resin washed with MeOH (25 mL) and CHCl3/MeOH 
(25 mL, 9:1). The filtrate was concentrated under reduced pressure. Purification of 
the residue by flash column chromatography (8% MeOH in CHCl3) provided 
thioamide 35 as a pale yellow solid (17 mg, 90%): Rf = 0.2 (8% MeOH in CHCl3); 
[]20D = +43.2 (c 1, CHCl3:CH3OH, 2:1); mp 136 – 137 C; max(film) / cm
–1 3368m 
br (O–H); H(400 MHz, CDCl3:CD3OD, 2:1) 0.84 (t, J 6.9, 6H, 2  CH2CH3), 1.14-
1.44 (stack, 69H, alkyl chain methylenes), 1.45-1.78 (stack, 3H), 2.56-2.66 (stack, 
2H), 3.50-3.58 (m, 1H), 3.65-3.83 (stack, 8H), 3.90 (d, J 2.9, 1H), 3.96 (dd, J 10.9, 
4.3, 1H), 4.85 (app. q, J 4.3, 1H) 4.94 (d, J 3.7, 1H), OH resonances not observed; 
C(100 MHz, CDCl3:CD3OD, 2:1) 14.3 (CH3, 2  CH2CH3), 23.1 (CH2), 26.4 (CH2), 
29.6 (CH2), [29.9, 30.0, 30.1, 30.17, 30.21 (CH2, alkyl chain, resonance overlap)], 
32.4 (CH2), 32.7 (CH2), 47.1 (CH2), 56.8 (CH), 62.3 (CH2), 66.8 (CH2), 69.5 (CH), 
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70.4 (CH), 70.8 (CH), 71.4 (CH), 72.6 (CH), 73.9 (CH), 100.2 (CH), 206.1 (C, 
C=S); MS (TOF ES+) m/z 896.8 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for 
C50H99NO8SNa [M + Na]
+ 896.6989, found 896.6998. 
 
 
(2S,3S,4R)-2-Azido-3,4-O-isopropylidene-1-O-(2’,3’,4’,6’-tetra-O-benzyl-α-D-
galactopyranosyl)octadecane-1,3,4-triol (79) 
 
 
 
Ph3P (1.46 g, 5.55 mmol) and CBr4 (1.84 g, 5.55 mmol) were added sequentially to 
a solution of 2,3,4,6-tetra-O-benzyl-D-galactose 51 (1.00 g, 1.85 mmol) in CH2Cl2 
(10 mL) at r.t. The reaction mixture was stirred for 3 h. In separate flasks, a 
solution of tetramethylurea (TMU) (1.2 mL) and Bu4NBr (1.79 g, 5.55 mmol) in 
CH2Cl2 (5 mL), and a solution of azide 78 (1.07 g, 2.78 mmol) in CH2Cl2 (5 mL) 
were stirred over activated 3 Å MS for 30 min, after which time, these solutions 
were added dropwise (15 min) and sequentially (TMU/Bu4NBr solution first) to the 
solution containing the glycosyl donor. The reaction mixture was stirred at r.t. for 3 
d until there was no evidence by TLC that the donor was still being consumed. The 
reaction mixture was then filtered through a silica plug, washing with CH2Cl2 (1.2 
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L) and then concentrated under reduced pressure.  Purification of the residue by 
flash column chromatography (10% EtOAc in hexane) afforded glycoside 79 as a 
colourless oil (1.56 g, 71%, -anomer only): Rf = 0.2 (10% EtOAc in hexane); 
[]D
22 = + 24.8 (c 1, CHCl3); lit. []D
rt = +32.1 (c 2.0, CHCl3);
180 max(film) / cm
-1 
2924s, 2854s, 2099s (N3), 1497w, 1455m, 1370m, 1249m, 1220m, 1110s, 1059s, 
735s, 697s; H(500 MHz, CDCl3) 0.87 (t, J 6.8, 3H, CH2CH3), 1.20-1.42 (stack, 
29H, alkyl chain methylenes, C(CH3)2), 1.47-1.64 (stack, 3H), 3.44-3.54 (stack, 
3H, C(6‟)H2, H-2), 3.71 (dd, J 10.8, 6.7, 1H, C(1)HaHb), 3.91-3.94 (m, 1H, H-4‟), 
3.95-4.12 (stack, 6H, H-2‟, H-3‟, H-5‟, C(1)HaHb, H-3, H-4), 4.39 (A of AB, J 11.9, 
1H, OCHaHbPh), 4.47 (B of AB, J 11.9, 1H, OCHaHbPh), 4.56 (A of AB, J 11.5, 1H, 
OCHaHbPh), 4.70 (A of AB, J 12.0, 1H,  OCHaHbPh), 4.71 (A of AB, J 11.8, 1H, 
OCHaHbPh), 4.79 (B of AB, J 12.0, 1H, OCHaHbPh), 4.84 (B of AB, J 11.8, 1H, 
OCHaHbPh), 4.93 (d, J  3.6, 1H, H-1‟), 4.94 (B of AB, J 11.5, 1H, OCHaHbPh), 
7.22-7.33 (stack, 16H, Ph), 7.36-7.38 (stack, 4H, Ph); C(125 MHz, CDCl3) 14.1 
(CH3, CH2CH3), 22.7 (CH2), 25.7 (CH3, 1  C(CH3)2), 26.6 (CH2), 28.1 (CH3, 1  
C(CH3)2), 29.3, 29.60, 29.65, 29.69 (CH2, alkyl chain, resonance overlap), 31.9 
(CH2), 59.8 (CH, C-2), 69.1 (CH2, C-6‟), 69.6 (CH2, C-1), 69.9 (CH), 72.9 (CH2, 
CH2Ph), 73.3 (CH2, CH2Ph), 73.4 (CH2, CH2Ph), 74.7 (CH2, CH2Ph), 75.3 (CH, C-
4‟), 75.4 (CH), 76.6 (CH), 77.8 (CH, C-4), 78.7 (CH), 98.8 (CH, C-1‟), 108.2 (C, 
C(CH3)2), [127.4, 127.5, 127.60, 127.64, 127.7 (CH, Ph, resonance overlap)], 
[128.20, 128.25, 128.29, 128.35 (CH, Ph, resonance overlap)], 138 (C, ipso Ph), 
138.7 (C, ipso Ph), 138.9 (C, 2  ipso Ph, resonance overlap); MS (TOF ES+) m/z 
928.7 ([M+Na]+, 100%); HRMS (TOF ES+) 928.5470 [M+Na]+. C55H75N3O8Na 
requires 928.5452. The unreacted azide was also recovered (394 mg, 37%). 
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Data were in agreement with those reported in the literature for 79 prepared by a 
different route.180 
 
 
(2S,3S,4R)-2-Amino-3,4-O-isopropylidene-1-O-(2’,3’,4’,6’-tetra-O-benzyl-α-D-
galactopyranosyl)octadecane-1,3,4-triol (80) 
 
 
 
PMe3 (930 L of a 1.0 M soln in THF, 0.93 mmol) was added dropwise over 5 min 
to a solution of azide 79 (700 mg, 0.77 mmol) in THF (7 mL).  The reaction mixture 
was stirred at r.t. for 3 h, after which time, H2O (0.5 mL) was added.  The reaction 
mixture was stirred for 1 h and then concentrated under reduced pressure.  The 
residual H2O was removed by co-evaporation with toluene (3  3 mL) to provide 
the crude product.  Purification by flash column chromatography (25% EtOAc in 
hexane) afforded amine 80 as a colourless oil (632 mg, 93%): Rf = 0.2 (25% 
EtOAc in hexane); []20D
 = +35.6 (c 1, CHCl3); max(film) / cm
–1 3372 br (NH); 
H(300 MHz, CDCl3) 0.87 (t, J 7.0, 3H, CH2CH3), 1.201.43 (stack, 24H, alkyl 
chain methylenes, 1  C(CH3)2), 1.37 (s, 3H, 1  C(CH3)2), 1.421.57 (stack, 5H), 
2.993.08 (m, 1H), 3.37 (dd, J 10.1, 7.6, 1H), 3.483.57 (stack, 2H), 3.813.98 
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(stack, 5H), 4.024.12 (stack, 2H), 4.38 (A of AB, JAB 11.8, 1H), 4.46 (B of AB, 
JBA 11.8, 1H), 4.57 (d, J 11.5, 1H), 4.68 (d, J 11.8, 1H), 4.714.83 (stack, 3H), 
4.914.93 (stack, 2H), 7.227.39 (stack, 20H, Ph), NH2 not observed; C(100 MHz, 
CDCl3) 14.1 (CH3, CH2CH3), 22.7 (CH2), 25.9 (CH3, 1  C(CH3)2), 26.2 (CH2),  
28.3 (CH3, 1  C(CH3)2), [29.3, 29.7, 29.8 (CH2, alkyl chain, resonance overlap), 
31.9 (CH2), 50.7 (CH, CHNH2), 69.0 (CH2), 69.5 (CH), 72.3 (CH2), 73.0 (CH2), 73.3 
(CH2), 73.5 (CH2), 74.8 (CH2), 75.0 (CH), 76.8 (CH), 77.9 (CH), 79.0 (CH), 79.1 
(CH), 99.0 (CH, C-1‟), 107.8 (C, C(CH3)2), [127.4, 127.5, 127.6, 127.7, 127.8 
128.2, 128.3 (CH, Ph, resonance overlap)], 138.0 (C, ipso Ph), [138.7, 138.8 (C, 3 
 ipso Ph, resonance overlap)]; MS (TOF ES+) m/z 880.8 ([M + H]+, 100%); 
HRMS (TOF ES+) calcd for C55H78NO8 [M + H]
+ 880.5727, found 880.5721. 
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(2S,3S,4R)-2-Hexacosanoylamino-3,4-O-isopropylidene-1-O-(2’,3’,4’,6’-tetra-
O-benzyl--D-galactopyranosyl)octadecane-1,3,4-triol (81) 
 
 
 
A screw-capped glass tube containing a solution of hexacosanoic acid (100 mg, 
0.25 mmol) in (COCl)2 (2.0 mL, 23 mmol) was closed tightly and heated at 70 ºC 
for 2 h, after which time, the volatiles were evaporated under a stream of argon 
and the tube then placed on a high vacuum line for at least 2 h to remove the 
residual volatiles.  The resulting hexacosanoyl chloride was used directly without 
further purification: a solution of freshly prepared hexacosanoyl chloride 47 (105 
mg, 0.25 mmol) in CH2Cl2 (0.5 mL) was added dropwise over 2 min to a solution of 
amine 80 (132 mg, 0.15 mmol) and NEt3 (42 L, 0.30 mmol) in CH2Cl2 (1.0 mL) at 
0 ºC.  The reaction mixture was stirred at r.t. for 12 h and then diluted with CH2Cl2 
(10 mL), washed sequentially with NaHCO3 solution (10 mL), brine (2 mL) and 
then dried over Na2SO4.  The drying agent was removed by filtration and the 
filtrate concentrated under reduced pressure.  Purification of the residue by flash 
column chromatography provided amide 81 as a white solid (160 mg, 85%): Rf = 
0.3 (10% EtOAc in hexane); []D
20 = + 41.6 (c 1, CHCl3); lit. []D
rt = + 44.2 (c 0.85, 
CHCl3);
180 mp 87 – 88 C; max(film) / cm
-1 2916s, 2849s, 1648m (C=O), 1541m, 
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1497w, 1469m, 1454m, 1380w, 1370w, 1250w, 1217m, 1158m, 1106s, 1044s, 
859m, 881w, 859w, 791w, 733s, 721s; H(500 MHz, CDCl3) 0.87 (t, J 6.9, 6H, 
CH2CH3), 1.15-1.34 (stack, 71H, alkyl chain methylenes, 1  C(CH3)2), 1.39 (s, 3H, 
1  C(CH3)2), 1.40-1.47 (stack, 2H, including C(3‟‟)HaHb), 1.48-1.56 (stack, 2H), 
1.93-2.01 (m, 1H, C(2‟‟)HaHb), 2.01-2.09 (m, 1H, C(2‟‟)HaHb), 3.37 (dd, J 9.4, 5.7, 
1H, C(6‟)HaHb), 3.54 (dd, J 9.4, 7.0, 1H, C(6‟)HaHb), 3.60 (br d, J 9.7, 1H, 
C(1)HaHb), 3.88-3.93 (stack, 3H, H-3‟, H-4‟, H-3 or H-4), 3.97 (app t, J 6.3, 1H, H-
5‟), 4.01-4.12 (stack, 4H, H-2‟, C(1)HaHb, H-2, H-3 or H-4), 4.36 (A of AB, JA-B 
11.8, 1H, C(6‟)OCHaHbPh), 4.47 (B of AB, JB-A 11.8, 1H, C(6‟)OCHaHbPh), 4.57 (A 
of AB, JA-B 11.6, 1H, C(4‟)OCHaHbPh), 4.65 (A of AB, JA-B 11.5, 1H, 
C(2‟)OCHaHbPh), 4.73 (A of AB, JA-B 11.8, 1H, C(3‟)OCHaHbPh), 4.79 (B of AB, JB-
A 11.5, 1H, C(2‟)OCHaHbPh), 4.80 (B of AB, JB-A 11.8, 1H, C(3‟)OCHaHbPh), 4.89 
(d, J 3.7, 1H, H-1‟), 4.91 (B of AB, JB-A 11.6, 1H, C(4‟)OCHaHbPh), 6.24 (d, J 8.9, 
1H, NH), 7.21-7.38 (stack, 20H, Ph); C(125 MHz, CDCl3) 14.1 (CH3, CH2CH3), 
22.6 (CH2), 25.6 (CH2), 25.9 (CH3, 1  C(CH3)2), 26.5 (CH2), 28.2 (CH3, 1  
C(CH3)2), 28.9 (CH2), [29.31, 29.37, 29.45, 29.55, 29.57, 29.62, 29.66, 29.68 
(CH2, alkyl chain, resonance overlap)], 31.9 (CH2), 36.7 (CH2, C-2‟‟), 48.7 (CH, C-
2), 69.5 (CH2, C-6‟), 69.9 (CH, C-5‟), 70.6 (CH2, C-1), 73.0 (CH2, C(3‟)OCH2Ph), 
73.46 (CH2, C(2‟)OCH2Ph), 73.54 (CH2, C(6‟)OCH2Ph), 74.6 (CH2, C(4‟)OCH2Ph), 
74.7 (CH, C-4‟), 75.4 (CH, C-3 or C-4), 76.8 (CH, C-2‟), 77.8 (CH, C-3 or C-4), 
78.9 (CH, C-3‟), 99.7 (CH, C-1‟), 107.8 (C, (CH3)2C), [127.4, 127.5, 127.7, 127.8, 
127.85, 127.91 (CH, Ph, some resonance overlap)], [128.2, 128.31, 128.34, 
128.36, 128.40 (CH, Ph, some resonance overlap)], 137.5 (C, ipso Ph on C-6‟), 
138.3 (C, ipso Ph), 138.4 (C, ipso Ph), 138.6 (C, ipso Ph on C-3‟), 172.4 (C, C=O); 
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MS (TOF ES+) m/z 1281.0 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for 
C81H127NO9Na [M + Na]
+ 1280.9409, found 1280.9417. 
 
Data were in agreement with those reported in the literature for 81 prepared using 
different reagents.180 
 
 
(2S,3S,4R)-3,4-Di-O-benzyl-1-O-(2’,3’,4’,6’-tetra-O-benzyl-D-galactopyra-
nosyl)-2-(tricosanylaminocarbonylamino)octadecane-1,3,4-triol (77) 
 
 
 
 
A screw-capped glass tube containing a solution of tetracosanoic acid 74 (450 mg, 
1.22 mmol) in (COCl)2 (2.0 mL, 23 mmol) was closed tightly and heated at 70 ºC 
for 2 h. The volatiles were then evaporated under a stream of argon and the tube 
then placed on a high vacuum line for at least 2 h to remove the residual volatiles.  
The resulting tetracosanoyl chloride 75 was used directly in the next step without 
further purification: a solution of freshly prepared tetracosanoyl chloride (450 mg, 
1.22 mmol) in THF (5 mL) was added dropwise over 10 min to a solution of NaN3 
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(300 mg, 4.62 mmol) in H2O (0.5 mL) at 0 ºC. The reaction mixture was stirred at 
r.t. for 5 h. The organic phase was then extracted with cold (~10 ºC) THF (5 mL) 
and dried over Na2SO4. The drying agent was removed by filtration. The solvent 
was removed under reduced pressure to provide tetracosanoyl azide as a white 
solid, which was used immediately in the next step: a solution of tetracosanoyl 
azide (481 mg, 1.22 mmol (assuming quantitative conversion in the previous step)) 
in toluene (5 mL) was heated under reflux for 4 h, after which time, the reaction 
mixture was cooled to r.t. The resulting solution of tricosanyl isocyanate product 48 
was used directly without further purification in the next step: a solution of amine 
46 (150 mg, 0.147 mmol) in toluene (5 mL) was added to a solution of tricosanyl 
isocyanate (1.22 mmol (assuming quantitative conversion)) in toluene (5 mL) at r.t. 
The reaction mixture was heated under reflux for 8 h and then concentrated under 
reduced pressure. Purification of the residue by flash column chromatography 
(20% EtOAc in hexane) afforded urea 77 as a pale yellow oil (140 mg, 68% based 
on amine):  Rf = 0.3 (20% EtOAc in hexane); []
20
D = +25.2 (c 1, CHCl3); max(film) 
/ cm–1 3363m (N-H), 1670m (C=O); H(500 MHz, CDCl3) 0.89 (t, J  7.0, 6H, 2  
CH2CH3), 1.10-1.39 (stack, 65H, alkyl chain methylenes), 1.39-1.51 (m, 1H, alkyl 
chain CHaHb), 1.56-1.64 (m, 1H, C(5)HaHb), 1.64-1.73 (m, 1H, C(5)HaHb), 2.90-
3.06 (stack, 2H, CHaHbNH), 3.33 (dd, J 9.5, 5.0, 1H, C(6‟)HaHb), 3.55 (dd, J  9.5, 
7.0, 1H, C(6‟)HaHb), 3.59-3.64 (m, 1H, H-4), 3.73 (dd, J 10.8, 3.1, 1H, C(1)HaHb), 
3.80-3.88 (stack, 3H, H-2, H-3, H-4‟), 3.89 (dd, J 10.1, 2.7, 1H, H-3‟), 3.98 (app. t, 
J 6.0, 1H, H-5‟), 4.05 (dd, J 10.1, 3.6, 1H, H-2‟), 4.11 (br dd, J 10.8, 4.5, 1H, 
C(1)HaHb), 4.38 (A of AB, JA-B 12.0, 1H, C(6‟)OCHaHbPh), 4.45-4.48 (stack, 2H, 
C(6‟)OCHaHbPh, C(4)OCHaHbPh), 4.54 (A of AB, JA-B 11.3, 1H, C(3)OCHaHbPh), 
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4.57 (A of AB, JA-B 11.8, 1H, C(4‟)OCHaHbPh), 4.61 (B of AB, JB-A 12.6, 1H, 
C(4)OCHaHbPh), 4.66 (A of AB, JA-B 11.7, 1H, C(2‟)OCHaHbPh), 4.75 (A of AB, JA-B 
11.8, 1H, C(3‟)OCHaHbPh), 4.78 (B of AB, JB-A 11.3, 1H, C(3)OCHaHbPh), 4.79 (B 
of AB, JB-A 11.7, 1H, C(2‟)OCHaHbPh), 4.81 (B of AB, JB-A 11.8, 1H, 
C(3‟)OCHaHbPh), 4.87 (d, J 3.6, 1H, H-1‟), 4.93 (B of AB, JB-A 11.8, 1H, 
C(4‟)OCHaHbPh), 5.00 (d, J 7.8, 1H, C(2)NH), 7.23-7.38 (stack, 30H, 6  Ph), 
CH2NH not observed; C(125 MHz, CDCl3) 14.1 (CH3, 2  CH2CH3), 22.7, 26.0, 
26.9, 29.4, 29.7, 29.9, 30.3, 31.9 (CH2, alkyl chain methylenes, resonance 
overlap), 40.3 (CH2, CH2NH), 51.7 (CH, C-2), 69.9 (CH2, C-6‟), 70.1 (CH, C-5‟), 
71.0 (CH2, C-1), 71.9 (CH2, C(4)OCH2Ph), 73.1 (CH2, C(3‟)OCH2Ph), 73.4 (CH2, 
C(2‟)OCH2Ph), 73.6 (CH2, C(6‟)OCH2Ph), 73.8 (CH2, C(3)OCH2Ph), 74.6 (CH2, 
C(4‟)OCH2Ph), 75.0 (CH, C-3), 76.8 (CH, C-2‟), 78.8 (CH, C-3‟), 79.9 (CH, C-4‟), 
80.3 (CH, C-4), 99.8 (CH, C-1‟), 127.5, 127.6, 127.67, 127.70, 127.84, 127.88, 
127.9, 128.25, 128.28, 128.34, 128.37, 128.5 (CH, Ph, resonance overlap)], 
137.39 (C, ipso Ph), 138.42 (C, ipso Ph), 138.48 (C, ipso Ph), 138.67 (C, ipso Ph), 
138.72 (C, ipso Ph), 138.8 (C, ipso Ph), 158.8 (C, C=O); MS (TOF ES+) m/z 
1408.0 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for C90H132N2O9Na [M + Na]
+ 
1407.9831, found 1407.9844. The unreacted amine was also recovered (40 mg, 
83%). 
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(2S,3S,4R)-1-O-(α-D-Galactopyranosyl)-2-(tricosanylaminocarbonylamino)-
octadecane-1,3,4-triol (36) 
 
 
 
Urea 36 was prepared from perbenzylated urea 77 (115 mg, 0.083 mmol) and 
Pd/C (26.5 mg, 10% wet) in THF (10 mL) according to the general procedure for 
catalytic hydrogenolysis.  After 22 h, work-up and purification by flash column 
chromatography (6% MeOH in CHCl3) afforded urea 36 as an amorphous, white 
solid (51 mg, 73%): Rf = 0.23 (6% MeOH in CHCl3); []
18
D = +28.0 (c 0.5, CHCl3); 
mp 154 – 155 C; max(film) / cm
–1 3363m (N-H), 1670m (C=O); H(500 MHz, 
CDCl3) 0.68 (t, J 6.5, 6H, 2  CH2CH3), 1.06-1.10 (stack, 62H, alkyl chain 
methylenes), 1.22-1.27 (stack, 2H), 1.33-1.36 (m, 1H), 1.48-1.52 (m, 1H), 1.67-
1.69 (stack, 2H), 2.83-2.96 (stack, 2H, CH2NH), 3.28-3.31 (m, 1H, H-3), 3.33-3.36 
(m, 1H, H-4), 3.49-3.63 (stack, 6H, H-3‟, 2  H-6‟, H-2‟, H-5‟, C(1)HaHb), 3.66 (dd, J 
10.5, 4.5, 1H, C(1)HaHb), 3.72 (br d, J 2.5, 1H, H-4‟), 3.97 (dd, J 9.0, 4.5, 1H, H-2), 
4.67 (d, J 3.5, 1H, H-1‟); C(125 MHz, CDCl3) 13.5 (CH3, 2  CH2CH3), 22.3, 25.1, 
25.5, 26.6, 29.0, 29.1, 29.3, 29.4, 29.8, 31.5, 32.7 (CH2, alkyl chain methylenes, 
resonance overlap), 39.8 (CH2, CH2NH), 50.6 (CH, C-2), 61.5 (CH2, C-6‟), 67.6 
(CH2, C-1), 68.6 (CH, C-2‟), 69.4 (CH, C-4‟), 70.0 (CH, C-3‟), 70.5 (CH, C-5‟), 72.1 
(CH, C-4), 75.2 (CH, C-3), 99.4 (CH, C-1‟), 158.9 (C, C=O); MS (TOF ES+) m/z 
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867.9 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for C48H96N2O9Na [M + Na]
+ 
867.7014, found 867.7026.  
 
 
 
Tetracosan-1-ol (82) 
 
 
 
A solution of tetracosanoic acid (2.00 g, 5.43 mmol) in THF (10 mL) was added 
dropwise to a suspension of LiAlH4 (310 mg, 8.14 mmol) in THF (45 mL) over 5 
min at r.t. The mixture was heated under reflux for 4 h, cooled to r.t. and then 
quenched carefully with freshly prepared saturated Na2SO4 solution (10 mL), 
followed by the addition of anhydrous MgSO4 (600 mg). The mixture was stirred 
vigorously for 10 min, filtered through a pad of Celite and washed with THF (2  40 
mL).  Removal of the solvent under reduced pressure and purification of the 
residue by flash column chromatography (10% EtOAc in toluene) provided 
tetracosan-1-ol as a white solid (1.69 g, 88%): Rf = 0.3 (10% EtOAc in hexane); 
mp 76 – 77 C (lit. 76.0 – 76.5 C);181 max(film) / cm
-1 3488 br (OH), 2974m, 
2917m, 2849m, 1462w, 1356w, 1181w, 1065s, 907m, 720w, 658w, 581w; H(300 
MHz, CDCl3) 0.87 (t, J 6.7, 3H, CH2CH3), 1.16-1.39 (stack, 40H, alkyl chain 
methylenes), 1.40-1.45 (stack, 2H), 1.51-1.62 (stack, 2H), 3.64 (t, J 6.6, 2H), OH 
resonance not observed; C(75 MHz, CDCl3) 14.1, (CH3, CH2CH3),  22.7 (CH2), 
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25.7 (CH2), 26.5 (CH2), 28.2 (CH3), 28.8 (CH2), 29.1 (CH2), [29.3, 29.4, 29.7, 29.8 
(CH2, alkyl chain, resonance overlap), 31.9 (CH2), 32.8 (CH2), 63.1 (CH2); MS  
(TOF ES+) m/z 377.5 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for C24H50ONa 
[M + Na]+ 377.3759, found 377.3755. 
 
Data were in agreement with those reported in the literature.182  
 
 
 
Carbonic acid, 2,5-dioxo-1-pyrrolidinyl tetracosanyl ester (49) 
 
 
 
N,N′-Disuccinimidyl carbonate 83 (190 mg, 0.75 mmol) was added to a solution of 
tetracosan-1-ol (177 mg, 0.50 mmol) and NEt3 (210 L, 1.5 mmol) in dry CH3CN 
(2.5 mL) at r.t. The resulting mixture was stirred at r.t. for 4 h and then 
concentrated under reduced pressure. The residue was diluted with NaHCO3 
solution (10 mL) and extracted with EtOAc (2  10 mL). The combined extracts 
were washed with brine (5 mL) and dried over Na2SO4. Evaporation of the solvent 
under reduced pressure provided the corresponding mixed carbonate 49 as a 
white solid, which was used directly in the next step (248 mg, quant.): Rf = 0.3 
(25% EtOAc in hexane); max(film) / cm
–1 1711m (C=O), 1693m (C=O); H(300 
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MHz, CDCl3) 0.88 (t, J 7.0, 3H, CH2CH3), 1.16-1.46 (stack, 42H, alkyl chain 
methylenes), 1.51-1.80 (stack, 2H), 2.84 (s, 4H), 4.31 (t, J 6.6, 2H); C(100 MHz, 
CDCl3) 14.1 (CH3, CH2CH3), 22.7 (CH2), 28.4 (CH2), [29.1, 29.36, 29.42, 29.5, 
29.7 (CH2, alkyl chain, resonance overlap), 31.9 (CH2), 71.7 (CH2), 151.6 (C, 
OC=O), 168.7 (C, NC=O); MS (TOF ES+) m/z 518.5 ([M + Na]+, 100%); HRMS 
(TOF ES+) calcd for C29H53NO5Na [M + Na]
+ 518.3821, found 518.3817. 
 
 
 
(2S,3S,4R)-3,4-O-Isopropylidene-1-O-(2’,3’,4’,6’-tetra-O-benzyl--D-galacto-
pyranosyl)-2-(tetracosanyloxycarbonylamino)octadecane-1,3,4-triol (84) 
 
 
 
A solution of carbonic acid, 2,5-dioxo-1-pyrrolidinyl tetracosanyl ester (50 mg, 0.10 
mmol) in CH2Cl2 (0.5 mL) was added to a stirred solution of amine 80 (60 mg, 
0.068 mmol) and NEt3 (24 L, 0.17 mmol) in CH2Cl2 (1 mL). The resulting mixture 
was stirred at r.t. until no mixed carbonate remained as determined by TLC (4 h).  
The mixture was then diluted with CH2Cl2 (8 mL) and washed sequentially with 
NaHCO3 solution (10 mL) and brine (10 mL).  The organic phase was dried over 
Na2SO4 and the solvent was evaporated under reduced pressure. Purification of 
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the residue by flash column chromatography (5% EtOAc in toluene) provided 
carbamate 84 as a colourless oil (70 mg, 82%): Rf = 0.3 (10% EtOAc in hexane); 
[]20D
 = +36.8 (c 1, CHCl3); max(film) / cm
–1 1689m (C=O); H(500 MHz, CDCl3) 
0.88 (t, J 6.8, 6H, 2  CH2CH3), 1.24-1.34 (stack, 64H, alkyl chain methylenes, 
C(CH3)2), 1.39-1.51 (stack, 8H), 1.57-1.59 (stack, 3H), 1.63-1.67 (m, 1H), 3.45 (dd, 
J 9.3, 6.3, 1H, C(6‟)HaHb), 3.52 (dd, J 9.3, 6.5, 1H, C(6‟)HaHb), 3.66-3.70 (m, 1H, 
H-3), 3.77-3.84 (m, 1H, H-2), 3.91-3.98 (stack, 6H, H-3‟, H-4‟, H-5‟, C(1)HaHb, H-4‟, 
C(1”)HaHb), 4.03-4.11 (stack, 3H, H-2‟, C(1)HaHb, C(1”)HaHb), 4.38 (A of AB, JA-B 
11.8, 1H, C(6‟)OCHaHbPh), 4.49 (B of AB, JB-A 11.8, 1H, C(6‟)OCHaHbPh), 4.56 (A 
of AB, JA-B 11.5, 1H, OCHaHbPh), 4.67 (A of AB, JA-B 11.7, 1H, OCHaHbPh), 4.74 
(A of AB, JA-B 11.7, 1H, C(2‟)OCHaHbPh) 4.78 (B of AB, JB-A 11.7, 1H, OCHaHbPh), 
4.83 (B of AB, JB-A 11.7, 1H, C(2‟)OCHaHbPh), 4.92 (B of AB, JB-A 11.5, 1H, 
OCHaHbPh), 4.95 (d, J 3.6, 1H, H-1‟), 5.32 (br d, J 9.5, 1H, NH), 7.23-7.35 (stack, 
18H, Ph), 7.38-7.39 (stack, 2H, Ph); C(125 MHz, CDCl3) 14.1 (CH3, 2  CH2CH3), 
22.7 (CH2), 25.9 (CH2, CH3, resonance overlap), 26.5 (CH2), 28.2 (CH3), 28.8 
(CH2), 29.1 (CH2), [29.3, 29.4, 29.7, 29.8 (CH2, alkyl chain, resonance overlap), 
32.0 (CH2), 50.7 (CH), 65.1 (CH2), 69.3 (CH2), 69.7 (CH), 69.9 (CH2), 73.1 (CH2), 
73.2 (CH2), 73.6 (CH2), 74.7 (CH2), 74.9 (CH), 75.5 (CH), 76.8 (CH), 77.8 (CH), 
79.0 (CH), 99.2 (CH, C-1‟), 107.7 (C, C(CH3)2), [127.5, 127.6, 127.8, 127.9 (CH, 
Ph, resonance overlap)], [128.23, 128.26, 128.34, 128.36, 128.4 (CH, Ph, 
resonance overlap)], 137.8 (C, ipso Ph), 138.6 (C, 2  ipso Ph), 138.8 (C, ipso 
Ph), 155.9 (C, C=O); MS (TOF ES+) m/z 1283.0 ([M + Na]+, 100%); HRMS (TOF 
ES+) calcd for C80H125NO10Na [M + Na]
+ 1282.9201, found 1282.9244. 
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(2S,3S,4R)-1-O-(α-D-Galactopyranosyl)-2-(tetracosanyloxycarbonylamino)-
octadecane-1,3,4-triol (37) 
 
 
 
TFA (120 L) was added dropwise over 1 min to a solution of acetal 84 (60 mg, 
0.048 mmol) in CH2Cl2 / CH3OH (2:1, 0.6 mL).  After stirring for 2 h at r.t., the 
reaction mixture was concentrated under reduced pressure and the residual TFA 
was removed by co-evaporation with Et2O (3  3 mL) to provide the acetal 
hydrolysis product as a white solid (58 mg, quant.), which was treated with 
Pd(OH)2/C (15 mg, 10% wet) and H2 in THF (6 mL) according to the general 
hydrogenolysis procedure.  After 6 h, work-up and purification by flash column 
chromatography (8% MeOH in CHCl3) afforded carbamate 37 as an amorphous 
white solid (31 mg, 75%): Rf = 0.3 (8% MeOH in CHCl3); []
18
D = +46.0 (c 1, 
CHCl3); mp 166 – 167 C; max(neat) / cm
–1 3388s br (OH), 1683m (C=O); H(500 
MHz, CDCl3:CD3OD, 2:1) 0.63 (t, J 6.8, 6H, 2  CH2CH3), 0.91-1.12 (stack, 66H, 
alkyl chain methylenes), 1.22-1.48 (stack, 4H), 3.27-3.38 (stack, 2H), 3.39-3.58 
(stack, 6H), 3.64-3.75 (stack, 4H), 3.77-3.84 (m, 1H), 4.65 (d, J 3.4, 1H, H-1‟), OH 
and NH resonances not observed; C(125 MHz, CDCl3:CD3OD, 2:1) 13.4, 22.2, 
25.3, 25.4, 28.6, 28.7, 28.9, 29.2, 31.4, 32.1, 51.3, 61.4, 64.8, 67.1, 68.5, 69.4, 
69.9, 70.4, 71.5, 74.4, 99.3, 156.9 (significant resonance overlap in the alkyl chain 
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methylene resonances); MS (TOF ES+) m/z 882.4 ([M + Na]+, 100%); HRMS 
(TOF ES+) calcd for C49H97NO10Na [M + Na]
+ 882.7010, found 882.7000. 
 
 
 
1-O-(tert-Butyldiphenylsilyl)-2,3-O-isopropylidene-L-threitol (92) 
 
 
 
A solution of (+)-2,3-O-isopropylidene-L-threitol 88 (1.000 g, 6.162 mmol) in THF 
(15 mL) was added dropwise over 10 min to a suspension of NaH (60% dispersion 
in mineral oil, 271 mg, 6.782 mmol) in THF (30 mL) at 0 oC. After 30 min, a 
solution of tBuPh2SiCl (1.864 g, 6.782 mmol) in THF (15 mL) was added dropwise 
over 20 min. After stirring at r.t. for 12 h, the reaction was quenched by the 
sequential addition of MeOH (5 mL) and NaHCO3 solution (60 mL). The phases 
were separated and the aqueous phase was washed with CH2Cl2 (3  60 mL). The 
combined organic phases were washed with brine (60 mL), dried (Na2SO4), filtered 
and the solvent was evaporated under reduced pressure. The residue was purified 
by silica gel flash column chromatography (eluent: 15% EtOAc in hexanes) to 
provide silyl ether 92 as a colourless oil (2.265 g, 92%); Rf = 0.25 (15% EtOAc in 
hexanes); []D
21 = 3.5 (c 1, CHCl3) (lit. []D
22 = +8.5 (c 0.2, CHCl3);
183 max(film) / 
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cm-1 3465br (OH), 3071w, 3049w, 2986m, 2931s, 2858s, 1589w, 1473m, 1463m, 
1428s, 1380m, 1371m, 1246m, 1216m, 1113s, 1080s, 823m, 704s; H(300 MHz, 
CDCl3) 1.06 (s, 9H, (CH3)3C), 1.39 (s, 3H, (CH3)2C), 1.41 (s, 3H, (CH3)2C), 2.03-
2.11 (m, 1H, CH2OH), 3.61-3.86 (stack, 4H), 3.91-4.01 (m, 1H), 4.03-4.11 (m, 1H), 
7.34-7.48 (stack, 6H, Ph), 7.61-7.70 (stack, 4H, Ph); C(100 MHz, CDCl3) 19.1 (C, 
(CH3)3C)], [26.8, 26.9, 27.0 (CH3, (CH3)3C, (CH3)2C)], 62.5 (CH2, CH2O), 64.1 
(CH2, CH2O), 77.4 (CH, CHO), 79.5 (CH, CHO), 109.1 (C, (CH3)2C), 127.7 (CH, 
Ph), 129.8 (CH, Ph), 132.8 (C, ipso Ph), 135.5 (CH, Ph); MS (TOF ES+) m/z 423.3 
([M + Na]+, 100%); HRMS (TOF ES+) calcd for C23H32O4SiNa [M + Na]
+ 423.1968, 
found 423.1956. 
 
Data were in agreement with those reported in the literature.183,184   
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(2S,3S,4R)-2-Azido-1-O-[4’-O-tert-butyldiphenylsilyl-2’,3’-O-isopropylidene-L-
threitol]-3,4-O-isopropylidene-octadecane-1,3,4-triol  (86) 
 
 
 
Tf2O (235 µL, 1.40 mmol) was added dropwise over 10 min to a solution of alcohol 
92 (561 mg, 1.40 mmol) and 2,6-di-tert-butylpyridine (346 µL, 1.54 mmol) in 
CH2Cl2 (14 mL) at 0 °C. After 30 min, the reaction mixture was diluted with CH2Cl2 
(15 mL) and the resulting solution washed sequentially with cold H2O (2  30 mL) 
and brine (10 mL), dried (Na2SO4) and filtered.  Removal of the solvent under 
reduced pressure provided crude triflate 87 as a colourless oil [Rf = 0.7 (15% 
EtOAc in hexanes)], which was used immediately in the next etherification step.  A 
solution of alcohol 78 (505 mg, 1.32 mmol) in THF (10 mL) was treated with NaH 
(60% in mineral oil, 56.0 mg, 1.40 mmol) at 0 oC.  After 1 h, a solution of triflate 87 
(assuming 100% conversion, 1.40 mmol) in THF (5 mL) was added dropwise over 
5 min. The resulting solution was stirred at this temperature for 1 h and then at r.t. 
for 12 h. The reaction was then quenched by the addition of MeOH (2 mL) 
followed by NaHCO3 solution (10 mL). The phases were separated and the 
aqueous phase was extracted with CH2Cl2 (3  20 mL). The combined organic 
fractions were washed with brine (15 mL) and dried (Na2SO4), filtered and the 
solvent was removed under reduced pressure. The residue was purified by flash 
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column chromatography (eluent: 5% EtOAc in hexanes) Rf = 0.2 (5% EtOAc in 
hexanes) to provide ether 86 as a colourless oil (815 mg, 80%); Rf = 0.6 (10% 
EtOAc in hexane); []D
21 = + 10.0 (c 1, CHCl3); max(film) / cm
-1 2925s, 2855s, 
2098s (N3), 1589w, 1463m, 1428m, 1379m, 1369s, 1218s, 1112s, 1082s, 822s, 
701s; H(300 MHz, CDCl3): 0.88 (t, J  7.0, 3H, CH2CH3), 1.08 (s, 9H, C(CH3)3), 
1.20-1.43 (stack, 35H, alkyl chain methylenes and 4  acetonide CH3), 1.49-1.63 
(stack, 3H), 3.58-3.75 (stack, 4H), 3.76-3.88 (stack, 3H), 3.91-3.99 (stack, 2H), 
4.10-4.24 (stack, 2H), 7.34-7.47 (stack, 6H, Ph), 7.64-7.72 (stack, 4H, Ph); c(100 
MHz, CDCl3) 14.1 (CH3, CH2CH3), 19.2 (C, C(CH3)3), 22.7 (CH2), 25.7 (CH3, 1  
CH3 from 1,2-anti-diol acetonide), 26.4 (CH2), 26.8 (CH3, 1  CH3 from 1,2-syn-diol 
acetonide), 27.0 (CH3, C(CH3)3), 27.1 (CH3, 1  CH3 from 1,2-syn-diol acetonide], 
28.2 (CH3, 1  CH3 from 1,2-anti-diol acetonide), [29.3, 29.7 (CH2, alkyl chain, 
some resonance overlap), 31.9 (CH2), 60.0 (CH), 64.2 (CH2), 72.4 (CH2), 80.0 
(CH2), 75.8 (CH), 77.8 (CH), 77.9 (2  CH), 108.2 (C, (CH3)2C), 109.4 (C, 
(CH3)2C), 127.7 (CH, Ph), 129.7 (CH, Ph), 133.2 (C, ipso Ph), 135.6 (CH, Ph); MS 
(TOF ES+) m/z 788.7 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for 
C44H71N3O6SiNa [M + Na]
+ 788.5010, found 788.5015. 
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(2S,3S,4R)-2-Amino-1-O-[4’-O-tert-butyldiphenylsilyl-2’,3’-O-isopropylidene-
L-threitol]-3,4-O-isopropylidene-octadecane-1,3,4-triol (85) 
 
 
 
PMe3 (0.7 mL of a 1.0 M soln in THF, 0.7 mmol) was added dropwise over 2 min 
to a solution of azide 86 (500 mg, 0.65 mmol) in THF / H2O (7 mL, 15:1).  The 
reaction mixture was stirred at r.t. for 4 h and then concentrated under reduced 
pressure.  The residual H2O was removed by co-evaporation with toluene (3  3 
mL) to provide the crude amine product.  Purification of the residue by flash 
column chromatography (30% EtOAc in hexane) afforded amine 85 as a 
colourless oil (433 mg, 90%): Rf = 0.3 (30% EtOAc in hexane); []
20
D
 = +45.6 (c 1, 
CHCl3); max(film) / cm
–1 3076w, 1113s, 1083s, 702s; H(300 MHz, CDCl3) 0.88 (t, 
J 7.0, 3H, H-18), 1.08 (s, 9H, C(CH3)3), 1.20-1.43 (stack, 35H, alkyl chain 
methylenes and acetonide CH3), 1.49-1.63 (stack, 3H), 3.58-3.75 (stack, 4H), 
3.76-3.88 (stack, 3H), 3.91-3.99 (stack, 2H), 4.10-4.24 (stack, 2H), 7.34-7.47 
(stack, 6H, Ph), 7.64-7.72 (stack, 4H, Ph); C(100 MHz, CDCl3): 14.1 (CH3, C-18), 
19.2 (CH2), 22.7 (CH2), 25.7 (CH3), 26.4 (CH2), [26.8, 27.0, 27.1, 28.2 (CH3, 
C(CH3)2, C(CH3)3, some resonance overlap], [29.3, 29.7 (CH2, alkyl chain, some 
resonance overlap), 31.9 (CH2), 60.0 (CH), 64.2 (CH2), 72.4 (CH2), 80.0 (CH2), 
75.8 (CH), 77.8 (CH), 77.9 (2  CH), 108.2 (C, (CH3)2C), 109.4 (C, (CH3)2C), 
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[127.7, 129.7 (CH, Ph, some resonance overlap)], 133.2 (C, ipso Ph), 135.6 (CH, 
Ph, some resonance overlap); MS (TOF ES+) m/z 740.6 ([M + H]+, 100%); HRMS 
(TOF ES+) calcd for C44H74NO6Si [M + H]
+ 740.5285, found 740.5293. 
 
 
(2S,3S,4R)-1-O-[4’-O-tert-Butyldiphenylsilyl-2’,3’-O-isopropylidene-L-threitol]-
2- Hexacosanoylamino-3,4-O-isopropylidene-octadecane-1,3,4-triol (94) 
 
 
 
A screw-capped glass tube containing a solution of hexacosanoic acid (163 mg, 
0.41 mmol) in (COCl)2 (2.0 mL, 23 mmol) was closed tightly and heated at 70 ºC 
for 2 h. The volatiles were then evaporated under a stream of argon and the tube 
then placed on a high vacuum line for at least 2 h to remove the residual volatiles. 
The resulting hexacosanoyl chloride 47 was used directly without further 
purification:  a solution of freshly prepared hexacosanoyl chloride 47 (187 mg, 0.41 
mmol) in CH2Cl2 (1 mL) was added dropwise over 2 min to a solution of amine 85 
(250 mg, 0.34 mmol) and NEt3 (95 L, 0.68 mmol) in CH2Cl2 (3 mL) at 0 ºC. The 
reaction mixture was stirred at r.t. for 12 h and then diluted with CH2Cl2 (10 mL), 
washed sequentially with NaHCO3 solution (10 mL), brine (2 mL) and then dried 
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over Na2SO4. The drying agent was removed by filtration and the filtrate 
concentrated under reduced pressure. Purification of the residue by flash column 
chromatography provided amide 94 as a colourless oil (323 mg, 85%): Rf = 0.3 
(10% EtOAc in hexane); []20D = +11.8 (c 1, CHCl3); max(film) / cm
–1 1646m 
(C=O); H(300 MHz, CDCl3) 0.88 (t, J 7.0, 6H, 2  CH2CH3), 1.06 (s, 9H, C(CH3)3), 
1.16-1.36 (stack, 69H, including (1.32 (s, 3H, C(CH3)2), alkyl chain methylenes, 1  
C(CH3)2), 1.40 (s, 3H, C(CH3)2), 1.41 (s, 3H, C(CH3)2), 1.42 (s, 3H, C(CH3)2), 1.45-
1.66 (stack, 6H), 2.05-2.18 (stack, 2H), 3.49-3.67 (stack, 3H), 3.74-3.89 (stack, 
4H), 4.00-4.23 (stack, 4H), 5.71 (br d, J 9.2, 1H), 7.34-7.48 (stack, 6H, Ph), 7.63-
7.72 (stack, 4H, Ph); C(100 MHz, CDCl3) 14.1 (CH3, C-18, C-26”), 22.7 (CH2), 
25.7 (CH2), 25.8 (CH3, C(CH3)2), 26.5 (CH2), 26.9 (CH3, C(CH3)3), 27.1 (CH3, 
C(CH3)2), 27.2 (CH3, C(CH3)2), 28.1 (CH3, C(CH3)2), 29.1 (CH2), [29.33, 29.37, 
29.38, 29.43, 29.67, 29.68, 29.69, 29.71, 29.73 (CH2, alkyl chain, some resonance 
overlap)], 31.9 (CH2), 37.0 (CH2), 48.2 (CH), 64.2 (CH2), 71.3 (CH2), 72.6 (CH2), 
76.0 (CH), 77.8 (CH), 77.9 (CH), 78.1 (CH), 107.9 (C, (CH3)2C), 109.5 (C, 
(CH3)2C), [127.75, 127.76, 129.79, 129.82, (CH, Ph, some resonance overlap)], 
133.1 (C, ipso Ph), [135.61, 135.62 (CH, Ph, some resonance overlap)], 172.4 (C, 
C=O); MS (TOF ES+) m/z 1140.5 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for 
C70H123NO7Na [M + Na]
+ 1140.8967, found 1140.8977. 
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(2S,3S,4R)-1-O-[4’-O-tert-Butyldiphenylsilyl-2’,3’-O-isopropylidene-L-threitol]-
2-hexacosanethioylamino-3,4-O-isopropylidene-octadecane-1,3,4-triol (97) 
 
 
 
Lawesson‟s reagent (81 mg, 0.2 mmol) was added to a solution of amide 94 (145 
mg, 0.13 mmol) in toluene (2 mL) at r.t. The reaction mixture was stirred at 80 ºC 
for 5 h and then the solvent was removed under reduced pressure. The residue 
was diluted with CH2Cl2 (10 mL), washed sequentially with H2O (5 mL), NaHCO3 
solution (10 mL), brine (2 mL) and then dried over Na2SO4. The drying agent was 
removed by filtration and the filtrate was concentrated under reduced pressure. 
Purification of the residue by flash column chromatography (15% EtOAc in 
hexane) provided thioamide 97 as a pale yellow oil (130 mg, 88%): Rf = 0.3 (15% 
EtOAc in hexane); []20D = +36.8 (c 0.5, CHCl3); max(film) / cm
–1 1258s, 1083s, 
736s, 702s; H(300 MHz, CDCl3) 0.88 (t, J 7.0, 6H, 2  CH2CH3), 1.06 (s, 9H, 
C(CH3)3), 1.17-1.35 (72H, stack, including (1.31 (s, 3H, C(CH3)2), alkyl chain 
methylenes, 1  C(CH3)2), 1.39 (s, 3H, C(CH3)2), 1.41 (s, 3H, C(CH3)2), 1.42 (s, 
3H, C(CH3)2), 1.44-1.58 (stack, 3H), 2.49-2.67 (stack, 2H), 3.49-3.58 (m, 1H), 
3.61-3.72 (stack, 2H), 3.74-3.91 (stack, 5H), 4.05-4.21 (stack, 2H), 4.28-4.35 (dd, 
J 7.7, 5.9, 1H), 4.77-4.88 (m, 1H), 7.30-7.49 (stack, 6H, Ph), 7.60-7.75 (stack, 4H, 
Ph); C(100 MHz, CDCl3) 14.1 (CH3, C-18, C-26”), 22.7 (CH2), 25.6 (CH3, 
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C(CH3)2), 26.7 (CH2), 26.9 (CH3, C(CH3)3), 27.0 (CH3, C(CH3)2), 27.2 (CH3, 
C(CH3)2), 27.7 (CH3, C(CH3)2), 29.0 (CH2), [29.37, 29.42, 29.56, 29.59, 29.61, 
29.7 (CH2, alkyl chain, some resonance overlap)], 31.9 (CH2), 47.6 (CH2), 54.6 
(CH), 64.2 (CH2), 69.7 (CH2), 72.6 (CH2), 75.5 (CH), 77.7 (CH), 77.8 (CH), 77.9 
(CH), 108.1 (C, (CH3)2C), 109.5 (C, (CH3)2C), [127.8, 129.8, (CH, Ph, some 
resonance overlap)], 133.1 (C, ipso Ph), 135.6 (CH, Ph, some resonance overlap), 
205.5 (C, C=S); MS (TOF ES+) m/z 1156.8 ([M + Na]+, 100%); HRMS (TOF ES+) 
calcd for C70H123NO6SiSNa [M + Na]
+ 1156.8738, found 1156.8749. 
 
 
 
(2S,3S,4R)-1-O-[L-Threitol]-2-(hexacosanylcarbonylamino)octadecane-1,3,4-
triol (24) 
 
 
 
TBAF (1.0 M solution in THF, 120 mL, 0.12 mmol) was added to a solution of silyl 
ether 94 (123 mg, 0.11 mmol) in THF (1 mL) at r.t.  After 4 h, NH4Cl solution (10 
mL) was added.  The phases were separated and the aqueous phase was 
extracted with CH2Cl2 (3  10 mL).  The solvent was removed under reduced 
pressure to provide the corresponding primary alcohol as a white solid (97 mg, 
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quant.), which was dissolved in CH2Cl2 / CH3OH (10:1, 1.1 mL) and treated with 
TFA (0.5 mL; dropwise addition over 1 min).  After stirring for 2 h at r.t., the 
reaction mixture was concentrated under reduced pressure and the residual TFA 
was removed by co-evaporation with Et2O (3  4 mL).  Purification of the residue 
by flash column chromatography (5% CH3OH in CHCl3) afforded ThrCer 24 as a 
white-yellow solid (65 mg, 74%): Rf = 0.3 (8% MeOH in CHCl3); []D the insolubility 
of this amphiphilic compound at r.t. prevented us from obtaining reliable optical 
rotation data; mp 107109 °C; max(neat) / cm
-1 3308br m (OH, NH), 2915s, 
2849s, 2098w, 1634m (C=O), 1540m, 1471m, 1108m, 1070m, 1026m, 718m; 
H(500 MHz, d8-THF, 45 °C) 0.89 (app t, J 6.7, 6H, 2  CH2CH3), 1.25-1.63 (stack, 
72H, alkyl chain), 2.12 (t, J 7.7, 2H, C(O)CH2), 3.40-3.47 (stack, 2H, H-3‟, H-4‟), 
3.47-3.57 (stack, 5H, C(1)H2, C(4)H2, H-2 or H-3), 3.59-3.63 (m, 1H, C(1‟)HaHb), 
3.67-3.72 (stack, 2H, C(1‟)HaHb, H-3 or H-2), 4.14-4.18 (m, 1H, H-2‟), 6.93-6.96 
(m, 1H, NH); C(125 MHz, d8-THF, 45 °C) 14.3 (CH3, 2  CH2CH3), [23.5 (CH2), 
26.6 (CH2), 26.8 (CH2), 29.3 (CH2), 30.3 (CH2), 30.5 (CH2), 30.59 (CH2), 30.64 
(CH2), 30.7 (CH2), 30.8 (CH2), 32.8 (CH2), 34.1 (CH2) alkyl chain methylenes, 
resonance overlap], 36.9 (CH2, C(O)CH2), 51.8 (CH, C-2‟), 64.6 (CH2, C-4), 71.3 
(CH, C-2 or C-3), 71.5 (CH2, C-1‟), 73.0 (CH, C-4‟), 73.1 (CH, C-3 or C-2), 74.1 
(CH2, C-1), 76.7 (CH, C-3‟), 173.0 (C, C=O); MS (TOF ES+) m/z 822.7 ([M+Na]
+, 
100%); HRMS (TOF ES+) calcd for C48H97NO7Na [M+Na]
+ 822.7163, found 
822.7175. 
 
Data were in agreement with those reported in the literature.124  
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(2’S,3’S,4’R)-2’-Hexacosanethioylamino-1’-O-[L-threitol]-octadecane-1’,3’,4’-
triol (38) 
 
 
 
TBAF (1.0 M solution in THF, 120 L, 0.12 mmol) was added to a solution of silyl 
ether 97 (125 mg, 0.11 mmol) in THF (1 mL) at r.t. After 4 h, NH4Cl solution (10 
mL) was added. The phases were separated and the aqueous phase was 
extracted with CH2Cl2 (3  10 mL). The solvent was removed under reduced 
pressure to provide the resulting primary alcohol as a white solid (98 mg, quant.), 
which was dissolved in CH2Cl2 / CH3OH (10:1, 1.1 mL) and treated with TFA (0.5 
mL; dropwise addition over 1 min).  After stirring for 2 h at r.t., the reaction mixture 
was concentrated under reduced pressure and the residual TFA was removed by 
co-evaporation with Et2O (3  4 mL).  Purification of the residue by flash column 
chromatography (5% CH3OH in CHCl3) afforded pentaol 38 as a pale yellow solid 
(65 mg, 73%): Rf  = 0.3 (8% CH3OH in CHCl3); []D the insolubility of this 
amphiphilic compound at r.t. prevented us from obtaining reliable optical rotation 
data; mp 96 – 97 C; max(film) / cm
–1 3324s br (O–H); H(500 MHz, CDCl3:CD3OD, 
2:1) 0.83 (t, J 7.0, 6H, 2  CH2CH3), 1.11-1.41 (stack, 69H, alkyl chain 
methylenes), 1.43-1.74 (stack, 3H), 2.60 (t, J 8.1, 2H, C(3”)H2), 3.48-3.54 (stack, 
3H, C(1‟)H2, H-4), 3.55-3.63 (stack, 3H, C(4‟)H2, H-3‟), 3.64-3.72 (stack, 2H, 
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C(1)HaHb, H-3), 3.74-78 (m, 1H, H-2‟), 3.80-3.86 (m, 1H, C(1)HaHb), 4.83-4.88 (m, 
1H, H-2); C(125 MHz, CDCl3:CD3OD, 2:1) 14.2 (CH3, 2  CH2CH3), 22.9 (CH2), 
26.2 (CH2), 29.3 (CH2), [29.6, 29.7, 29.8, 30.0 (CH2, alkyl chain, resonance 
overlap)], 32.2 (CH2), 32.7 (CH2, C-5), 46.9 (CH2, C-2”), 56.1 (CH, C-2), 63.7 (CH2, 
C-4‟), 69.6 (CH2, C-1), 70.6 (CH, C-2‟), 72.2 (CH, C-3‟), 73.0 (CH2, C-4), 73.2 
(CH2, C-1‟), 74.1 (CH, C-3), 205.9 (C, C=S); MS (TOF ES+) m/z 838.7 ([M + Na]
+, 
100%); HRMS (TOF ES+) calcd for C50H99NO8SNa [M + Na]
+ 838.6934, found 
838.6946. 
 
 
(2’S,3’S,4’R)-3’,4’-Di-O-acetyl-1’-O-(2,3,4-tri-O-acetyl-L-threitol]-2’-(hexacosa-
noylamino)octadecane-1’,3’,4’-triol (95) 
 
 
 
Ac2O (420 L, 4.5 mmol) was added dropwise over 1 min to a solution of ThrCer 
24 (120 mg, 0.15 mmol) in pyridine (2 mL). The reaction mixture was stirred at r.t. 
for 10 h, after which time, the volatiles were removed under reduced pressure. The 
residue was diluted with CH2Cl2 (10 mL), washed sequentially with H2O (5 mL), 
NaHCO3 solution (10 mL), brine (3 mL) and then dried over Na2SO4. The drying 
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agent was removed by filtration and the filtrate was concentrated under reduced 
pressure. The crude product was purified by flash column chromatography (25% 
EtOAc in hexane) to afford hexa-acetate 95 as a white solid (144 mg, 95%): Rf = 
0.26 (25% EtOAc in hexane); []20D = +18.4 (c 1, CHCl3); max(film) / cm
-1 2917 s, 
2850s, 1739s, 1650m, 1540w, 1468m, 1371m, 1220s, 1132m, 1046m, 978w, 
720m, 682m; H(500 MHz, CDCl3) 0.88 (t, J 7.1, 6H, CH2CH3), [1.21-1.33 (stack, 
68H, alkyl chain methylenes)], 1.53-1.72 (stack, 4H, C(5‟)HaHb, C(2”)HaHb,), 2.01 
(s, 3H, C(4‟)COCH3), 2.05 (s, 3H, C(4)COCH3), 2.08 (stack, 6H, C(2)COCH3, 
C(3)COCH3), 2.10 (s, 3H, C(4‟)COCH3), 2.22 (t, J 7.6, 2H, C(1”)HaHb), 3.41 (A of 
ABX, dd, J 9.7, 3.2, 1H, C(1‟)HaHb), 3.43-3.48 (stack, 2H, C(1)HaHb, C(1‟)HaHb), 
3.53 (B of ABX, dd, J 10.9, 5.6, 1H, C(1)HaHb), 4.04 (dd, J 11.8, 6.8, 1H, 
C(4)HaHb), 4.26-4.32 (stack, 2H, C(4)HaHb, H2‟), 4.89-4.93 (m, 1H, H4‟), 5.12-5.18 
(stack, 2H, H2, H3‟), 5.28-5.33 (m, 1H, H3), 6.21 (1H, br d, J 9.2, NH); c(125 
MHz): 14.1 (CH3, C18‟, C25‟‟), 20.7 (CH3, (C4)COCH3), 20.75 (2 x CH3, 
(C2)COCH3, (C3)COCH3), 20.8 (CH3, (C3‟)COCH3), 21.0 (CH3, (C4‟)COCH3), 22.7 
(CH2), (alkyl chain, some resonance overlap), 25.6 (CH2), 25.7 (CH2, C2‟‟), 28.0 
(CH2, C5‟), [29.3-29.4 (CH2, alkyl chain, some resonance overlap)], [29.4, 29.56, 
29.58, 29.7 (CH2, alkyl chain, some resonance overlap)], 31.9 (CH2), 36.6 (CH2, 
C1‟‟), 47.9 (CH, C2‟), 62.2 (CH2, C4), 69.17 (CH2, C1), 69.24 (CH, C3), 69.66 (CH, 
C2), 69.72 (CH2, C1‟), 71.8 (CH, C3‟), 73.2 (CH, C4‟), 169.8 (C, (C3‟)COCH3), 
170.2 (2 x C, (C2)COCH3, (C3)COCH3), 170.5 (C, (C4)COCH3), 170.8 (C, 
(C4‟)COCH3), 173.0 (C, C=O); MS (TOF ES+) m/z 1032.6 ([M + Na]
+, 100%); 
HRMS (TOF ES+) calcd for C68H120N2O7SiNa ([M+Na]
+) 1032.7691, found 
1032.7698. 
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 (2’S,3’S,4’R)-3,4-Di-O-acetyl-1-O-(2,3,4-tri-O-acetyl-L-threitol]-2’-(hexacosa-
thioylamino)octadecane-1’,3’,4’-triol (96) 
 
 
 
Lawesson‟s reagent (60 mg, 0.12 mmol) was added to a solution of amide 95 (102 
mg, 0.10 mmol) in toluene (2 mL) at r.t. The reaction mixture was stirred at 80 ºC 
for 4 h and then the solvent was removed under reduced pressure. The residue 
was diluted with CH2Cl2 (10 mL), washed sequentially with H2O (5 mL), NaHCO3 
solution (10 mL), brine (2 mL) and then dried over Na2SO4. The drying agent was 
removed by filtration and the filtrate was concentrated under reduced pressure. 
Purification of the residue by flash column chromatography (20% EtOAc in 
hexane) provided thioamide 96 as a pale yellow solid (92 mg, 87%): Rf = 0.26 
(20% EtOAc in hexane); []D
20= +54.0 (c 1, CHCl3); H(500 MHz, CDCl3): 0.88 (t, J 
7.1, 6H, CH2CH3), [1.19-1.36 (stack, 68H, alkyl chain methylenes)], 1.54-1.64 (m, 
1H, C(5‟)HaHb), 1.66-1.83 (stack, 3H, C(5‟)HaHb, C(2”)HaHb), [2.04, 2.05, 2.08, 
2.09, 2.11, (stack, 15H, 5 x COCH3)], 2.63-2.74 (stack, 2H, C(1”)HaHb), 3.46 (A of 
ABX, dd, J 10.8, 5.2, 1H, C(1)HaHb), 3.53-3.58 (stack, 2H, C(1)HaHb, C(1‟)HaHb), 
3.61 (B of ABX, dd, J 10.0, 3.1, 1H, C(1‟)HaHb), 4.04 (A of ABX, dd, J 11.8, 6.9, 
1H, C(4)HaHb), 4.30 (B of ABX, dd, J 10.0, 3.1, 1H, C(4)HaHb), 4.86-4.91 (m, 1H, 
H4‟), 5.05-5.12 (m, 1H, H2‟), 5.16 (app q, J 10.1, 5.2, 1H, H2), 5.28 (dd, J 8.0, 3.2, 
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1H, H3‟), 5.31-5.33 (m, 1H, H3), 8.07 (br d, J 9.0, 1H, NH); c(125 MHz): 14.1 
(CH3, C18‟, C25‟‟), [20.7, 20.8, 21.0 (CH3, 5 x COCH3, some resonance overlap), 
22.7 (CH2), 25.5 (CH2), 28.8 (CH2, C5‟), 29.0 (CH2), 29.4 (CH2 ,C2‟‟), [29.5, 29.6, 
29.7, (CH2, alkyl chain, some resonance overlap)], 31.9 (CH2), 47.2 (CH2, C1‟‟), 
53.8 (CH, C2‟), 62.2 (CH2, C4), 68.3 (CH2, C1‟), 69.2 (CH, C3), 69.3 (CH2, C1), 
69.6 (CH, C2), 71.5 (CH, C3‟), 73.1 (CH, C4‟), 169.9 (C, (C3‟)COCH3), 170.1 (C, 
(C2)COCH3), 170.2 (C, (C3)COCH3), 170.5 (C, (C4)COCH3), 170.9 (C, 
(C4‟)COCH3), 206.8 (C, C=S); MS (TOF ES+) m/z 1048.9 ([M + Na]
+, 100%); 
HRMS (TOF ES+) calcd for C68H120N2O7SiNa ([M+Na]
+) 1048.7463, found 
1048.7466. 
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(2S,3S,4R)-1-O-[4’-O-tert-Butyldiphenylsilyl-2’,3’-O-isopropylidene-L-threitol]-3,4-O-
isopropylidene-2-(tetracosanyloxycarbonylamino)octadecane-1,3,4-triol (98) 
 
 
 
A solution of carbonic acid, 2,5-dioxo-1-pyrrolidinyl tetracosanyl ester (110 mg, 
0.21 mmol) in CH2Cl2 (0.5 mL) was added to a stirred solution of amine 85 (104 
mg, 0.14 mmol) and NEt3 (42 L, 0.3 mmol) in CH2Cl2 (1 mL). The resulting 
mixture was stirred at r.t. until no mixed carbonate remained as determined by 
TLC (5 h).  The mixture was then diluted with CH2Cl2 (10 mL) and washed 
sequentially with NaHCO3 solution (10 mL) and brine (10 mL). The organic phase 
was dried over Na2SO4 and the solvent was evaporated under reduced pressure.  
Purification of the residue by flash column chromatography (10% EtOAc in 
toluene) provided carbamate 99 as a colourless oil (135 mg, 86%): Rf = 0.3 (10% 
EtOAc in hexane); []22D
 = +28.8 (c 0.5, CHCl3); max(film) / cm
–1 1687m (C=O); 
H(500 MHz, CDCl3) 0.88 (t, J 7.1, 6H, 2  CH2CH3), 1.06 (s, 9H, C(CH3)3), 1.26-
1.34 (stack, 70H, alkyl chain methylenes), 1.40 (s, 6H, C(CH3)2), 1.42 (s, 3H, 
C(CH3)2), 1.59 (s, 3H, C(CH3)2), 3.52-3.65 (stack, 3H, C(1)HaHb, C(1‟)HaHb), 3.74-
3.81 (stack, 3H, C(4‟)HaHb,,C(1)HaHb), 3.82-3.90 (stack, 2H, H-3‟, H-2), 3.98 (m, 
1H, C(1”)HaHb), 4.00-4.11 (stack, 3H, H-3, H-4, C(1”)HaHb), 4.14-4.20 (m, 1H, H-
2‟), 4.97 (br d, J 9.5, 1H, NH), 7.36-7.46 (stack, 6H, Ph), 7.66-7.70 (stack, 4H, Ph); 
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C(125 MHz, CDCl3) 14.1 (CH3, C-18, C-24”), 19.2 (C, (CH3)3CSi), 22.7 (CH2), 
25.8 (CH3, C(CH3)2), 25.9 (CH2), 26.4 (CH2), 26.8 (CH3, C(CH3)3), 27.0 (CH3, 
C(CH3)2), 27.2 (CH3, C(CH3)2), 28.1 (CH3, C(CH3)2), 28.9 (CH2), 29.1 (CH2), 29.4 
(CH2), [29.6, 29.7 (CH2, alkyl chains, some resonance overlap), 31.9 (CH2), 50.3 
(CH, C-2), 64.1 (CH2, C-4‟), 65.2 (CH2, C-1”), 71.6 (CH2, C-1), 72.6 (CH2, C-1‟), 
75.9, (CH, C-3), 77.7 (CH, C-2‟), 77.8 (CH, C-4), 78.2 (CH, C-3‟), 107.8 (C, 
(CH3)2C), 109.4 (C, (CH3)2C), [127.7, 129.75, 129.79, (CH, Ph, some resonance 
overlap)], 133.2 (C, ipso Ph), 135.6 (CH, Ph, some resonance overlap), 156.0 (C, 
C=O); MS (TOF ES+) m/z 1142.7 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for 
C69H121NO8SiNa [M + Na]
+ 1142.8759, found 1142.8767. 
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(2S,3S,4R)-2-Tetracosanyloxycarbonylamino-1-O-[L-threitol]-octadecane-
1,3,4-triol (40) 
 
 
 
TBAF (1.0 M solution in THF, 180 L, 0.18 mmol) was added to a solution of silyl 
ether 99 (179 mg, 0.16 mmol) in THF (1.5 mL) at r.t.  After 4 h, NH4Cl solution (10 
mL) was added. The phases were separated and the aqueous phase was 
extracted with CH2Cl2 (3  10 mL). The solvent was removed under reduced 
pressure to provide the crude primary alcohol as a white solid (141 mg, quant.), 
which was dissolved in CH2Cl2 / CH3OH (10:1, 1.2 mL) and treated with TFA (0.6 
mL; dropwise addition over 1 min).  After stirring for 2 h at r.t., the reaction mixture 
was concentrated under reduced pressure and the residual TFA was removed by 
co-evaporation with Et2O (3  4 mL) to provide the crude product, which was 
purified by flash column chromatography (10% CH3OH in CHCl3) to afford pentaol 
40 as a pale yellow solid (90 mg, 70%): Rf = 0.3 (10% CH3OH in CHCl3); []D the 
insolubility of this amphiphilic compound at r.t. prevented us from obtaining reliable 
optical rotation data; mp 55  56 C; max(film) / cm
–1 3340m br (O–H), 1683s 
(C=O); H(500 MHz, CDCl3:CD3OD, 2:1) 0.83 (t, J 7.2, 6H, 2  CH2CH3), 1.16-1.45 
(stack, 65H, alkyl chain methylenes), 1.46-1.68 (stack, 5H), 3.12-3.20 (m, 1H), 
3.49-3.64 (stack, 8H), 3.67-3.79 (stack, 2H), 3.85-4.07 (stack, 3H), OH 
Chapter 5         Experimental Section 
228 
 
resonances not observed; C(125 MHz, CDCl3:CD3OD, 2:1) 14.2 (CH3, 2  
CH2CH3), 20.1 (CH2), 23.0 (CH2), 24.1 (CH2), 26.2 (CH2), [29.5, 29.7, 30.0, 30.4, 
(CH2, alkyl chains, some resonance overlap)], 32.3 (CH2), 32.9 (CH2), 52.1 (CH), 
63.9 (CH2), 65.8 (CH2), 70.8 (CH), 71.2 (CH2), 72.5 (CH), 72.8 (CH), 73.4 (CH2), 
75.5 (CH), 157.7 (C, C=O); MS (TOF ES+) m/z 824.8 ([M + Na]+, 100%); HRMS 
(TOF ES+) calcd for C50H99NO8SNa [M + Na]
+ 809.6955, found 824.6940. 
 
 
 
(2S,3S,4R)-1-O-[4’-O-tert-Butyldiphenylsilyl-2’,3’-O-isopropylidene-L-threitol]-
3,4-O-isopropylidene-2-(tricosanylaminocarbonylamino)-octadecane-1,3,4-
triol (98) 
 
 
 
A solution of amine 85 (155 mg, 0.21 mmol) in toluene (1.5 mL) was added to a 
solution of tricosanyl isocyanate 48 (121 mg, 0.33 mmol; prepared as reported 
previously (see page 198) in the synthesis of urea 77) in toluene (1 mL) at r.t. The 
reaction mixture was heated under reflux for 8 h and then concentrated under 
reduced pressure to provide the crude product. Purification of the residue by flash 
column chromatography (15% EtOAc in hexane) afforded urea 98 as a pale yellow 
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oil (186 mg, 80% based on amine): Rf = 0.3 (10% EtOAc in hexane); []
22
D
 = +48.8 
(c 1, CHCl3); max(film) / cm
–1 1632m (C=O); H(500 MHz, CDCl3) 0.88 (t, J 7.1, 6H, 
2  CH2CH3), 1.06 (s, 9H, C(CH3)3), 1.21-1.32 (stack, 68H, alkyl chain 
methylenes), 1.39 (s, 3H, 1  C(CH3)2), 1.40 (s, 3H, 1  C(CH3)2), 1.41 (s, 3H, 1  
C(CH3)2), 1.61 (s, 3H, 1  C(CH3)2), 3.03-3.17 (stack, 2H, C(1”)HaHb), 3.53-3.60 
(stack, 2H, C(1‟)HaHb, C(1)HaHb), 3.65 (dd, J 10.5, 3.2, 1H, C(1‟)HaHb), 3.72-3.80 
(stack, 3H, C(4‟)HaHb, C(1)HaHb), 3.82-3.87 (m, 1H, H-3‟), 3.92-3.97 (m, 1H, H-2), 
4.04-4.11 (stack, 2H, H-3, H-4), 4.13-4.18 (m, 1H, H-2‟), 4.31 (br s, 1H, CH2NH), 
4.49 (br d, J 9.2, 1H, CHNH), 7.37-7.46 (stack, 6H, Ph), 7.64-7.70 (stack, 4H, Ph); 
C(125 MHz, CDCl3) 14.1 (CH3, 2  CH2CH3), 19.2 (C, C(CH3)3), 22.7 (CH2), 25.8 
(CH3, 1  C(CH3)2), 26.4 (CH2), 26.8 (CH3, C(CH3)3), 26.9 (CH2), 27.1 (CH3, 1  
C(CH3)2), 27.2 (CH3, 1  C(CH3)2), 28.1 (CH3, 1  C(CH3)2), 29.1 (CH2), [29.4, 29.7 
(CH2, alkyl chain, resonance overlap)], 30.2 (CH2), 31.9 (CH2), 40.6 (CH2, C-1”), 
49.7 (CH, C-2), 64.3 (CH2, C-4‟), 72.0 (CH2, C-1), 72.7 (CH2, C-1‟), 76.3 (CH, C-3), 
77.3 (CH, C-2‟), 77.9 (CH, C-4), 78.2 (CH, C-3‟), 107.8 (C, C(CH3)2), 109.5 (C, 
C(CH3)2), 127.8 (CH, Ph), 129.8 (CH, Ph), 133.1 (C, ipso Ph), 135.6 (CH, Ph), 
157.4 (C, C=O); MS (TOF ES+) m/z 1127.7 ([M + Na]+, 100%); HRMS (TOF ES+) 
calcd for C68H120N2O7SiNa [M + Na]
+ 1127.8763, found 1127.8737. 
 
 
 
 
 
Chapter 5         Experimental Section 
230 
 
(2S,3S,4R)-1-O-[L-Threitol]-2-(tricosanylaminocarbonylamino)octadecane-
1,3,4-triol (39) 
 
 
 
TBAF (1.0 M solution in THF, 170 L, 0.17 mmol) was added to a solution of silyl 
ether 98 (167 mg, 0.15 mmol) in THF (1.5 mL) at r.t.  After 4 h, NH4Cl solution (10 
mL) was added. The phases were separated and the aqueous phase was 
extracted with CH2Cl2 (3  10 mL). The solvent was removed under reduced 
pressure to provide a white solid (primary alcohol product, 130 mg, quant.), which 
was dissolved in CH2Cl2 / CH3OH (10:1, 1.2 mL). TFA (0.6 mL) was added 
dropwise over 1 min. After stirring for 2 h at r.t., the reaction mixture was 
concentrated under reduced pressure and the residual TFA was removed by co-
evaporation with Et2O (3  4 mL) to provide the crude product, which was purified 
by flash column chromatography (10% CH3OH in CHCl3) to afford the pentaol 39 
as a white solid (85 mg, 72%): Rf  = 0.3 (10% CH3OH in CHCl3); []D the 
insolubility of this amphiphilic compound at r.t. prevented us from obtaining reliable 
optical rotation data; mp 131  132 C; max(film) / cm
–1 3344s br (O–H), 1607s 
(C=O); H(500 MHz, CDCl3:CD3OD, 2:1) 0.84 (t, J 6.9, 6H, 2  CH2CH3), 
1.151.55 (stack, 67H, alkyl chain methylenes), 1.581.69 (m, 1H), 2.993.15 
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(stack, 2H), 3.463.66 (stack, 8H), 3.713.80 (stack, 2H), 3.933.99 (m, 1H), OH 
and NH resonances not observed; C(125 MHz, CDCl3:CD3OD, 2:1) 14.3 (CH3, 2  
CH2CH3), 23.2 (CH2), 26.4 (CH2), 27.4 (CH2), [29.8, 29.9, 30.1, 30.2, 30.3 (CH2, 
alkyl chain, resonance overlap)], 30.7 (CH2), 32.4 (CH2), 33.5 (CH2), 40.7 (CH2), 
51.2 (CH), 64.1 (CH2), 70.7 (CH), 72.1 (CH2), 72.5 (CH), 73.5 (CH), 73.9 (CH2), 
75.9 (CH), 159.9 (C, C=O); MS (TOF ES+) m/z 809.8 ([M + Na]+, 100%); HRMS 
(TOF ES+) calcd for C50H99NO8SNa [M + Na]
+. 809.6959, found 809.6950. 
 
 
-Bromo hexacosanoic acid (115) 
 
 
 
A mixture of hexacosanoic acid (600 mg, 1.51 mmol) and red phosphorus (47 mg, 
1.5 mmol) was heated to 95 °C and Br2 (270 µL, 5.29 mmol) was added dropwise 
over 2 min at this temperature with stirring. The mixture was stirred for 6 h and 
then cooled to r.t., diluted with Et2O (30 mL) and washed with H2O (30 mL). The 
aqueous phase was extracted with Et2O (2  30 mL), and the combined organic 
fractions were washed with brine (10 mL), dried with MgSO4, filtered and the 
solvent was removed under reduced pressure to yield the -bromo acid as a white 
solid, which was recrystallised from hexanes and used without further purification 
in the next reaction (481 mg, 67%). Rf = 0.35 (30% EtOAc in hexane); mp 73 - 74 
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°C (from hexane); max(film) / cm
1 3300-2600w v br (OH), 2915s, 2849s, 1715m 
(C=O), 1697s (C=O), 1477w, 1462m, 1429w, 1241w (br), 1164w, 1120w, 906w, 
725m, 662m; H(300 MHz, CDCl3) 0.88 (t, J 6.8, 3H, CH2CH3), 1.21-1.33 (stack, 
44H, alkyl chain), 1.95-2.21 (m, 2H, CH2CHBr), 4.24 (app t, J 7.6, 1H, CH2CHBr), 
OH not observed; c(100 MHz, CDCl3) 14.1 (CH3, CH2CH3), 22.7 (CH2), 27.2 
(CH2), 28.8 (CH2), 29.3, 29.4, 29.5, 29.7, 29.8 (CH2, alkyl chain, resonance 
overlap), 32.0 (CH2), 34.7 (CH2, CH2CHBr), 45.4 (CH, CH2CHBr), 176.0 (C, 
C=O); m/z (TOF ES) 475.3 ([M(81Br isotopomer) – H], 100%), 473.3 (100, 
[M(79Br isotopomer) – H]).  HRMS m/z (TOF ES) calcd for C26H50
79BrO2 [M – H]
 
473.2994, found 473.2989. 
 
 
-Azido hexacosanoic acid (116) 
 
 
 
NaN3 (690 mg, 10.6 mmol) was added to a solution of -bromo acid 115 (481 mg, 
1.01 mmol) in DMF (5 mL). The reaction mixture was stirred vigorously at 60 °C. 
After 48 h, the reaction mixture was allowed to cool to r.t., diluted with Et2O (20 
mL) and washed with 1 M hydrochloric acid (50 mL). The phases were separated 
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and the aqueous phase was extracted with Et2O (2  25 mL). The combined 
organic fractions were washed with brine (20 mL) and dried with MgSO4. Removal 
of the volatiles under reduced pressure and purification of the residue by flash 
column chromatography (eluent 15% EtOAc in toluene) afforded -azido acid 116 
as a white solid (394 mg, 60% over 2 steps from hexacosanoic acid); Rf = 0.2 
(30% EtOAc in hexane); mp 77 - 78 °C; max(neat) / cm
1 3300-2600w v br (OH), 
2915s, 2849s, 2124m (N3), 1717m (C=O), 1471m, 1256m, 717m; H(300 MHz, 
CDCl3) 0.88 (t, J 6.9, 3H, CH2CH3), 1.19-1.40 (stack, 41H, CH2 resonances in alkyl 
chain), 1.41-1.54 (stack, 3H,), 1.72-1.96 (stack, 2H, CH2CHN3), 4.24 (dd, J 8.3, 
5.2, 1H, CH2CHN3), OH resonance not observed; c(100 MHz, CDCl3): 14.1 (CH3, 
CH2CH3), 22.7 (CH2), 25.7 (CH2), 29.1 (CH2), 29.4, 29.5, 29.7 (CH2, alkyl chain, 
significant resonance overlap), 31.3 (CH2), 32.0 (CH2, CH2CHN3), 61.9 (CH, 
CH2CHN3), 176.6 (C, C=O); MS (TOF ES) m/z 436.4 ([M1]
, 100%); HRMS 
(TOF ES) calcd for C26H50N3O2 [M1]
 436.3903, found 436.3920. 
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(2S,3S,4R)-2-Amino-1-O-[2’,3’-O-isopropylidene-L-threitol]-3,4-O-
isopropylidene-octadecane-1,3,4-triol (118)  
 
 
TBAF (1.0 M solution in THF, 1.1 mL, 1.1 mmol) was added to a solution of silyl 
ether 85 (750 mg, 0.98 mmol) in THF (10 mL) at r.t.  After 4 h, NH4Cl solution (10 
mL) was added.  The phases were separated and the aqueous phase was 
extracted with CH2Cl2 (3  10 mL). The solvent was removed under reduced 
pressure and the residue purified by flash column chromatography (eluent: 25% 
EtOAc in hexanes) to provide alcohol 118 as a colourless oil (490 mg, 95%). Rf = 
0.35 (30% EtOAc in hexane); []D
21 = 22.0 (c 1, CHCl3); max(film) / cm
1 3487br 
(OH), 2923s, 2098s (N3), 1458w, 1370m, 1250s, 1219s, 1168m, 1058s, 989m, 
846s, 707w; H(300 MHz, CDCl3) 0.87 (t, J  6.2, 3H, CH2CH3), 1.22-1.34 (stack, 
25H,), 1.40-1.45, (stack, 9H,), 1.46-1.65 (stack, 4H), 1.99 (dd, J 7.8, 4.8, 1H, OH), 
3.51-4.18 (broad stack, 11H,); C(100 MHz, CDCl3) 14.1 (CH3), 22.7 (CH2), 25.6 
(CH3, (CH3)2C), 26.4 (CH2), 27.0 (CH3, (CH3)2C, some resonance overlap), 28.1 
(CH3, (CH3)2C), [29.4, 29.6 (CH2, alkyl chain, some resonance overlap), 31.9 
(CH2), 59.9 (CH), 62.3 (CH2), 71.9 (CH2), 72.9 (CH2), 75.6 (CH), 76.0 (CH), 77.8 
(CH), 79.4 (CH), 108.3 (C, (CH3)2C)), 109.4 (C, (CH3)2C)); MS (TOF ES+) m/z 
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550.5 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for C28H53N3O6Na [M + Na]
+  
550.3832, found 550.3853. 
 
 
(2S,3S,4R)-2-[2’’-Azido-hexacosanoylamino]-1-O-[2’,3’-O-isopropylidene-L-
threitol]octadecane-O-isopropylidene-octadecane-1,3,4-triol (119) 
 
 
 
A solution of α-azido acid 116 (44 mg, 0.11 mmol) in (COCl)2 (2 mL) was heated at 
70 °C.  After 2 h, the volatiles were removed under a stream of N2 and the residual 
solvent removed on the vacuum line (1 h) to provide the corresponding acid 
chloride 117 as a pale yellow oil, which was used directly in the next step without 
further purification (50 mg, quant.):  A solution of freshly prepared acid chloride 
117 (50 mg, 0.11 mmol) in CH2Cl2 (0.6 mL) was added dropwise over 2 min to a 
solution of amine 118 (69 mg, 0.14 mmol) and NEt3 (32 µL, 0.23 mmol) in CH2Cl2 
(0.8 mL) at 0 ºC. The reaction mixture was stirred at rt for 12 h and then diluted 
with CH2Cl2 (10 mL), washed sequentially with NaHCO3 solution (10 mL), brine (2 
mL) and then dried over Na2SO4. The drying agent was removed by filtration and 
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the filtrate concentrated under reduced pressure.  Purification of the residue by 
flash column chromatography provided amide 119 as a colourless oil (92 mg, 
91%, 1:1 mixture of epimers).  Data on epimeric mixture: Rf = 0.3 (20% EtOAc in 
hexane); max(film) / cm
-1 3309br (OH), 2918s, 2859s, 2109m (N3), 1651m, 1534w, 
1467m, 1370m, 1245m, 1218m, 1072m, 872w, 756s, 722m; H(500 MHz, CDCl3) 
0.87 (t, J 6.8, 6H, 2  CH2CH3), 1.20-1.34 (stack, 68H), 1.39-1.43 (stack, 12H), 
1.44-1.56 (stack, 2H), 1.74-1.94 (stack, 2H, incl. C(3”)H2), 2.25-2.31 (br OH), 3.52-
3.61 (stack, 2H, C(1‟)HaHb for both epimers, C(1)HaHb for both epimers), 3.62-3.71 
(stack, 2H, C(1)HaHb for both epimers, C(4)HaHb for both epimers), 3.74-3.83 
(stack, 2H, C(4)HaHb for both epimers, C(1‟)HaHb for both epimers), 3.88-3.95 
(stack, 1.5H, C(2”)H for epimer 1, C(3)H for both epimers), 3.91-4.04 (stack, 1.5H, 
C(2”)H for epimer 2, C(2)H for both epimers), 4.05-4.20 (stack, 3H, C(2‟)H for both 
epimers, C(3‟)H for both epimers, C(4‟)H for both epimers), 6.48-6.56 (stack, 1H, 
NH for both epimers); C(125 MHz, CDCl3): 14.0 (CH3, C18‟, C26”), 22.6 (CH2), 
25.2 (CH2), 25.4 (CH2), [25.62, 25.67 (CH3, C(CH3)2 of 1,2-anti diol for both 
epimers], 26.4 (CH2), 26.5 (CH2), [26.90, 26.94, 26.97 (CH3, C(CH3)2 of 1,2-syn 
diol for both epimers (resonance overlap))], [27.8, 27.9 (CH3, C(CH3)2 of 1,2-anti 
diol for both epimers)], [29.0, 29.1, 29.16, 29.21, 29.27, 29.34, 29.42, 29.44, 
29.56, 29.59, 29.6, 29.7 (CH2, alkyl chain, some resonance overlap)], 31.9 (CH2), 
32.1 (CH2), 32.2 (CH2), [48.4, 48.6 (CH, C2‟)], [62.3, 62.4, (CH2, C4)], [64.2, 64.5 
(CH, C2”)], 71.3 (CH2, C1‟), [71.71, 71.73 (CH2, C1)], [75.9, 76.0 (CH, C4‟)], [76.4, 
76.5 (CH, C2)], [77.6, 77.7 (CH, C3‟)], [79.2, 79.3 (CH, C3)], [108.0, 108.1 (C, 
(CH3)2C of 1,2-anti diol)], [109.28, 109.30 (C, (CH3)2C of 1,2-syn diol)], [168.8, 
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168.9 (C, C=O)]; MS (TOF ES+) m/z 943.7 [M + Na]+, 100%; HRMS (TOF ES+) 
calcd for C54H104N4O7Na [M + Na]
+ 943.7803, found 943.7800. 
 
 
3-(2-(2-( 2-(2-t-butoxycarbonyl)aminoethoxy)ethoxy)ethoxy)prop-1-yne (114) 
 
 
 
 
 
 
Di-tert-butyl dicarbonate (120 mg, 0.56 mmol) was added to a solution of 3-(2-(2-
(2-aminoethoxy)ethoxy)ethoxy)prop-1-yne144 (55 mg, 0.28 mmol) and NEt3 (58 µL, 
0.42 mmol) in CH3CN (3 mL). After stirring for 6 h at r.t., the volatiles were 
removed under reduced pressure and the residue was purified by flash column 
chromatography (30% EtOAc in hexane) to afford Boc amide 114 as a dark yellow 
oil (74 mg, 92%). Rf = 0.2 (30% EtOAc in hexane); max(film) / cm
1 3351br , 
2869m, 1706s (C=O), 1509m, 1455w, 1368m, 1249m, 1218m, 1117s, 1070s, 
865w, 755s, 1391w, 1365m, 1271m, 1248m, 1170s, 1095s, 1033m, 864w, 780w; 
H(300 MHz, CDCl3) 1.43 (s, 9H, C(CH3)3), 2.43 (t, J 2.4, 1H, CH), 3.26-3.35 
(stack, 2H), 3.50-3.57 (stack, 2H), 3.58-3.76 (stack, 8H), 4.18-4.23 (stack, 2H), 
5.04 (br s, 1H, NH); C(100 MHz, MeOD) 28.4 (CH3, C(CH3)3), 40.4 (CH2), 58.4 
(CH2), 69.1 (CH2), 70.2 (CH2), 70.2 (CH2), 70.4 (CH2), 70.5 (CH2), 74.6 (CH), 79.2 
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(C), 79.6 (C), 154.2 (C, C=O); MS (TOF ES+) m/z 310.1 [M + Na]+, 100%; HRMS 
(TOF ES+) calcd for C14H25NO5Na [M + Na]
+ 310.1630, found 310.1617. 
 
 
 
 
Triazole 121 
 
 
 
 
 
CuSO4 solution (7 µL of a 0.5 M solution, 7 µmol) and sodium ascorbate solution 
(30 µL of a 1 M solution, 30 µmol) were added to a solution of azide 119 (65 mg, 
0.074 mmol) and alkyne 114 (34 mg, 0.11 mmol) in tBuOH / H2O (1 mL, 1:1) at r.t. 
The reaction mixture was heated for 10 h at 50 °C and then diluted with CHCl3 (10 
mL), and washed with brine (3 mL).  The phases were separated and the aqueous 
layer was extracted with CHCl3 (2  5 mL). The combined organic layers were 
dried over Na2SO4 and the volatiles were removed under reduced pressure. 
Purification of the residue by flash column chromatography (gradient: CHCl3 to 5% 
CH3OH in CHCl3) afforded 1,2,3-triazole 121 as a colourless oil (78 mg, 87%, 
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isolated as a 2:1 mixture of epimers).  Data on epimeric mixture: Rf = 0.2
*** (5% 
CH3OH in CHCl3); max(film) / cm
1 3319br (OH), 2917s, 2850s, 1700m (C=O), 
1659m (C=O), 1545w, 1471m, 1368m, 1249m, 1218m, 1117s, 1070s, 865w, 755s; 
H(500 MHz, CDCl3) 0.88 (t, J 6.8, 6H, 2  CH2CH3), 1.19-1.32 (stack, 73H, incl. 1 
 C(CH3)2 of 1,2-anti diol), 1.38-1.40 (stack, 6H, 1  C(CH3)2 of 1,2-anti diol, 1  
C(CH3)2 of 1,2-syn diol), 1.41 (s, 3H, 1  C(CH3)2 of 1,2-syn diol), 1.44 (s, 9H, 
C(CH3)3), 2.03-2.12 (m, 1H, C(3”)HaHb), 2.17-2.27 (m, 1H, C(3”)HaHb), 2.40-2.72 
(br s, 1H, OH), 3.25-3.36 (stack, 2H, CH2NHBoc), 3.40-3.46 (m, 1H, C(1‟)HaHb), 
3.50-3.58 (stack, 4H, CH2CH2NHBoc, C(1)H2), 3.59-3.65 (stack, 4H), 3.65-3.69 
(stack, 2H), 3.69-3.74 (stack, 3H, incl. C(4)HaHb), 3.74-3.79 (stack, 2H, C(4)HaHb, 
C(1‟)HaHb), 3.87-3.99 (stack, 2H, incl. C(2)H), 4.00-4.07 (stack, 2H), 4.07-4.15 (m, 
1H, C(2‟)H), 4.66-4.73 (stack, 2H, C(3‟”)H2), [4.95-4.98 (m, 0.34H, C(2‟‟)H for 
minor epimer), 5.00-5.15 (stack, 1.66H, C(2”)H for major epimer, NHBoc)], [6.59-
6.69 (m, 0.66H, CONH for major epimer), 6.78-6.84 (m, 0.34H, CONH for minor 
epimer)], [7.71-7.75 (s, 0.34H, C(1‟”)H for minor epimer), 7.76-7.82 (s, 0.66H, 
C(1‟”)H for major epimer)]; C(125 MHz, CDCl3) 14.1 (CH3, C18‟, C26”), 22.7 
(CH2), 25.6 (CH3, C(CH3)2 of 1,2-anti diol), 25.8 (CH2), 26.48 (CH2), 26.50 (CH2), 
26.9 (CH3, C(CH3)2 of 1,2-syn diol), 27.1 (CH3, C(CH3)2 of 1,2-syn diol), 27.9 (CH3, 
C(CH3)2 of 1,2-anti diol), 28.4 (CH3, C(CH3)3), [28.9, 29.0, 29.1, 29.3, 29.4, 29.5, 
29.7 (CH2, alkyl chain, some resonance overlap)], 31.5 (CH2), 31.9 (CH2), 32.4 
(CH2, C3”), 32.7 (CH2), 40.4 (CH2, CH2NHBoc), [48.8 (CH, C2‟ for minor epimer), 
49.0 (CH, C2‟ for major epimer)], 61.8 (CH2), 62.7 (CH2, C4), [64.6 (CH, C2” for 
major epimer and CH2, C3‟”, resonance overlap), 65.6 (CH, C2” for minor epimer)], 
                                               
***
 The two epimers can be observed by TLC; however they have very similar Rf values. 
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[69.9, 70.0, 70.2, 70.50, 70.52 (CH2, 5  CH2O in PEG linker)], 70.9 (CH2, C1‟), 
71.7 (CH2, C1), 75.8 (CH), 76.5 (CH), 79.1 (CH), [79.4 (CH and C, incl. OC(CH3)3, 
resonance overlap)], 108.1 (C, (CH3)2C of 1,2-anti diol), 109.2 (C, (CH3)2C of 1,2-
syn diol), 122.3 (CH, C1‟”), 145.4 (C, C2‟”), 156.0 (C, C=ONHBoc), 167.3 (C, 
C=ONH); MS (TOF ES+) m/z 1230.9 [M + Na]+, 100%; HRMS (TOF ES+) m/z 
calcd for C68H129N5O12Na [M + Na]
+ 1230.9535, found 1230.9541. 
 
 
 
Biotinylated ThrCer (106) 
 
 
 
TFA (60 µL) was added dropwise over 1 min to a solution of Boc amide 121 (60 
mg, 0.050 mmol) in CH2Cl2 / CH3OH (2:1, 0.6 mL).  After stirring overnight at r.t., 
the reaction mixture was concentrated under reduced pressure and the residual 
TFA was removed by co-evaporation with Et2O (3  3 mL) to provide crude amine 
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122 as a white solid (51 mg, quant.), which was used in the step without further 
purification: selected data: MS (TOF ES+) m/z 1029.1 ([M + H]+, 100%); HRMS 
(TOF ES+) m/z 1028.8572 [M + H]+.  C57H114N5O10 requires 1028.8566. 
 
NEt3 (33 µL, 0.24 mmol) was added to a solution of crude amine (51 mg, 0.050 
mmol) in DMF (0.5 mL). After stirring for 1 h at r.t., (+)-biotin N-hydroxysuccinimide 
ester 123 (10 mg, 0.029 mmol) was added.  The reaction mixture was stirred for 
12 h at r.t. and then the volatiles were removed under reduced pressure.  
Purification of the residue by flash column chromatography (eluent: first EtOAc to 
remove N-hydroxysuccinimide by-product, then gradient 1-10% CH3OH in CHCl3) 
afforded biotinylated ThrCer 106 as a white solid (52 mg, 83%, 1:1 mixture of 
epimers);  data on mixture unless stated otherwise: Rf = 0.3 for epimer A, Rf = 0.2 
for epimer B (10% CH3OH in CHCl3); max(film) / cm
1 3333br (OH), 2921m, 
2852m, 1672s (C=O), 1467m, 1352w, 1203s, 1184s, 1133s, 908w, 840m, 800m, 
722s; H(500 MHz, CDCl3/CD3OD, 2:1) 0.66 (t, J 6.7, 6H, 2  CH2CH3), 0.91-1.15 
(stack, 66H), 1.17-1.28 (stack, 4H), 1.32-1.55 (stack, 6H, incl. C(12‟”)H2 (middle of 
stack), C(14‟”)HaHb (LHS of stack), C(14‟‟‟)HaHb (RHS of stack)), 1.81-1.90 (stack, 
1H, C(3”)HaHb), 1.91-2.03 (stack, 3H, C(3”)HaHb, C(11‟”)H2), 2.51 (d, J 12.8, 1H, 
C(18‟”)HaHb), 2.68-2.74 (stack, 1H, C(18‟”) HaHb), 2.92-3.00 (stack, 1H, C(15‟”)H), 
3.15-3.21 (stack, 2H, C(9‟”)H2), 3.23-3.54 (stack, 18.5H, incl. C(1‟)HaHb for both 
epimers, C(4‟”)H2), 3.55-3.66 (stack, 1.5H, incl. C(1‟)HaHb for epimer A (LHS of 
stack), C(1‟)HaHb for epimer B (RHS of stack)), 3.95-4.02 (stack, 1H, C(2‟)H 
(epimer A, LHS of stack; epimer B, RHS of stack)), 4.08-4.14 (stack, 1H,  
C(16‟”)H), 4.27-4.32 (stack, 1H, C(17‟”)H), 4.45-4.49 (stack, 2H, C(3‟”)H2), 5.08-
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5.14 (app. q, J 6.7, 1H, C(2”)H), 7.79 (s, 1H, C(1”‟)H); C(125 MHz, CDCl3/CD3OD, 
2:1) 13.4 (CH3, C18‟, C26” (resonance overlap)),  22.2 (CH2), 25.1 (CH2, C(12‟”)), 
25.2 (CH2), 25.3 (CH2), 25.4 (CH2), 25.5 (CH2), 27.7 (CH2), 28.0 (CH2), 28.58 
(CH2), 28.63 (CH2), [29.1, 29.2, 29.3, 29.4 (CH2, alkyl chain, some resonance 
overlap)], 31.5 (CH2), 31.9 (CH2), 32.3 (CH2, C(3”)), 32.5 (CH2), 35.2 (CH2, 
C(11‟”)), [38.72, 38.78 (CH2, C(9‟”) for both epimers)], [39.81, 39.84 (CH2, C(18‟”) 
for both epimers)], [49.8, 49.9 (CH, C(2‟) for both epimers)], 55.3 (CH, C(15‟”)), 
59.9 (CH, C(17‟”)), 61.6 (CH, C(16‟”)), [63.00, 63.05 (CH2, C(4) for both epimers)], 
[63.6, 63.7 (CH, C(2”) for both epimers)], [63.79, 63.83 (CH2, C(3‟”) for both 
epimers)], 69.2 (CH2, C(4‟”)), 69.4 (CH2, PEG chain), [69.46, 69.51 (CH, for both 
epimers)], [69.54, 69.57, 69.84, 69.87, 69.90, 69.92 (3  CH2, PEG chain for both 
epimers)], [70.0, 70.1 (CH2, C(1‟) for both epimers)], [71.4, 71.5 (CH, for both 
epimers)], [72.0, 72.1 (CH, for both epimers)], [72.9, 73.1 (CH2, C(1) for both 
epimers)], 73.8 (CH, C(3‟)), [122.2, 122.3 (CH, C(1‟”) for both epimers)], [144.1, 
144.2 (C, C(2‟”) for both epimers)], [163.95, 164.04 (C, NHC=ONH for both 
epimers)], [167.98, 168.04 (C, C(1”) for both epimers)], [174.21, 174.23 (C, C(10‟”) 
for both epimers)]; MS (TOF ES+) m/z 1277.1 ([M + Na]+, 100%); HRMS (TOF 
ES+) calcd for C67H127N7O12SNa [M + Na]
+ 1276.9161, found 1276.9182. 
 
Careful column chromatography (eluent: gradient 3-8% CH3OH in CHCl3) on a 
small sample of the purified mixture of epimers allowed their separation. Selected 
data for epimer A – (less polar), Rf = 0.3 (10% CH3OH in CHCl3); H(500 MHz, 
CDCl3/CD3OD, 2:1) 0.66 (t, J 6.7, 6H, 2  CH2CH3), 0.91-1.15 (stack, 66H), 1.17-
1.28 (stack, 4H), 1.32-1.55 (stack, 6H, incl. C(12‟”)H2 (middle of stack), 
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C(14‟”)HaHb (LHS of stack), C(14‟‟‟)HaHb (RHS of stack)), 1.81-1.90 (stack, 1H, 
C(3”)HaHb), 1.91-2.03 (stack, 3H, C(3”)HaHb, C(11‟”)H2), 2.51 (d, J 12.8, 1H, 
C(18‟”)HaHb), 2.68-2.74 (m, 1H, C(18‟”) HaHb), 2.92-3.00 (m, 1H, C(15‟”)H), 3.15-
3.21 (m, 2H, C(9‟”)H2), 3.24-3.52 (stack, 18H, incl. C(1‟)HaHb, C(4‟”)H2), 3.57-3.62 
(stack, 2H, incl. C(1‟)HaHb), 3.97-4.00 (m, 1H, C(2‟)H), 4.08-4.14 (m, 1H, 
C(16‟”)H), 4.27-4.32 (m, 1H, C(17‟”)H), 4.44-4.47 (stack, 2H, C(3‟”)H2), 5.08-5.12 
(t, J 6.9, 1H, C(2”)H), 7.77 (s, 1H, C(1”‟)H). Selected data for epimer B – (more 
polar), Rf = 0.2 (10% CH3OH in CHCl3); H(500 MHz, CDCl3/CD3OD, 2:1) 0.66 (t, J 
6.7, 6H, 2  CH2CH3), 0.91-1.15 (stack, 66H), 1.17-1.28 (stack, 4H), 1.32-1.55 
(stack, 6H, incl. C(12‟”)H2 (middle of stack), C(14‟”)HaHb (LHS of stack), 
C(14‟‟‟)HaHb (RHS of stack)), 1.81-1.90 (stack, 1H, C(3”)HaHb), 1.91-2.03 (stack, 
3H, C(3”)HaHb, C(11‟”)H2), 2.51 (d, 1H, J 12.8, C(18‟”)HaHb), 2.68-2.74 (m, 1H, 
C(18‟”) HaHb), 2.92-3.00 (m, 1H, C(15‟”)H), 3.15-3.21 (stack, 2H, C(9‟”)H2), 3.22-
3.53 (stack, 19H, incl. C(1‟)HaHb, C(4‟”)H2), 3.54-3.60 (m, 1H, C(1‟)HaHb), 3.93-
3.98 (m, 1H, C(2‟)H), 4.08-4.14 (m, 1H, C(16‟”)H), 4.27-4.32 (m, 1H, C(17‟”)H), 
4.45-4.49 (stack, 2H, C(3‟”)H2), 5.07-5.12 (t, J 6.8, 1H, C(2”)H), 7.78 (s, 1H, 
C(1”‟)H). 
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Alexa 488-labelled ThrCer (107) 
 
 
 
TFA (60 µL) was added dropwise over 1 min to a solution of Boc amide 121 (60 
mg, 0.050 mmol) in CH2Cl2 / CH3OH (2:1, 0.6 mL).  After stirring overnight at r.t., 
the reaction mixture was concentrated under reduced pressure and the residual 
TFA was removed by co-evaporation with Et2O (3  3 mL) to provide crude amine 
122 as a white solid (51 mg, quant.), which was used in the step without further 
purification: selected data: MS (TOF ES+) m/z 1029.1 ([M + H]+, 100%); HRMS 
(TOF ES+) calcd for C57H114N5O10 [M + H]
+ 1028.8566, found 1028.8572. 
 
NEt3 (1 µL, 7.2 μmol) was added to a solution of crude amine 122 (2.3 mg, 2.3 
μmol) in DMF (10 μL). After stirring for 1 h at r.t., Alexa Fluor® 488 carboxylic acid, 
2,3,5,6-tetrafluorophenyl ester 124 (1.0 mg, 1.1 μmol) was added.  The reaction 
mixture was stirred for 12 h at r.t. and then the volatiles were removed under 
reduced pressure.  Purification of the residue by flash column chromatography 
(eluent: gradient 0-50% CH3OH in CHCl3) afforded compound 107 as a red solid 
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(1.2 mg, 73%); selected data: Rf = 0.3 for epimer A, Rf = 0.2 for epimer B in 
65:35:4  CHCl3 / MeOH / aq. NH3. 
 
 
(2S,3S,4R)-2-Azido-3,4-O-isopropylidene-1-O-(2’,3’,4’,6’-tetra-O-p-
methoxybenzyl-D-galactopyranosyl)octadecane-1,3,4-triol (127) 
 
 
 
 
Ph3P (1.46 g, 5.55 mmol) and CBr4 (1.84 g, 5.55 mmol) were added sequentially to 
a solution of 2,3,4,6-tetra-O-p-methoxybenzyl-D-galactose 126 (1.22 g, 1.85 mmol) 
in CH2Cl2 (10 mL) at r.t. The reaction mixture was stirred for 3 h. In separate 
flasks, a solution of tetramethylurea (TMU) (1.2 mL) and Bu4NBr (1.79 g, 5.55 
mmol) in CH2Cl2 (5 mL), and a solution of azide 78 (1.07 g, 2.78 mmol) in CH2Cl2 
(5 mL) were stirred over activated 3 Å MS for 30 min, after which time, these 
solutions were added dropwise (15 min) and sequentially (TMU/Bu4NBr solution 
first) to the solution containing the glycosyl donor. The reaction mixture was stirred 
at r.t. for 3 d until there was no evidence by TLC that the donor was still being 
consumed. The reaction mixture was then filtered through a silica plug, washing 
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with CH2Cl2 (1.2 L) and then concentrated under reduced pressure. Purification of 
the residue by flash column chromatography (15% EtOAc in hexane) afforded 
glycoside 127 as a colourless oil (1.33 g, 70%, -anomer only): Rf = 0.3 (20% 
EtOAc in hexane); H(300 MHz, CDCl3) 0.88 (t, J 6.8, 3H, CH2CH3), 1.20-1.42 
(stack, 28H, alkyl chain methylenes, C(CH3)2), 1.47-1.70 (stack, 4H), 3.36-3.54 
(stack, 3H), 3.70 (dd, J 10.8, 6.7, 1H), 3.75-4.17 (stack, 19H), 4.27-4.54 (stack, 
3H), 4.56-4.67 (stack, 2H), 4.68-4.79 (stack, 2H), 4.80-4.91 (stack, 2H), 6.76-6.96 
(stack, 8H), 7.13-7.23 (stack, 4H), 7.24-7.37 (stack, 4H); C(100 MHz, CDCl3) 14.1 
(CH3, CH2CH3), 22.7 (CH2), 25.7 (CH3, 1  C(CH3)2), 26.6 (CH2), 28.1 (CH3, 1  
C(CH3)2), 29.31 (CH2), 29.34 (CH2), [29.57, 29.59, 29.63, 29.64, 29.65, 29.68 
(CH2, alkyl chain, resonance overlap), 31.9 (CH2), [55.22, 55.24 (CH3, 4  
ArOCH3 resonance overlap)], 59.8 (CH), 68.8 (CH2), 69.6 (CH2), 69.8 (CH), 72.5 
(CH2), 72.9 (CH2), 73.0 (CH2), 74.2 (CH2), 74.7 (CH) , 75.4 (CH), 76.2 (CH), 77.8 
(CH), 78.4 (CH), 98.9 (CH), 108.2 (C, C(CH3)2), [113.56, 113.60, 113.68, 113.73 
(CH, Ar ortho to OMe)], [129.16, 129.23, 129.4, 129.9 (CH, Ar meta to OMe)], 
[130.1, 130.8, 131.05, 131.09 (C, Ar para to OMe)], [159.01, 159.02, 159.1, 159.2 
(C, Ar ipso to OMe)]. 

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(2S,3S,4R)-2-Amino-3,4-O-isopropylidene-1-O-(2’,3’,4’,6’-tetra-O-p-
methoxybenzyl-D-galactopyranosyl)octadecane-1,3,4-triol (128) 
  
 
 
PMe3 (1.53 mL of a 1.0 M soln in THF, 1.53 mmol) was added dropwise over 5 
min to a solution of azide 127 (1.30 g, 1.27 mmol) in THF (10 mL). The reaction 
mixture was stirred at r.t. for 3 h, after which time, H2O (0.5 mL) was added. The 
reaction mixture was stirred for 1 h and then concentrated under reduced 
pressure. The residual H2O was removed by co-evaporation with toluene (3  3 
mL) to provide the crude product.  Purification by flash column chromatography 
(40% EtOAc in hexane) afforded amine 128 as a colourless oil (1.14 g, 90%): Rf = 
0.3 (40% EtOAc in hexane); max(film) / cm
–1 3380 br (NH), 2923s, 2854s, 
1497m, 1454s, 1368m, 1244m, 1216m, 1096s, 1057s, 909s, 872w, 732s, 697s; 
H(300 MHz, CDCl3) 0.88 (t, J 7.0, 3H, CH2CH3), 1.14-1.61 (stack, 32H, alkyl chain 
methylenes, C(CH3)2), 3.11-3.22 (m, 1H), 3.35-3.52 (stack, 3H), 3.70-4.18 (stack, 
20H), 4.28-4.53 (stack, 3H), 4.54-4.78 (stack, 5H), 4.79-4.88 (stack, 2H), 6.75-
6.93 (stack, 8H), 7.09-7.36 (stack, 8H); C(100 MHz, CDCl3) 14.1 (CH3, CH2CH3), 
22.7 (CH2), 25.9 (CH3, 1  C(CH3)2), 26.3 (CH2), 28.1 (CH3, 1  C(CH3)2), [29.3, 
29.7 (CH2, alkyl chain, resonance overlap), 31.9 (CH2), 50.9 (CH), [55.2 (CH3, 4  
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ArOCH3 resonance overlap)], 68.8 (CH2), 69.6 (CH2), 69.8 (CH), 72.5 (CH2), 72.9 
(CH2), 73.0 (CH2), 74.2 (CH2), 74.7 (CH), 75.4 (CH), 76.2 (CH), 77.8 (CH), 78.4 
(CH), 98.9 (CH), 108.2 (C, C(CH3)2), [113.56, 113.60, 113.68, 113.73 (CH, Ar 
ortho to OMe)], [129.16, 129.23, 129.4, 129.9 (CH, Ar meta to OMe)], [130.1, 
130.8, 131.05, 131.09 (C, Ar para to OMe)], [159.01, 159.02, 159.1, 159.2 (C, Ar 
ipso to OMe)]. 
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(2’S,3’S,4’R)-2’-[2’’-Azido-hexacosanoylamino]-1’-O-[2,3,4,6-tetra-O-benzyl-D-
galactopyranosyl]octadecane-O-isopropylidene-octadecane-1’,3’,4’-triol 
(129) 
 
 
    
A solution of α-azido acid 116 (88 mg, 0.22 mmol) in (COCl)2 (2 mL) was heated at 
70 °C.  After 2 h, the volatiles were removed under a stream of N2 and the residual 
solvent removed on the vacuum line (1 h) to provide the corresponding acid 
chloride 117 as a pale yellow oil, which was used directly in the next step without 
further purification (100 mg, quant.): A solution of freshly prepared acid chloride 
117 (100 mg, 0.22 mmol) in CH2Cl2 (1.0 mL) was added dropwise over 2 min to a 
solution of amine 128 (280 mg, 0.28 mmol) and NEt3 (32 µL, 0.23 mmol) in CH2Cl2 
(2.0 mL) at 0 ºC. The reaction mixture was stirred at rt for 12 h and then diluted 
with CH2Cl2 (20 mL), washed sequentially with NaHCO3 solution (20 mL), brine (5 
mL) and then dried over Na2SO4. The drying agent was removed by filtration and 
the filtrate concentrated under reduced pressure. Purification of the residue by 
flash column chromatography provided amide 129 as a colourless oil (281 mg, 
90%, 1:1 mixture of epimers).  Data on epimeric mixture: Rf = 0.3 (20% EtOAc in 
hexane); max(film) / cm
-1 2922s, 2852s, 2105m (N3), 1685m, 1613m, 1513s, 
1465m, 1368m, 1247s, 1037s, 821s, 729s; H(500 MHz, CDCl3) 0.84-0.89 (stack, 
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6H, 2  CH2CH3), 1.16-1.50 (stack, 56H), 1.61-1.86 (stack, 2H, C(3”)H2), 3.34-3.40 
(stack, 1H, C(6‟)HaHb for both epimers), 3.41-3.46 (stack, 1H, C(6‟)HaHb for both 
epimers), 3.58-3.62 (stack, 1H, C(1)HaHb for both epimers), 3.67-3.70 (m, 0.5H, 
C(2”)H for epimer 1), 3.74-3.81 (stack, 12H, 4  ArOCH3 for both epimers, and 1H, 
C(2”)H for epimer 2), 3.82-3.89 (stack, 3H, C(3‟)H for both epimers, C(4‟)H for both 
epimers, C(5‟)H for both epimers), 3.89-4.00 (stack, 3H, C(1)HaHb for both 
epimers, C(4)H for both epimers, C(2‟)H for both epimers), 4.03-4.09 (stack, 1H, 
C(2)H for both epimers), 4.09-4.18 (stack, 1H, C(3)H for both epimers), 4.27 (A of 
AB, JA-B 11.6, 1H, C(6‟)OCHaHbAr for epimer 1), 4.28 (A of AB, JA-B 11.6, 1H, 
C(6‟)OCHaHbAr for epimer 2), 4.40 (B of AB, JB-A 11.6, 1H, C(6‟)OCHaHbAr for 
epimer 1), 4.42 (B of AB, JB-A 11.6, 1H, C(6‟)OCHaHbAr for epimer 1), 4.46 (A of 
AB, JA-B 11.2, 1H, C(4‟)OCHaHbAr for epimer 1), 4.47 (A of AB, JA-B 11.2, 1H, 
C(4‟)OCHaHbAr for epimer 2), 4.56 (A of AB, JA-B 11.2, 1H, C(2‟)OCHaHbAr for 
epimer 1), 4.57 (A of AB, JA-B 11.2, 1H, C(2‟)OCHaHbAr for epimer 2), 4.63 (A of 
AB, JA-B 11.2, 1H, C(3‟)OCHaHbAr for epimer 1), 4.64 (A of AB, JA-B 11.2, 1H, 
C(3‟)OCHaHbAr for epimer 2), 4.70 (B of AB, JB-A 11.2, 1H, C(3‟)OCHaHbAr for both 
epimers), 4.72 (B of AB, JB-A 11.2, 1H, C(2‟)OCHaHbAr for epimer 1), 4.73 (B of 
AB, JB-A 11.2, 1H, C(2‟)OCHaHbAr for epimer 2), 4.80 (B of AB, JB-A, 1H, 
C(4‟)OCHaHbAr for both epimers), 4.84-4.87 (stack, 1H, C(1‟)H, for both epimers), 
6.74-6.89 (8H, stack, 8H, Ar), 7.13-7.18 (stack, 4H, Ar), 7.23-7.31 (stack, 4H, Ar); 
C(125 MHz, CDCl3) [14.1 (CH3, C18‟, C26”)], [22.7 (CH2)], [25.6, 25.7 (CH2, alkyl 
chain (resonance overlap)], [25.9, 26.0 (CH3, C(CH3)2 for both epimers)], 26.6 
(CH2), 26.7 (CH2), [28.1, 28.2 (CH3, C(CH3)2 for both epimers)], [28.96, 29.03, 
29.3, 29.4, 29.5, 29.7, (CH2, alkyl chain, some resonance overlap)], 31.9  (CH2), 
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32.0 (CH2), 32.1 (CH2), [48.8, 49.1 (CH, C2)], [55.22, 55.24 (CH3, 4  ArOCH3, 
resonance overlap)], [64.2, 64.5 (CH, C2”)], 68.6 (CH2, C1 for epimer 1), [68.88, 
68.91 (CH2, C6‟)], 69.0 (CH2, C1 for epimer 2), 69.8 (CH, C5‟ for both epimers 
(resonance overlap)), [72.6, 72.7 (CH2, C(3‟)OCH2Ar), [73.08, 73.12, 73.15 (CH2, 
C(2‟)OCH2Ar and C(6‟)OCH2Ar (resonance overlap))], 74.2 (CH2, OCH2Ar for both 
epimers (resonance overlap)), [74.4, 74.5 (CH, C4‟)], [75.1, 75.2 (CH, C3)], 76.5 
(CH, C2‟ for both epimers (resonance overlap)), [77.69, 77.73 (CH, C4)], [78.8, 
78.9 (CH, C3‟)], [99.0, 99.3 (CH, C1‟)], [107.88, 107.94 (C, (CH3)2C)], [113.6, 
113.73, 113.75 113.77 (CH, Ar ortho to OMe)], 127.9 (CH, CH=CH), 128.0 (CH, 
CH=CH), [129.0, 129.4, 129.5, 129.8, 129.9, (CH, Ar meta to OMe)], 130.0 (CH, 
CH=CH), 130.2 (CH, CH=CH), [130.66, 130.75, 130.78, 130.9 (C, Ar para to OMe, 
some resonance overlap)], [159.1, 159.2, 159.3 (C, Ar ipso to OMe)], [168.6, 168.9 
(C, C=O)]; MS (TOF ES+) m/z 1442.4 ([M + Na]+, 100%). 
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Triazole 130 
 
 
 
 
 
 
 
 
 
CuSO4 solution (14 µL of a 0.5 M solution, 7 µmol) and sodium ascorbate solution 
(60 µL of a 1 M solution, 60 µmol) were added to a solution of azide 129 (65 mg, 
0.15 mmol) and alkyne 114 (66 mg, 0.23 mmol) in tBuOH / H2O (1 mL, 1:1) at r.t. 
The reaction mixture was heated for 10 h at 50 °C and then diluted with CHCl3 (20 
mL), and washed with brine (10 mL). The phases were separated and the 
aqueous layer was extracted with CHCl3 (2  10 mL). The combined organic layers 
were dried over Na2SO4 and the volatiles were removed under reduced pressure. 
Purification of the residue by flash column chromatography (gradient: CHCl3 to 5% 
CH3OH in CHCl3) afforded 1,2,3-triazole 130 as a colourless oil (231 mg, 91%, 
isolated as a 1:1 mixture of epimers).  Data on epimeric mixture: Rf = 0.2
††† (40% 
EtOAc in hexane); max(film) / cm
1 3343br (NH), 2923s, 2853s, 1687m (C=O), 
1613m (C=O), 1586w, 1513s, 1465m, 1471m, 1367m, 1302m, 1248s, 1173s, 
1093s, 1038s, 822m; H(500 MHz, CDCl3) 0.83-0.88 (stack, 6H, 2  CH2CH3), 
1.11-1.36 (stack, 69H, alkyl chain methylenes, C(CH3)a(CH3)b), 1.37-1.45 [stack, 
                                               
†††
 The two epimers can be observed by TLC; however they have very similar Rf values. 
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16H, including C(CH3)a(CH3)b, C(CH3)3))], 1.92-2.09 (stack, 2H, C(3”)H2), 3.20-
3.35 (stack, 3H, C(6‟)HaHb for both epimers, CH2NHBoc), 3.39-3.46 (stack, 1H, 
C(6‟)HaHb for both epimers), 3.47-3.54 (stack, 3H, CH2CH2NHBoc, C(1)HaHb for 
both epimers), 3.55-3.73 (stack, 12H, including 4  PEG CH2O, C(4‟‟‟)H2), 3.75-
3.83 (stack, 13H, 4  ArOCH3 for both epimers, C(3‟)H for epimer 1 and C(4‟)H for 
epimer 1), 3.84-4.16 (stack, 8H, including C(2‟)H for both epimers, C(3‟)H for 
epimer 2, C(4‟)H for epimer 2, C(1)HaHb for both epimers, C(2)H for both epimers, 
C(4)H for both epimers, C(3)H for both epimers, 1  PEG CH2O), 4.24-4.31 (stack, 
2H, A of AB, C(6‟)OCHaHbAr for both epimers), 4.40-4.59 (stack, 3H), 4.64-4.76 
(stack, 2H), 4.76-4.82 (stack, 2H, including C(1‟)H, for both epimers), 4.90-4.95 
(stack, 1H, C(2‟‟)H for both epimers), 4.99-5.06 (stack, 1H, NHBoc for both 
epimers), 6.72-6.88 (stack, 8H, Ar), 7.10-7.18 (stack, 4H, Ar), 7.22-7.30 (stack, 
4H, Ar), 7.65 (br s, 0.5H, C(1‟”)H) for epimer 1), 7.71 (br s, 0.5H, C(1‟”)H) for 
epimer 2), CONH resonance not observed; C(125 MHz, CDCl3) [14.0, 14.1 14.2 
(CH3, resonance overlap, C18, C26”)], 22.5 (CH2), 22.7 (CH2), [25.86, 25.89 CH3, 
C(CH3)a(CH3)b], 26.5 (CH2), 28.2 (CH3, C(CH3)a(CH3)b, 28.4 (CH3, C(CH3)3), 28.8 
(CH2), 29.0 (CH2), [29.2, 29.31, 29.33, 29.4 (CH2, resonance overlap)], [29.58, 
29.63, 29.70 (CH2, resonance overlap)], 31.5 (CH2), 31.9 (CH2), 33.1 (CH2, C3‟‟), 
40.3 (CH2, CH2NHBoc), [49.4, 49.5 (CH, C2)], [55.21, 55.24 (CH3, 4  ArOCH3, 
resonance overlap)], [64.3, 64.6 (CH, C2”)], 64.7 (CH2, C3‟”), 68.2 (CH2, C1), 
[69.1, 69.2 (CH2, C6‟, resonance overlap), [70.0, 70.2, 70.4, 70.50, 70.52 (CH2, 4  
CH2O in PEG linker)], [72.6, 72.9 (CH2, OCH2Ar), [73.04, 73.12, 73.15 (CH2, 
OCH2Ar (resonance overlap))], [74.1, 74.2 (CH2, OCH2Ar (resonance overlap)), 
[74.4, 74.5 (CH, C4‟)], [75.1, 75.2 (CH, C3)], 76.2 (CH, C2‟ for both epimers 
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(resonance overlap)), 77.6 (CH, C4, for both epimers (resonance overlap)], [78.8, 
78.9 (CH, C3‟ for both epimers (resonance overlap)], 79.4 (CH, C3 and C, 
C(CH3)3) [98.9, 99.6 (CH, C1‟)], [107.87, 107.91 (C, (CH3)2C)], [113.6, 113.73, 
113.75 113.77 (CH, Ar ortho to OMe)], [121.8, 122.1 (CH, C1‟”)], [129.0, 129.4, 
129.5, 129.8, 129.9, (CH, Ar meta to OMe)], [130.6, 130.7, 130.9 (C, Ar para to 
OMe, some resonance overlap)], [145.4, 145.2 (C, C2‟”)], [159.1, 159.2, 159.3 (C, 
Ar ipso to OMe)], [167.31, 167,33 (C, CH2C(O)NH)], [171.1 C of Boc]; MS (TOF 
ES+) m/z 1729.1 [M + Na]+, 100%; 
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Alexa 488-labelled α-GalCer (108) 
 
 
 
TFA (60 µL) was added dropwise over 1 min to a solution of Boc amide 121 (60 
mg, 0.050 mmol) in CH2Cl2 / CH3OH (2:1, 0.6 mL).  After stirring overnight at r.t., 
the reaction mixture was concentrated under reduced pressure and the residual 
TFA was removed by co-evaporation with Et2O (3  3 mL) to provide crude amine 
122 as a white solid (51 mg, quant.), which was used in the step without further 
purification: selected data: MS (TOF ES+) m/z 1108.9 ([M + Na]+, 100%); HRMS 
(TOF ES+) 1108.8462 [M + Na]+. C59H115N5O12Na requires 1108.8440. 
 
NEt3 (1 µL, 7.2 μmol) was added to a solution of crude amine 122 (2.5 mg, 2.3 
μmol) in DMF (10 μL). After stirring for 1 h at r.t., Alexa Fluor® 488 carboxylic acid, 
2,3,5,6-tetrafluorophenyl ester 124 (1.0 mg, 1.1 μmol) was added.  The reaction 
mixture was stirred for 12 h at r.t. and then the volatiles were removed under 
reduced pressure.  Purification of the residue by flash column chromatography 
(eluent: gradient 0-50% CH3OH in CHCl3) afforded compound 108 as a red solid 
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(1.2 mg, 83%); selected data: Rf = 0.3 for epimer A, Rf = 0.2 for epimer B in 
65:35:4  CHCl3 / MeOH / aq. NH3; MS (TOF ES-) m/z 1622.9 ([M + Na - H]
-, 
100%); 
 
(Z,Z)-Octadeca-9,12-dien-1-ol (139) 
 
 
 
Cs2CO3 (5.21 g, 16.0 mmol) was added to a solution of linoleic acid 138 (3.00 g, 
10.7 mmol) in DMF (10 mL).  After stirring for 20 min at r.t., MeI (735 µL, 11.8 
mmol) was added to the suspension.  After 2 h, the mixture was poured into H2O 
(10 mL) and extracted with Et2O (2  20 mL).  The organic phases were washed 
with H2O (3  20 mL), dried over Na2SO4, filtered and concentrated under reduced 
pressure to give the methyl ester as a colourless oil (3.15 g, 100%), which was 
used in the next step without further purification. A solution of methyl linoleate 
(3.15 g, 10.7 mmol) in Et2O (20 mL) was added over 5 min via syringe to a stirred 
suspension of LiAlH4 (0.800 g, 21.0 mmol) in Et2O (20 mL). After the initial 
vigorous  reaction  had  subsided, the mixture was heated at reflux for 3 h and 
then cooled to r.t., poured into  NH4Cl solution  (100 mL) and H2O (20 mL). The 
layers were separated and the aqueous layer was extracted with Et2O (3  20 mL).  
The organic layer and the ethereal extracts were combined and the mixture was 
dried (Na2SO4) and concentrated under reduced pressure. The residue was 
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purified by flash column chromatography (10% EtOAc in hexane) to afford alcohol 
139 as a colourless oil (2.57 g, 90%).  Rf = 0.3 (15% EtOAc in hexane); max(film) / 
cm-1 3327 br OH, 3010w, 2925s, 2855m, 1467m, 1378w, 1054m, 986m, 723m; 
H(300 MHz, CDCl3) 0.86 (t, J 6.8,  3H, CH2CH3), 1.21-1.42 (stack, 15H, alkyl 
chain), 1.50-1.63 (stack, 3H), 1.97-2.11 (stack, 4H, 2  CH2CH=CH), 2.72-2.82 (m, 
2H, CH=CHCH2CH=CH), 3.64 (t, J 6.6, 2H, CH2OH), 5.27-5.44 (stack, 4H, 2  
CH=CH), OH resonance not observed; c(100 MHz, CDCl3) 14.0 (CH3, CH2CH3), 
22.5 (CH2), 25.6 (CH2), 25.7 (CH2), 27.2 (CH2), [29.2, 29.3, 29.4, 29.5, 29.6 (CH2, 
alkyl chain, resonance overlap), 31.5 (CH2), 31.7 (CH2), 62.9 (CH2, CH2OH), 
127.86 (CH, CH=CH), 127.93 (CH, CH=CH), 130.0 (CH, CH=CH), 130.1 (CH, 
CH=CH); MS (TOF ES+) m/z 266.3 ([M+Na]+, 100%); HRMS (TOF ES+) calcd for 
C18H34ONa ([M+Na]
+) 266.2610, found 266.2617 
 
Data were in agreement with those reported in the literature.165  
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(Z,Z)-1-Bromo-octadeca-9,12-diene (137)  
 
 
CBr4 (2.43 g, 7.34 mmol) was added in small portions to a cooled (0 °C) solution of 
alcohol 139 (1.85 g, 6.99 mmol) and PPh3 (1.93 g, 7.34 mmol) in CH2Cl2 (35 mL).  
The mixture was stirred at r.t. for 16 h and then concentrated under reduced 
pressure.  The residual solid was washed with H2O (50 mL) and extracted with 
Et2O (2  50 mL).  The ethereal extracts were dried (Na2SO4) and concentrated 
under reduced pressure. The residue was purified by flash column 
chromatography (hexane) to afford bromide 137 as a colourless oil (2.51 g, 92%). 
Rf = 0.7 (Hexane); max(film) / cm
-1 3008m, 2924s, 2854s, 1459m, 723m; H(300 
MHz, CDCl3) 0.89 (t, J 6.8, 3H, CH2CH3), 1.19-1.49 (stack, 16H, alkyl chain), 1.79-
1.91 (stack, 2H), 1.98-2.12 (stack, 4H, 2  CH2CH=CH), 2.71-2.84 (m, 2H, 
CH=CHCH2CH=CH), 3.41 (t, J 6.8, 2H, CH2Br), 5.26-5.45 (stack, 4H, 2  CH=CH); 
c(100 MHz, CDCl3) 14.1 (CH3, CH2CH3), 22.6 (CH2), 25.6 (CH2), 27.2 (CH2), 28.2 
(CH2), 28.7 (CH2), [29.2, 29.3, 29.6 (CH2, alkyl chain, resonance overlap), 31.5 
(CH2), 32.8 (CH2), 33.9 (CH2), 127.9 (CH, CH=CH), 128.0 (CH, CH=CH), 130.0 
(CH, CH=CH), 130.2 (CH, CH=CH); MS (TOF ES+) m/z 328.2 ([M(79Br 
isotopomer)]+, 100%); HRMS (TOF ES+) calcd for C18H33
79Br ([M(79Br 
isotopomer)] +) 328.1766, found 328.1762. 
 
Data were in agreement with those reported in the literature.165 
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(Z,Z)-1-Cyano-octadeca-9,12-diene (136) 
 
 
 
A solution of bromide 137 (1.10 g, 3.34 mmol) in DMSO (10 mL) was added over 5 
min to a stirred solution of NaCN (180 mg, 3.67 mmol) in DMSO (25 mL) at 40 ºC.  
Soon after the addition, an exothermic reaction was observed and a salt (NaBr) 
precipitated. The mixture was stirred and heated at 60 ºC for 40 min, and then 
poured into ice-water (30 mL) and extracted with Et2O (2  50 mL). The extract 
was washed sequentially with H2O (50 mL) and brine (20 mL), dried (Na2SO4) and 
concentrated under reduced pressure.  The residue was purified by flash column 
chromatography (3% EtOAc in hexane) to afford nitrile 136 as a colourless oil (830 
mg, 90%). Rf = 0.3 (2% EtOAc in hexane); max(film) / cm
-1 3009w, 2925s, 2855s, 
2246w (CN), 1459m, 1398w, 913w, 723s; H(300 MHz, CDCl3) 0.89 (t, J 6.9, 3H, 
CH2CH3), 1.23-1.50 (stack, 16H, alkyl chain), 1.59-1.72 (stack, 2H), 1.98-2.12 
(stack, 4H, CH2CH=CHCH2CH=CHCH2), 2.34 (t, J 7.1, 2H, CH2CN), 2.73-2.81 (m, 
2H, CH=CHCH2CH=CH), 5.27-5.43 (stack, 4H, 2  CH=CH); c(100 MHz, CDCl3) 
14.0 (CH3, CH2CH3), 17.0 (CH2), 22.4 (CH2), 25.2 (CH2), 25.5 (CH2), 27.0 (CH2), 
27.1 (CH2), [28.5, 28.6, 29.0, 29.1, 29.2, 29.4 (CH2, alkyl chain, resonance 
overlap), 31.4 (CH2), 119.6 (. C, C≡N), 127.7 (CH, CH=CH), 127.9 (CH, CH=CH), 
129.8 (CH, CH=CH), 130.0 (CH, CH=CH); MS (TOF ES+) m/z 298.1 ([M + Na]+, 
100%); HRMS (TOF ES+) calcd for C19H33NNa ([M + Na]
+) 298.2511, found 
298.2500. 
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(Z,Z)-Nonadeca-10,13-dienal (135) 
 
 
 
DIBALH (10.8 mL of a 1 M soln in CH2Cl2, 10.8 mmol,) was added dropwise over 
10 min to a stirred solution of nitrile 136 (2.30 g, 8.35 mmol) in CH2Cl2 (40 mL) at 
78 ºC. The reaction mixture was stirred for 1.5 h and then quenched with iPrOH 
(10 mL) and H2O (5 mL) at 78 ºC before warming to r.t. Silica gel (1.00 g) was 
added and the resulting mixture was stirred for 1 h, before diluting with EtOAc (50 
mL) and filtering through a pad of celite. The filtrate was concentrated under 
reduced pressure and the residue purified by flash column chromatography (2% 
EtOAc in hexane) to afford aldehyde 135 as a colourless oil (2.77 g, 92%). Rf = 0.4 
(2% EtOAc in hexane); max(film) / cm
-1 3317 br, 3009m, 2924s, 2854s, 1742m 
(C=O), 1465m, 1374w, 1240m, 1047w, 723m; H(300 MHz, CDCl3) 0.89 (t, J 6.9, 
3H, CH2CH3), 1.23-1.42 (stack, 16H, alkyl chain), 1.57-1.70 (stack, 2H), 1.98-2.12 
(stack, 4H, CH2CH=CHCH2CH=CHCH2), 2.37-2.46 (m, 2H, CH2CHO), 2.73-2.82 
(m, 2H, CH=CHCH2CH=CH), 5.27-5.44 (stack, 4H, 2  CH=CH), 9.77 (t, J 1.9, 1H, 
CHO); c(100 MHz, CDCl3): 14.1 (CH3, CH2CH3), 22.1 (CH2), 22.6 (CH2), 25.7 
(CH2), 27.2 (CH2), [29.1, 29.2, 29.3, 29.6 (CH2, alkyl chain, resonance overlap), 
31.6 (CH2), 43.9 (CH2), 127.9 (CH, CH=CH), 128.0 (CH, CH=CH), 130.1 (CH, 
CH=CH), 130.2 (CH, CH=CH), 202.8 (CH, C=O); MS (TOF ES+) m/z 277.2 ([M – 
Chapter 5         Experimental Section 
261 
 
H]+, 100%); HRMS (TOF ES+) calcd for C19H33O ([M – H]
+) 277.2531, found 
277.2542. 
 
 
(Z,Z)-2-Amino-1-cyano-nonadeca-10,13-diene (134) 
 
 
 
A solution of NH4Cl (350 mg, 6.48 mmol) in aqueous NH3 (30% solution, 7 mL) 
was added to a solution of aldehyde 135 (450 mg, 1.62 mmol) in MeOH (8 mL).  
The reaction mixture was stirred at r.t. for 1 h before NaCN (160 mg, 3.24 mmol) 
was added.  After 24 h, the solvent was removed under reduced pressure. The 
resulting solid was partitioned between EtOAc (50 mL) and H2O (50 mL).  The 
separated organic layer was dried over Na2SO4 and evaporated under reduced 
pressure to provide a yellowish residue, which was purified by flash column 
chromatography (50% EtOAc in hexane) to afford α-amino nitrile 134 as a 
colourless oil (370 mg, 75%). Rf = 0.3 (40% EtOAc in hexane); max(film) / cm
-1: 
3343 br m (NH2), 2973m, 2927w, 2883m, 2246w (CN), 1453w, 1380w, 1328w, 
1274w, 1088m, 1046s, 880s; H(300 MHz, CDCl3): 0.89 (t, J 6.9, 3H, CH2CH3), 
1.19-1.55 (stack, 16H, alkyl chain), 1.60-1.79 (stack, 4H), 1.97-2.11 (stack, 4H, 
CH2CH=CHCH2CH=CHCH2), 2.77 (app. t J 5.9, 2H, CH=CHCH2CH=CH), 3.67 (t, 
J 7.1, 1H, CHNH2), 5.26-5.44 (stack, 4H, 2  CH=CH), resonance for NH2 not 
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observed; c(100 MHz, CDCl3): 14.0 (CH3, CH2CH3), 22.5 (CH2), 25.4 (CH2), 25.6 
(CH2), 27.1 (CH2), 28.9, 29.2, 29.3, 29.6 (CH2, alkyl chain, resonance overlap), 
31.5 (CH2), 35.3 (CH2), 43.4 (CH, CHNH2), 122.2 (C, C≡N), 127.9 (CH, CH=CH), 
128.0 (CH, CH=CH), 130.0 (CH, CH=CH), 130.1 (CH, CH=CH); MS (TOF ES+) 
m/z 327.3 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for C20H36N2Na ([M + Na]
+) 
327.2776, found 327.2767. 
 
 
 
(Z,Z)-2-Amino-eicosa-11,14-dienoic acid (133) 
 
 
 
40% Aqueous KOH solution (KOH (250 mg, 4.54 mmol) in H2O (0.5 mL)) was 
added to a stirred solution of nitrile 134 (138 mg, 0.454 mmol) in EtOH (3 mL).  
The resulting mixture was heated at 80 °C for 8 h.  After cooling the mixture to r.t., 
H2O (10 mL) and MeOH (10 mL) were added sequentially.  The reaction mixture 
was cooled to 0 °C, acidified (to pH 3.0) with hydrochloric acid (10 mL of a 10% 
solution).  The mixture was extracted with Et2O (3  20 mL), and then the 
combined organic extracts were dried with Na2SO4 and the volatiles evaporated 
under reduced pressure to afford the crude α-amino acid 133 as a white solid (140 
mg, 95%), which was used in the next step without further purification.  Rf = 0.2 
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(20% MeOH in CHCl3); H(300 MHz, CD3OD): 0.88 (t, J 7.0, 3H, CH2CH3), 1.18-
1.59 (stack, 16H, alkyl chain), 1.72-1.92 (stack, 4H, alkyl chain), 1.93-2.10 (stack, 
4H, CH2CH=CHCH2CH=CHCH2), 2.70 (app. t, J 5.7, 2H, CH=CHCH2CH=CH), 
3.89 (t, J 6.1, 1H, CHNH2), 5.19-5.36 (stack, 4H, 2  CH=CH), 8.83 (d, J 5.4, 2H, 
NH2), OH resonance not observed; c(100 MHz, CDCl3): 14.5 (CH3, CH2CH3), 23.6 
(CH2), 25.9 (CH2), 26.6 (CH2), 28.2 (CH2), 30.3, 30.4, 30.5, 30.8 (CH2, alkyl chain, 
resonance overlap), 31.5 (CH2), 32.7 (CH2), 54.0 (CH, CHNH2), 128.9 (CH, 
CH=CH), 129.1 (CH, CH=CH), 130.9 (CH, CH=CH), 131.0 (CH, CH=CH), 171.9 
(C, C=O); MS (TOF ES–) m/z 322.2 ([M – H], 100%); HRMS (TOF ES–) calcd for 
C20H36NO2 ([M – H]
, 100%) 322.2746, found 322.2743. 
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(Z,Z)-2-Azido-eicosa-11,14-dienoic acid (132) 
 
 
 
Imidazole-1-sulfonyl azide hydrochloride90 (156 mg, 0.74 mmol, CAUTION: 
potential explosion risk during purification of this reagent) was added to a 
suspension of amine 133 (120 mg, 0.37 mmol), CuSO4·5H2O (2 mg, 2 µmol) and 
K2CO3 (374 mg, 2.71 mmol) in MeOH (5 mL).  The mixture was stirred at r.t. for 18 
h and then concentrated under reduced pressure.  H2O (15 mL) was added to the 
residue which was then acidified (to pH 3.0) with hydrochloric acid (5 mL of a 10% 
solution). The mixture was extracted with EtOAc (3  10 mL). The combined 
organic layers were dried with Na2SO4 and the volatiles were removed under 
reduced pressure. The crude product was purified by flash column 
chromatography (20% EtOAc in toluene) to afford α-azido acid 132 as a colourless 
oil (110 mg, 85%). Rf = 0.3 (20% EtOAc in toluene); max(film) / cm
-1 3400-2500w v 
br (OH), 2927s, 2856m, 2108s (N3), 1719s (C=O), 1457m, 1377w, 1186m, 1080m, 
907s, 732s; H(300 MHz, CDCl3) 0.89 (t, J 6.9, 3H, CH2CH3), 1.23-1.52 (stack, 
17H, alkyl chain), 1.53-1.70 (m, 1H, alkyl chain), 1.72-1.94 (stack, 2H, alkyl chain), 
1.98-2.14 (stack, 4H, CH2CH=CHCH2CH=CHCH2), 2.77 (app. t J 5.9, 2H, 
CH=CHCH2CH=CH), 3.88 (dd, J 8.4, 5.2, 1H, CHN3), 5.27-5.44 (stack, 4H, 2  
CH=CH), 10.03 (v br s, 1H, OH); c(100 MHz, CDCl3) 14.0 (CH3, CH2CH3), 22.6 
(CH2), 25.6 (CH2), 25.7 (CH2), 27.2 (CH2), 28.9, 29.0, 29.2, 29.3, 29.4, 29.6, 29.7 
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(CH2, alkyl chain, resonance overlap), 31.3 (CH2), 31.5 (CH2), 61.7 (CH, CHN3), 
127.9 (CH, CH=CH), 128.0 (CH, CH=CH), 130.0 (CH, CH=CH), 130.2 (CH, 
CH=CH), 176.1 (C, C=O); MS (TOF ES–) m/z 348.3 ([M – H], 100%); HRMS 
(TOF ES–) calcd for C20H34N3O2Na ([M – H]
, 100%) 348.2651, found 348.2665. 
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(2’S,3’S,4’R)-2’-[(Z,Z)-2’’-Azido-eicosa-11,14-dienoylamino]-1’-O-[2,3-O-
isopropylidene-L-threitol]octadecane-O-isopropylidene-octadecane-1’,3’,4’-
triol (145) 
 
 
 
 
DMF (1 µL, 13 µmol) was added to a solution of (Z,Z)-2-azido-eicosa-11,14-
dienoic acid 132 (45 mg, 0.129 mmol) in CH2Cl2 (1 mL) and the mixture was 
cooled to 0 ºC.  A solution of oxalyl chloride (22 µL, 0.258 mmol) in CH2Cl2 (0.5 
mL) was added dropwise over 2 min. After 2 h, the volatiles were removed under 
reduced pressure to provide the corresponding acid chloride 140 as a pale yellow 
oil, which was used directly in the next step without further purification (48 mg, 
quant.):  A solution of freshly prepared acid chloride 140 (48 mg, 0.129 mmol) in 
CH2Cl2 (0.5 mL) was added dropwise over 2 min to a solution of amine 118 (97 
mg, 019 mmol) and NEt3 (36 µL, 0.26 mmol) in CH2Cl2 at 0 ºC. The reaction 
mixture was stirred for 12 h and then diluted with CH2Cl2 (10 mL), washed 
sequentially with NaHCO3 solution (10 mL), brine (2 mL) and then dried over 
Na2SO4. The drying agent was removed by filtration and the filtrate concentrated 
under reduced pressure. Purification of the residue by flash column 
chromatography (20% EtOAc in hexane) provided amide 145 as a colourless oil 
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(97 mg, 90%, 1:1 mixture of epimers); data on epimeric mixture: Rf = 0.3 (25% 
EtOAc in hexane); max(film) / cm
-1 3395br (OH), 2925s, 2855s, 2100m (N3), 
1660m (C=O), 1543w, 1465m, 1370m, 1251m, 1219m, 1080m, 1057m, 850w, 
721w; H(500 MHz, CDCl3) 0.84-0.88 (stack, 6H, 2  CH2CH3), 1.19-1.41 (stack, 
54H), 1.45-1.55 (stack, 2H), 1.71-1.93 (stack, 2H, C(3”)H2), 2.03 (app. q, J 7.2, 4H, 
CH2CH=CHCH2CH=CHCH2), 2.15-2.20 (br s, 1H, OH), 2.75 (app. t, J 6.6, 2H, 
CH=CHCH2CH=CH), 3.51-3.60 (stack, 2H, C(1‟)HaHb for both epimers, C(1)HaHb 
for both epimers), 3.63-3.70 (stack, 2H, C(1)HaHb for both epimers, C(4)HaHb for 
both epimers), 3.72-3.80 (stack, 2H, C(4)HaHb for both epimers, C(1‟)HaHb for both 
epimers), 3.87-3.93 (stack, 1.5H, C(2”)H for epimer 1, C(3)H for both epimers), 
3.95 (dd, J 7.3, 4.6, 0.5H, C(2”)H for epimer 2), 3.97-4.02 (stack, 1H, C(2)H for 
both epimers), 4.03-4.11 (stack, 2H, C(3‟)H for both epimers, C(4‟)H for both 
epimers), 4.12-4.18 (stack, 1H, C(2‟)H for both epimers), 5.27-5.39 (stack, 4H, 2  
CH=CH), 6.46 (d, J 9.0, 0.5H, NH for epimer 1), 6.49 (d, 0.5H, J 9.7, NH for 
epimer 2); C(125 MHz, CDCl3) [14.0, 14.1 (CH3, C18‟, C20”)], [22.5, 22.7 (CH2, 
C3‟‟‟], 25.3 (CH2), 25.4 (CH2), 25.6 (CH2, C13”), 25.7 (CH3, C(CH3)a(CH3)b of 1,2-
anti diol for both epimers (resonance overlap)], 26.5 (CH2), 26.6 (CH2), [26.91, 
26.94, 26.98 (CH3, C(CH3)2 of 1,2-syn diol for both epimers (resonance overlap))], 
[27.18, 27.20 (CH2, C10”, C16”)], [27.86, 27.93 (CH3, C(CH3)a(CH3)b of 1,2-anti 
diol)], 29.0 (CH2), [29.16, 29.20, 29.25, 29.33, 29.4, 29.5, 29.6, 29.7 (CH2, alkyl 
chain, some resonance overlap)], 31.5 (CH2), 31.9 (CH2), [32.1, 32.3 (CH2, C3”)], 
[48.4, 48.6 (CH, C2‟)], [62.4, 62.5, (CH2, C4)], [64.3, 64.6 (CH, C2”)], 71.4 (CH2, 
C1‟ for both epimers (resonance overlap)), [71.71, 71.73 (CH2, C1)], [76.0, 76.1 
(CH, C3‟ or C4‟)], [76.49, 76.50 (CH, C2)], [77.6, 77.7 (CH, C4‟ or C3‟)], [79.2, 79.4 
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(CH, C3)], [108.1, 108.2 (C, (CH3)2C of 1,2-anti diol)], [109.29, 109.31 (C, (CH3)2C 
of 1,2-syn diol)], 127.9 (CH, CH=CH), 128.0 (CH, CH=CH), 130.0 (CH, CH=CH), 
130.2 (CH, CH=CH), [168.8, 168.9 (C, C=O)]; MS (TOF ES+) m/z 855.2 [M + Na]+, 
100%; HRMS (TOF ES+) 855.6579 [M + Na]+.  C48H88N4O7Na requires 855.6551. 
 
 
 
Triazole 146 
 
 
 
CuSO4 solution (10 µL of a 0.5 M aqueous solution, 10 µmol) and sodium 
ascorbate solution (40 µL of a 1 M aqueous solution, 40 µmol) were added to a 
solution of azide 145 (80 mg, 0.096 mmol) and alkyne 114 (33 mg, 0.115 mmol) in 
tBuOH / H2O (1 mL, 1:1) at r.t. The reaction mixture was heated for 10 h at 50 °C 
and then diluted with CHCl3 (10 mL), and washed with brine (3 mL).  The phases 
were separated and the aqueous layer was extracted with CHCl3 (2  5 mL). The 
combined organic layers were dried over Na2SO4 and the volatiles were removed 
under reduced pressure. Purification of the residue by flash column 
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chromatography (gradient: 50%  90% EtOAc in hexane) afforded 1,2,3-triazole 
146 as a colourless oil (108 mg, 95%, isolated as 45 mg of a more polar epimer, 
40 mg of less polar epimer and 23 mg of 1:1 mixture of two epimers).  Data for 
less polar epimer:  Rf = 0.3 (40% EtOAc in hexane); []D
20 = + 5.6 (c 1, CHCl3); 
max(film) / cm
-1 3316br (OH), 2924s, 2855s, 1717m (C=O), 1688s (C=O), 1515m, 
1458m, 1367s, 1248s, 1220w, 1171w, 1100s, 848w, 723w; H(500 MHz, CDCl3) 
0.84-0.89 (stack, 6H, 2  CH2CH3), 1.18-1.34 (stack, 43H, alkyl chain methylenes, 
C(CH3)a(CH3)b for 1,2-anti-diol), 1.35-1.50 [stack, 22H, including (1.37 (stack, 6H, 
C(CH3)a(CH3)b of 1,2-anti diol, C(CH3)a(CH3)b of 1,2-syn diol), 1.39 (s, 3H, 
C(CH3)a(CH3)b of 1,2-syn diol), 1.42 (s, 9H, C(CH3)3))], 1.98-2.05 (stack, 4H, 
CH2CH=CHCH2CH=CHCH2), 2.08-2.24 (stack, 2H, C(3”)H2), 2.74 (app. t, J 6.8, 
2H, CH=CHCH2CH=CH), 3.25-3.32 (stack, 2H, CH2NHBoc), 3.40-3.44 (m, 1H, 
C(1‟)HaHb), 3.48-3.54 (stack, 4H, CH2CH2NHBoc, C(1)H2), 3.58-3.63 (stack, 4H, 
PEG CH2O), 3.64-3.72 (stack, 7H, C(4)H2, C(1‟)HaHb, C(4‟‟‟)H2, 2  PEG CH2O), 
3.85-3.89 (m, 1H, C(2)H), 3.90-3.95 (m, 1H, C(3)H), 3.93-4.03 (stack, 2H, C(3‟)H, 
C(4‟)H), 4.06-4.12 (m, 1H, C(2‟)H), 4.66-4.69 (stack, 2H, C(3‟”)H2), 4.93-4.99 (m, 
1H, C(2‟‟)H), 5.02-5.09 (m, 1H, NHBoc), 5.26-5.39 (stack, 4H, 2  CH=CH), 6.76 
(d, J 8.3, 1H, NH), 7.70  (br s, 1H, C(1‟”)H), OH resonance not observed; C(125 
MHz, CDCl3) [14.0, 14.1 (CH3, C18‟, C26”)], 22.5 (CH2), 22.7 (CH2), [25.6 (CH2, 
CH=CHCH2CH=CH, and CH3, C(CH3)a(CH3)b of 1,2-anti diol)], 25.9 (CH2), 26.5 
(CH2), 26.9 (CH3, C(CH3)a(CH3)b of 1,2-syn diol), 27.1 (CH3, C(CH3)a(CH3)b of 1,2-
syn diol), [27.17, 27.19 (CH2, CH2CH=CHCH2CH=CHCH2)], 27.9 (CH3, 
C(CH3)a(CH3)b of 1,2-anti diol), 28.4 (CH3, C(CH3)3), 28.9 (CH2), 29.0 (CH2), [29.2, 
29.32, 29.34, 29.4 (CH2, resonance overlap)], [29.58, 29.63, 29.70 (CH2, 
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resonance overlap)], 31.5 (CH2), 31.9 (CH2), 33.1 (CH2, C3‟‟), 40.4 (CH2, 
CH2NHBoc), 48.8 (CH, C2‟), 62.7 (CH2, C4), 64.6 (CH2, C3‟”), 65.6 (CH, C2”), 70.0 
(CH2, C4‟‟‟), [70.2, 70.3, 70.50, 70.52 (CH2, 4  CH2O in PEG linker)], 71.0 (CH2, 
C1‟), 71.6 (CH2, C1), 75.9 (CH, C3‟ or C4‟), 76.5 (CH, C2), 77.5 (CH, C4‟ or C3‟), 
79.4 (CH, C3 and C, C(CH3)3), 108.1 (C, (CH3)2C of 1,2-anti diol), 109.2 (C, 
(CH3)2C of 1,2-syn diol), 123.2 (CH, C1‟”), 127.9 (CH, CH=CH), 128.0 (CH, 
CH=CH), 130.0 (CH, CH=CH), 130.2 (CH, CH=CH), 145.4 (C, C2‟”), 167.3 (C, 
CH2C(O)NH), C=O of Boc not observed; MS (TOF ES+) m/z 1142.9 [M + Na]
+, 
100%; HRMS (TOF ES+) calcd for C62H113N5O12Na [M + Na]
+ 1142.8283, found 
1142.8251. 
 
Data for more polar epimer:  Rf = 0.2 (40% EtOAc in hexane); []D
20 = + 11.2 (c 1, 
CHCl3); max(film) / cm
-1 3293br (OH), 2925s, 2854s, 1715m (C=O), 1685m (C=O), 
1532m, 1463m, 1368m, 1249m, 1220w, 1108m, 724w; H(500 MHz, CDCl3) 0.84-
0.89 (stack, 6H, 2  CH2CH3), 1.19-1.34 (stack, 43H, alkyl chain methylenes, 
C(CH3)a(CH3)b for 1,2-anti-diol), 1.35-1.50 [stack, 22H, (including 1.37 (6H, stack, 
C(CH3)a(CH3)b of 1,2-anti diol, C(CH3)a(CH3)b of 1,2-syn diol), 1.39 (s, 3H, 
C(CH3)a(CH3)b of 1,2-syn diol), 1.42 (s, 9H, C(CH3)3))], 1.98-2.05 (stack, 5H, 
CH2CH=CHCH2CH=CHCH2, C(3”)HaHb), 2.16-2.25 (m, 1H, C(3”)HaHb), 2.74 (app. 
t, J 6.6, 2H, CH=CHCH2CH=CH), 3.24-3.33 (stack, 2H, CH2NHBoc), 3.38-3.43 (m, 
1H, C(1‟)HaHb), 3.49-3.56 (stack, 4H, CH2CH2NHBoc, C(1)H2), 3.58-3.67 (stack, 
6H, PEG CH2O), 3.64-3.72 (stack, 5H, C(4)H2, C(1‟)HaHb, 2  PEG CH2O), 3.89-
3.97 (stack, 2H, C(2)H, C(3)H), 3.98-4.05 (stack, 2H, C(3‟)H, C(4‟)H), 4.05-4.11 
(m, 1H, C(2‟)H), 4.66-4.69 (stack, 2H, C(3‟”)H2), 4.99-5.10 (stack, 2H, C(2‟‟)H, 
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NHBoc), 5.26-5.39 (stack, 4H, 2  CH=CH), 6.57 (d, J 8.4, 1H, NH), 7.75 (br s, 1H, 
C(1‟”)H), OH resonance not observed; C(125 MHz, CDCl3) [14.0, 14.1 (CH3, C18‟, 
C20”)], 22.5 (CH2), 22.7 (CH2), [25.6 (CH2, CH=CHCH2CH=CH, and CH3, 
C(CH3)a(CH3)b of 1,2-anti diol)], 25.8 (CH2), 26.5 (CH2), 26.9 (CH3, C(CH3)a(CH3)b 
of 1,2-syn diol), 27.1 (CH3, C(CH3)a(CH3)b of 1,2-syn diol), [27.17, 27.19 (CH2, 
CH2CH=CHCH2CH=CHCH2)], 27.9 (CH3, C(CH3)a(CH3)b of 1,2-anti diol), 28.4 
(CH3, C(CH3)3), 29.0 (CH2), 29.1 (CH2), [29.22, 29.27, 29.31, 29.33, 29.4 (CH2, 
resonance overlap)], [29.6, 29.7 (CH2, resonance overlap)], 31.5 (CH2), 31.9 
(CH2), 32.4 (CH2, C3‟‟), 40.3 (CH2, CH2NHBoc), 49.0 (CH, C2‟), 62.7 (CH2, C4), 
64.6 (CH2, C3‟” and CH, C2”), [70.0, 70.2, 70.49, 70.51 (CH2, 5  CH2O in PEG 
linker, resonance overlap)], 70.9 (CH2, C1‟), 71.7 (CH2, C1), 75.8 (CH, C3‟ or C4‟), 
76.7 (CH, C2 or C3), 77.5 (CH, C4‟ or C3‟), 79.1 (CH, C3 or C2 and C, C(CH3)3), 
108.1 (C, (CH3)2C of 1,2-anti diol), 109.2 (C, (CH3)2C of 1,2-syn diol), 122.2 (CH, 
C1‟”), 127.9 (CH, CH=CH), 128.0 (CH, CH=CH), 130.0 (CH, CH=CH), 130.2 (CH, 
CH=CH), 145.5 (C, C2‟”), 156.0 (C, OC(O)NH), 167.3 (C, amide C=O); 
 
 
 
 
 
Chapter 5         Experimental Section 
272 
 
Alexa 594-labelled ThrCer (110) 
 
 
 
TFA (60 µL) was added dropwise over 1 min to a solution of Boc amide 146 (60 
mg, 0.050 mmol) in CH2Cl2 / CH3OH (2:1, 0.6 mL).  After stirring overnight at r.t., 
the reaction mixture was concentrated under reduced pressure and the residual 
TFA was removed by co-evaporation with Et2O (3  3 mL) to provide crude amine 
147 as a white solid (51 mg, quant.), which was used in the step without further 
purification.  
NEt3 (1 µL, 7.2 μmol) was added to a solution of crude amine 147 (2.1 mg, 2.3 
μmol) in DMF (10 μL). After stirring for 1 h at r.t., Alexa Fluor® 488 carboxylic acid, 
succinimidyl ester 144 (1.2 mg, 1.1 μmol) was added.  The reaction mixture was 
stirred for 12 h at r.t. and then the volatiles were removed under reduced pressure.  
Purification of the residue by flash column chromatography (eluent: gradient 0-
50% CH3OH in CHCl3) afforded compound 110 as a dark blue solid (0.7 mg, 62%); 
selected data: Rf = 0.3 for epimer A, Rf = 0.2 for epimer B in 65:35:4  CHCl3 / 
MeOH / aq. NH3; 
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(2S,3S,4R)-2-(Z,Z)-2’’-Azido-eicosa-11’’,14’’-dienoylamino-3,4-O-
isopropylidene-1-O-(2’,3’,4’,6’-tetra-O-benzyl--D-galactopyra-
nosyl)octadecane-1,3,4-triol (141) 
 
 
DMF (1 µL, 13µmol) was added to a solution of (Z,Z)-2-azido-eicosa-11,14-dienoic 
acid (32 mg, 0.093 mmol) in CH2Cl2 (1 mL) and the mixture was cooled to 0 ºC.  A 
solution of oxalyl chloride (16 µL, 0.186 mmol) in CH2Cl2 (0.5 mL) was added 
dropwise over 2 min. After 2 h, the volatiles were removed under reduced 
pressure to provide the corresponding acid chloride 140 as a pale yellow oil, which 
was used directly in the next step without further purification (48 mg, quant.):  A 
solution of freshly prepared acid chloride 140 (34 mg, 0.093 mmol) in CH2Cl2 (0.5 
mL) was added dropwise over 2 min to a solution of amine 128 (57 mg, 0.062 
mmol) and NEt3 (18 µL, 0.013 mmol) in CH2Cl2 at 0 ºC. The reaction mixture was 
stirred for 12 h and then diluted with CH2Cl2 (10 mL), washed sequentially with 
NaHCO3 solution (10 mL), brine (2 mL) and then dried over Na2SO4. The drying 
agent was removed by filtration and the filtrate concentrated under reduced 
pressure. Purification of the residue by flash column chromatography (20% EtOAc 
in hexane) provided amide 141 as a colourless oil (70 mg, 85%, 1:1 mixture of 
epimers); data on epimeric mixture: Rf = 0.3 (20% EtOAc in hexane); max(film) / 
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cm-1 2923s, 2853m, 2103m (N3), 1683m, (C=O), 1586w, 1513s, 1464m, 1368w, 
1302m, 1247s, 1172m, 1092m, 1038s, 822m, 720w; H(500 MHz, CDCl3) 0.84-
0.90 (stack, 6H, 2  CH2CH3), 1.16-1.40 (stack, 54H), 1.41-1.52 (stack, 2H), 1.61-
1.86 (stack, 2H, C(3”)H2), 1.99-2.07 (stack, 4H, CH2CH=CHCH2CH=CHCH2), 
2.73-2.78 (stack, 2H, CH=CHCH2CH=CH), 3.33-3.41 (stack, 1H, C(6‟)HaHb for 
both epimers), 3.42-3.47 (stack, 1H, C(6‟)HaHb for both epimers), 3.58-3.65 (stack, 
1H, C(1)HaHb for both epimers), 3.67-3.71 (m, 0.5H, C(2”)H for epimer 1), 3.74-
3.81 (stack, 12H, 4  ArOCH3 for both epimers, and 1H, C(2”)H for epimer 2), 
3.81-3.89 (stack, 3H, C(3‟)H for both epimers, C(4‟)H for both epimers, C(5‟)H for 
both epimers), 3.90-4.01 (stack, 3H, C(1)HaHb for both epimers, C(4)H for both 
epimers, C(2‟)H for both epimers), 4.02-4.10 (stack, 1H, C(2)H for both epimers), 
4.11-4.19 (stack, 1H, C(3)H for both epimers), 4.27 (A of AB, JA-B 11.6, 1H, 
C(6‟)OCHaHbAr for epimer 1), 4.28 (A of AB, JA-B 11.6, 1H, C(6‟)OCHaHbAr for 
epimer 2), 4.40 (B of AB, JB-A 11.6, 1H, C(6‟)OCHaHbAr for epimer 1), 4.42 (B of 
AB, JB-A 11.6, 1H, C(6‟)OCHaHbAr for epimer 1), 4.46 (A of AB, JA-B 11.2, 1H, 
C(4‟)OCHaHbAr for epimer 1), 4.47 (A of AB, JA-B 11.2, 1H, C(4‟)OCHaHbAr for 
epimer 2), 4.56 (A of AB, JA-B 11.2, 1H, C(2‟)OCHaHbAr for epimer 1), 4.57 (A of 
AB, JA-B 11.2, 1H, C(2‟)OCHaHbAr for epimer 2), 4.63 (A of AB, JA-B 11.2, 1H, 
C(3‟)OCHaHbAr for epimer 1), 4.64 (A of AB, JA-B 11.2, 1H, C(3‟)OCHaHbAr for 
epimer 2), 4.70 (B of AB, JB-A 11.2, 1H, C(3‟)OCHaHbAr for both epimers), 4.72 (B 
of AB, JB-A 11.2, 1H, C(2‟)OCHaHbAr for epimer 1), 4.73 (B of AB, JB-A 11.2, 1H, 
C(2‟)OCHaHbAr for epimer 2), 4.81 (B of AB, JB-A, 1H, C(4‟)OCHaHbAr for both 
epimers), 4.89 (stack, 1H, C(1‟)H, for both epimers), 5.27-5.41 (stack, 4H, 2  
CH=CH), 6.75-6.89 (stack, 8H, Ar), 7.12-7.19 (stack, 4H, Ar), 7.23-7.32 (stack, 4H, 
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Ar); C(125 MHz, CDCl3) [14.0, 14.1 (CH3, C18‟, C20”)], [22.6, 22.7 (CH2)], [25.6, 
25.7 (CH2, alkyl chain and C13” (resonance overlap)], [25.9, 26.0 (CH3, C(CH3)2 
for both epimers)], 26.6 (CH2), 26.7 (CH2), [27.18, 27.23 (CH2, C10”, C16”)], [28.1, 
28.2 (CH3, C(CH3)2 for both epimers)], 28.1 (CH2), [28.95, 29.02, 29.25, 29.30, 
29.32, 29.35, 29.38, 29.45, 29.48, 29.54, 29.57, 29.62, 29.65, 29.69, (CH2, alkyl 
chain, some resonance overlap)], 31.5 (CH2), 31.9  (CH2, C3”), 32.0 (CH2), 32.1 
(CH2), [48.8, 49.1 (CH, C2)], [55.21, 55.24 (CH3, 4  ArOCH3, resonance overlap)], 
[64.3, 64.6 (CH, C2”)], 68.6 (CH2, C1 for epimer 1), [68.88, 68.91 (CH2, C6‟)], 69.0 
(CH2, C1 for epimer 2), 69.8 (CH, C5‟ for both epimers (resonance overlap)), [72.6, 
72.7 (CH2, C(3‟)OCH2Ar), [73.07, 73.12, 73.15 (CH2, C(3‟)OCH2Ar and 
C(3‟)OCH2Ar (resonance overlap))], 74.2 (CH2, C(4‟)OCH2Ar for both epimers 
(resonance overlap)), [74.4, 74.5 (CH, C4‟)], [75.1, 75.2 (CH, C3)], 76.2 (CH, C2‟ 
for both epimers (resonance overlap)), [77.68, 77.72 (CH, C4)], [78.8, 78.9 (CH, 
C3‟)], [99.0, 99.2 (CH, C1‟)], [107.87, 107.93 (C, (CH3)2C)], [113.6, 113.73, 113.75 
113.77 (CH, Ar ortho to OMe)], 127.9 (CH, CH=CH), 128.0 (CH, CH=CH), [129.0, 
129.4, 129.5, 129.8, 129.9, (CH, Ar meta to OMe)], 130.0 (CH, CH=CH), 130.2 
(CH, CH=CH), [130.6, 130.7, 130.9 (C, Ar para to OMe, some resonance 
overlap)], [159.1, 159.2, 159.3 (C, Ar ipso to OMe)], [168.8, 168.9 (C, C=O)]; MS 
(TOF ES+) m/z 1353.8 [M + Na]+, 100%; HRMS (TOF ES+) calcd for 
C79H118N4O13Na [M + Na]
+ 1353.8593, found 1353.8610. 
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Triazole 142 
 
 
 
CuSO4 solution (10 µL of a 0.5 M aqueous solution, 10 µmol) and sodium 
ascorbate solution (40 µL of a 1 M aqueous solution, 40 µmol) were added to a 
solution of azide 145 (100 mg, 0.075 mmol) and alkyne 114 (32 mg, 0.115 mmol) 
in tBuOH / H2O (1 mL, 1:1) at r.t. The reaction mixture was heated for 10 h at 50 
°C and then diluted with CHCl3 (10 mL), and washed with brine (3 mL).  The 
phases were separated and the aqueous layer was extracted with CHCl3 (2  5 
mL). The combined organic layers were dried over Na2SO4 and the volatiles were 
removed under reduced pressure. Purification of the residue by flash column 
chromatography (gradient: 50%  90% EtOAc in hexane) afforded 1,2,3-triazole 
142 as a colourless oil (95 mg, 78% %, 1:1 mixture of epimers); data on epimeric 
mixture: Rf = 0.3 (40% EtOAc in hexane); max(film) / cm
-1 2916s, 2849m, 1789m, 
1735, 1473m, 1368w, 1302m, 1206s, 1075m, 1172m, 909s, 730s; H(500 MHz, 
CDCl3) 0.84-0.89 (stack, 6H, 2  CH2CH3), 1.12-1.36 (stack, 44H, alkyl chain 
methylenes, C(CH3)a(CH3)b), 1.37-1.44 [stack, 16H, including C(CH3)a(CH3)b, 
C(CH3)3))], 1.92-2.08 (stack, 6H, CH2CH=CHCH2CH=CHCH2, C(3”)H2), 2.73 (app. 
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t, J 6.7, 2H, CH=CHCH2CH=CH), 3.21-3.33 (stack, 3H, C(6‟)HaHb for both 
epimers, CH2NHBoc), 3.39-3.46 (stack, 1H, C(6‟)HaHb for both epimers), 3.47-3.54 
(stack, 3H, CH2CH2NHBoc, C(1)HaHb for both epimers), 3.55-3.74 (stack, 12H, 
including 4  PEG CH2O, C(4‟‟‟)H2), 3.75-3.82 (stack, 13H, 4  ArOCH3 for both 
epimers, C(3‟)H for epimer 1 and C(4‟)H for epimer 1), 3.84-4.16 (stack, 8H, 
including C(2‟)H for both epimers, C(3‟)H for epimer 2, C(4‟)H for epimer 2, 
C(1)HaHb for both epimers, C(2)H for both epimers, C(4)H for both epimers, C(3)H 
for both epimers, 1  PEG CH2O), 4.17-4.21 (1H, stack), 4.24-4.31 (stack, 2H, A of 
AB, C(6‟)OCHaHbAr for both epimers), 4.40-4.59 (stack, 2H), 4.64-4.76 (stack, 
2H), 4.76-4.82 (stack, 2H, including C(1‟)H, for both epimers), 4.90-4.95 (stack, 
1H, C(2‟‟)H for both epimers), 4.99-5.06 (stack, 1H, NHBoc for both epimers), 
5.25-5.39 (stack, 4H, 2  CH=CH), 6.72-6.88 (stack, 8H, Ar), 7.11-7.19 (stack, 4H, 
Ar), 7.22-7.30 (stack, 4H, Ar), 7.66 (br s, 0.5H, C(1‟”)H) for epimer 1), 7.72  (br s, 
0.5H, C(1‟”)H) for epimer 2), CONH resonance not observed; C(125 MHz, CDCl3) 
[14.0, 14.1 14.2 (CH3, resonance overlap, C18, C20”)], 22.5 (CH2), 22.7 (CH2), 
[25.6, 25.7 (CH2, CH=CHCH2CH=C)], [25.86, 25.89 CH3, C(CH3)a(CH3)b], 26.5 
(CH2), [27.18, 27.20 (CH2, CH2CH=CHCH2CH=CHCH2)], 28.2 (CH3, 
C(CH3)a(CH3)b, 28.4 (CH3, C(CH3)3), 28.8 (CH2), 29.0 (CH2), [29.2, 29.31, 29.33, 
29.4 (CH2, resonance overlap)], [29.58, 29.63, 29.70 (CH2, resonance overlap)], 
31.5 (CH2), 31.9 (CH2), 33.1 (CH2, C3‟‟), 40.3 (CH2, CH2NHBoc), [49.4, 49.5 (CH, 
C2)], [55.21, 55.24 (CH3, 4  ArOCH3, resonance overlap)], [64.3, 64.6 (CH, C2”)], 
64.7 (CH2, C3‟”), 68.2 (CH2, C1), [69.1, 69.2 (CH2, C6‟, resonance overlap), [70.0, 
70.2, 70.4, 70.50, 70.52 (CH2, 4  CH2O in PEG linker)], [72.6, 72.9 (CH2, 
OCH2Ar), [73.04, 73.12, 73.15 (CH2, OCH2Ar (resonance overlap))], [74.1, 74.2 
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(CH2, OCH2Ar (resonance overlap)), [74.4, 74.5 (CH, C4‟)], [75.1, 75.2 (CH, C3)], 
76.2 (CH, C2‟ for both epimers (resonance overlap)), 77.6 (CH, C4, for both 
epimers (resonance overlap)], [78.8, 78.9 (CH, C3‟ for both epimers (resonance 
overlap)], 79.4 (CH, C3 and C, C(CH3)3) [98.9, 99.6 (CH, C1‟)], [107.87, 107.91 (C, 
(CH3)2C)], [113.6, 113.73, 113.75 113.77 (CH, Ar ortho to OMe)], [121.8, 122.1 
(CH, C1‟”)], 127.9 (CH, CH=CH), 128.0 (CH, CH=CH), [129.0, 129.4, 129.5, 129.8, 
129.9, (CH, Ar meta to OMe)], 130.0 (CH, CH=CH), 130.2 (CH, CH=CH), [130.6, 
130.7, 130.9 (C, Ar para to OMe, some resonance overlap)], [145.4, 145.2 (C, 
C2‟”)], [159.1, 159.2, 159.3 (C, Ar ipso to OMe)], [167.31, 167,33 (C, 
CH2C(O)NH)], [171.1 C of Boc]; MS (TOF ES+) m/z 1641.0 [M + Na]
+, 100%; 
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Alexa 594-labelled GalCer(C20:2) (109) 
 
 
 
TFA (60 µL) was added dropwise over 1 min to a solution of Boc amide 142 (84 
mg, 0.050 mmol) in CH2Cl2 / CH3OH (2:1, 0.6 mL).  After stirring overnight at r.t., 
the reaction mixture was concentrated under reduced pressure and the residual 
TFA was removed by co-evaporation with Et2O (3  3 mL) to provide crude amine 
143 as a white solid (49 mg, quant.), which was used in the step without further 
purification: selected data: MS (TOF ES+) m/z 1020.8 ([M + Na]+, 100%);  
NEt3 (1 µL, 7.2 μmol) was added to a solution of crude amine 143 (2.3 mg, 2.3 
μmol) in DMF (10 μL). After stirring for 1 h at r.t., Alexa Fluor® 594 carboxylic acid, 
succinimidyl ester 144 (1.0 mg, 1.2 μmol) was added.  The reaction mixture was 
stirred for 12 h at r.t. and then the volatiles were removed under reduced pressure.  
Purification of the residue by flash column chromatography (eluent: gradient 0-
50% CH3OH in CHCl3) afforded compound 109 as a dark blue solid (0.9 mg, 70%); 
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selected data: Rf = 0.3 for epimer A, Rf = 0.2 for epimer B in 65:35:4  CHCl3 / 
MeOH / aq. NH3. 
 
 
Methyl 3’,4’-O-isopropylidene-2’-O-(2,3,4,6-tetra-O-p-methoxybenzyl-D-
galactopy-ranosyl)-(1→2)-L-threonate (155) 
 
 
 
PPh3 (1.46 g, 5.55 mmol) and CBr4 (1.84 g, 5.55 mmol) were added sequentially to 
a solution of 2,3,4,6-tetra-O-p-methoxybenzyl-D-galactose 126 (1.22 g, 1.85 mmol) 
in CH2Cl2 (10 mL) at r.t. The reaction mixture was stirred for 3 h. In separate 
flasks, a solution of TMU (1.2 mL), DIPEA (1.6 mL) and Bu4NBr (1.79 g, 5.55 
mmol) in CH2Cl2 (5 mL), and a solution of methyl 3,4-O-isopropylidene-L-threonate 
154 (493 mg, 2.59 mmol) in CH2Cl2 (5 mL) were stirred over activated 3 Å MS for 
30 min, after which time, these solutions were added dropwise over 5 min, and 
sequentially (TMU/DIPEA/Bu4NBr solution first), to the solution containing the 
glycosyl donor.  The reaction mixture was stirred at r.t. for 2 d until there was no 
evidence by TLC that the donor was still being consumed.  The reaction mixture 
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was then concentrated under reduced pressure, re-suspended in toluene (10 mL), 
filtered through a silica plug, washed with toluene (150 mL) and concentrated 
under reduced pressure to provide the crude product.  Purification of the residue 
by flash column chromatography (20% EtOAc in hexane) afforded glycoside 153 
as a colourless oil (693 mg, 45%, single α-anomer); Rf = 0.3 (20% EtOAc in 
hexane); []D
18 = + 11.2 (c 1, CHCl3); max(film) / cm
-1: 2935w, 2872w, 1739m 
(C=O), 1623m, 1581w, 1485m, 1415m, 1323s, 1128s, 1103s, 1064s, 883m, 843s, 
736s, 697s; H(500 MHz, CDCl3) 1.30 (s, 3H, 1  C(CH3)2), 1.35 (s, 3H, 1  
C(CH3)2), 3.40 (A of ABX, JA-B 8.9, JA-X 5.7, 1H, C(6)HaHb), 3.44-3.49 (m, 1H, 
C(6)HaHb), 3.72 (s, 3H, C(O)OCH3), 3.76 (s, 3H, ArOCH3), 3.775 (s, 3H, ArOCH3), 
3.778 (s, 3H, ArOCH3), 3.79 (s, 3H, ArOCH3), 3.90 (dd, J 8.9, 6.3, 1H, C(4‟)HaHb), 
3.92-3.96 (stack, 2H, H3, H4), 4.00-4.06 (stack, 2H, H2, C(4‟)HaHb), 4.15 (app t, J 
6.5, 1H, H5), 4.27 (d, J 7.0, 1H, H2‟), 4.30 (A of AB, JA-B 11.4, 1H, C(6)OCHaHbAr), 
4.35 (B of AB, JB-A 11.4, 1H, C(6)OCHaHbAr), 4.41 (app. q, J 6.6, 1H, H3‟), 4.48 (A 
of AB, JA-B 11.2, 1H, C(4)OCHaHbAr), 4.615 (A of AB, JA-B 11.2, 1H, 
C(3)OCHaHbAr), 4.620 (A of AB, JA-B 11.4, 1H, C(2)OCHaHbAr), 4.73 (B of AB, JB-A 
11.4, 1H, C(2)OCHaHbAr), 4.74 (A of AB, JA-B 11.2, 1H, C(3)OCHaHbAr), 4.82 (B of 
AB, JB-A 11.2, 1H, C(4)OCHaHbAr), 5.09 (d, J 3.7, 1H, H1), 6.73-6.87 (stack, 8H, 
Ar), 7.15-7.19 (stack, 4H, Ar), 7.23-7.33 (stack, 4H, Ar); c(125 MHz, CDCl3) 25.3 
(CH3, 1  C(CH3)2), 26.1 (CH3, 1  C(CH3)2), 52.0 (CH3, C(O)OCH3), 55.2 (CH3, 4 
 ArOCH3 resonance overlap), 66.1 (CH2, C4‟), 68.3 (CH2, C6), 69.7 (CH, C5), 
72.0 (CH2, C(2)OCH2Ar), 72.9 (CH2, C(3)OCH2Ar), 73.1 (CH2, C(6)OCH2Ar), 74.2 
(CH2, C(4)OCH2Ar), 74.4 (CH, C4), 75.3 (CH, C3‟), 75.4 (CH, C2‟), 75.6 (CH, C2), 
78.3 (CH, C3), 96.0 (CH, C1), 109.7 (C, (CH3)2C), [113.51, 113.54, 113.6, 113.7 
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(CH, Ar ortho to OMe)], [129.0, 129.5, 129.8 (CH, Ar meta to OMe, some 
resonance overlap)], 130.0 (C, Ar para to OMe), 130.8 (C, Ar para to OMe), 130.9 
(C, Ar para to OMe), 131.2 (C, Ar para to OMe), 158.9 (C, Ar ipso to OMe), 159.0 
(C, Ar ipso to OMe), 159.1 (C, Ar ipso to OMe), 159.2 (C, Ar ipso to OMe), 169.9 
(C, C=O); MS (TOF ES+) m/z 855.2 ([M + Na]+, 100%); HRMS (TOF ES+) calcd 
for C46H56O14Na ([M + Na]
+) 855.3568, found 855.3531. 
 
This reaction was first performed without the addition of Hünig‟s base, which led to 
the formation of a mixture of two glycosyl products 155 and 156.  Selected data for 
156: 
 
 
 
 
H(500 MHz, CDCl3) selected data: 1.43 (s, 3H, 1  C(CH3)2), 1.44 (s, 3H, 1  
C(CH3)2), 3.65 (dd, J 11.6, 5.0, 1H, C(4‟)HaHb), 3.73 (s, 3H, C(O)OCH3), 3.78 (s, 
3H, ArOCH3), 3.79 (s, 6H, 2  ArOCH3), 3.80 (s, 3H, ArOCH3), 4.42-4.44 (m, 1H, 
H2‟), 4.90 (d, J 3.5, 1H, H1); c(125 MHz, CDCl3) selected data: 25.9 (CH3, 1  
C(CH3)2), 26.8 (CH3, 1  C(CH3)2), 52.3 (CH3, C(O)OCH3), 55.2 (CH3, 4  ArOCH3 
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resonance overlap), 67.5, 68.6, 69.5, 72.6, 72.7, 73.0, 74.2, 74.6, 75.54, 76.2, 
78.4, 78.5, 98.2 (CH, C1), 111.5 (C, (CH3)2C), 170.9 (C, C=O). 
 
 
 
 
3’,4’-O-isopropylidene-2’-O-(2,3,4,6-tetra-O-p-methoxybenzyl-D-
galactopyranosyl)-(1→2)-L-threitol (153) 
 
 
 
 
A solution of methyl ester 155 (200 mg, 0.24 mmol) in Et2O (1 mL) was added over 
5 min to a stirred suspension of LiAlH4 (14 mg, 0.36 mmol) in Et2O (2 mL).  After 
an initial vigorous reaction had subsided, the mixture was heated at reflux for 3 h 
and then cooled to r.t., diluted with Et2O (10 mL) and poured into NH4Cl solution (5 
mL).  H2O (5 mL) was added and the layers were separated.  The aqueous phase 
was extracted with Et2O (3  10 mL).  The combined organic extracts were dried 
(Na2SO4) and concentrated under reduced pressure.  Purification of the residue by 
flash column chromatography (30% EtOAc in hexane) afforded alcohol 153 as a 
colourless oil (183 mg, 95%).  Rf = 0.3 (40% EtOAc in hexane); []D
18 = + 39.6 (c 1, 
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CHCl3); max(film) / cm
-1: 3465 br (OH), 2920w, 2878w, 1497w, 1454m, 1370m, 
1209m, 1078s, 1049s, 911m, 850m, 736s, 698s; H(500 MHz, CDCl3) 1.25 (s, 3H, 
1  C(CH3)2), 1.34 (s, 3H, 1  C(CH3)2), 3.40-3.49 (stack, 2H, C(6)HaHb), 3.57-3.61 
(stack, 2H, C(1‟)HaHb), 3.61-3.68 (m, 1H, H2‟), 3.766 (s, 3H, ArOCH3), 3.769 (s, 
3H, ArOCH3), 3.774 (s, 3H, ArOCH3), 3.799 (s, 3H, ArOCH3), 3.84 (dd, J 8.4, 5.8, 
1H, C(4‟)HaHb), 3.89-3.95 (stack, 3H, C(4‟)HaHb, H3, H4), 4.01 (dd, J 9.9, 3.8, 1H, 
H2), 4.08-4.12 (m, 1H, H5), 4.16 (app. q, J 5.9, 1H, H3‟), 4.33 (A of AB, JA-B 11.7, 
1H, C(6)OCHaHbAr), 4.39  (B of AB, JB-A 11.7, 1H, C(6)OCHaHbAr), 4.48 (A of AB, 
JA-B 11.3, 1H, C(4)OCHaHbAr), 4.62 (A of AB, JA-B 11.2, 1H, C(2)OCHaHbAr), 4.65 
(s, 2H, C(3)OCH2Ar), 4.80 (B of AB, JB-A 11.2, 1H, C(2)OCHaHbAr),  4.82 (B of AB, 
1H, JB-A 11.3, C(4)OCHaHbAr), 4.89 (d, J 3.9, 1H, H1), 6.78-6.91 (stack, 8H, Ar), 
7.13-7.26 (stack, 6H, Ar), 7.27-7.32 (stack, 2H, Ar); c(125 MHz, CDCl3) 24.9 
(CH3, 1  C(CH3)2), 26.3 (CH3, 1  C(CH3)2), 55.15 (CH3, ArOCH3), 55.19 (CH3, 2 
 ArOCH3, resonance overlap), 55.22 (CH3, ArOCH3), 62.0 (CH2, C1‟), 65.4 (CH2, 
C4‟), 68.4 (CH2, C6), 69.7 (CH, C5), 72.1 (CH2, C(3)OCH2Ar), 73.0 (CH2, 
C(6)OCH2Ar), 74.05 (CH, C4), 74.13 (CH2, C(2)OCH2Ar), 74.2 (CH2, 
C(4)OCH2Ph), 75.2 (CH, C3‟), 75.8 (CH, C2), 79.3 (CH, C3), 81.9 (CH, C2‟), 100.2 
(CH, C1), 109.3 (C, (CH3)2C), [113.5, 113.69, 113.74, 113.8 (CH, Ar ortho to 
OMe)], [129.0, 129.4, 129.7, 130.0 (CH, Ar meta to OMe)], [130.6, 130.8 (C, Ar 
para to OMe, some resonance overlap)], [159.08, 159.11, 159.2, 159.3 (C, Ar ipso 
to OMe)]; MS (TOF ES+) m/z 827.1 ([M + Na]+, 100%); HRMS (TOF ES+) calcd 
for C45H56O13Na ([M + Na]
+) 827.3619, found 827.3621. 
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Methyl 3’,4’-O-isopropylidene-2-O-(2,3,4,6-tetra-O-benzyl-D-galactopyra-
nosyl)-(1→2)-L-threonate (157) 
  
 
 
PPh3 (1.46 g, 5.55 mmol) and CBr4 (1.84 g, 5.55 mmol) were added sequentially to 
a solution of 2,3,4,6-tetra-O-benzyl-D-galactose 51 (1.00 g, 1.85 mmol) in CH2Cl2 
(10 mL) at r.t. The reaction mixture was stirred for 3 h.  In separate flasks, a 
solution of TMU (1.2 mL), DIPEA (1.6 mL) and Bu4NBr (1.79 g, 5.55 mmol) in 
CH2Cl2 (5 mL), and a solution of methyl 3,4-O-isopropylidene-L-threonate 154 (493 
mg, 2.59 mmol) in CH2Cl2 (5 mL) were stirred over activated 3 Å MS for 30 min, 
after which time, these solutions were added dropwise (over 5 min) and 
sequentially (TMU/DIPEA/Bu4NBr solution first) to the solution containing the 
glycosyl donor.  The reaction mixture was stirred at r.t. for 2 d until there was no 
evidence by TLC that the donor was still being consumed.  The reaction mixture 
was then concentrated under reduced pressure, re-suspended in toluene (10 mL), 
filtered through a silica plug, washed with toluene (150 mL) and concentrated 
under reduced pressure to provide the crude product.  Purification of the residue 
by flash column chromatography (10% EtOAc in hexane) afforded glycoside 157 
as a colourless oil (593 mg, 45%, single α-anomer). Rf = 0.3 (15% EtOAc in 
hexane); []D
20 = + 50.0 (c 1, CHCl3); max(film) / cm
-1: 2991m, 2902m, 1742s 
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(C=O), 1613m, 1500w, 1455m, 1373m, 1266w, 1208m, 1101s, 1075s, 739m, 
698m; H(500 MHz, CDCl3) 1.32 (s, 3H, 1  C(CH3)2), 1.36 (s, 3H, 1  C(CH3)2), 
3.47 (A of ABX, JA-B 9.0, JA-X 5.8, 1H, C(6)HaHb), 3.53-3.56 (m, 1H, C(6)HaHb), 
3.72 (s, 3H, OCH3), 3.91 (dd, 1H, J 8.6, 6.3, C(4‟)HaHb), 3.99-4.03 (stack, 2H, H3, 
H4), 4.06 (dd, J 8.6, 6.6, 1H, C(4‟)HaHb), 4.09 (dd, J 10.1, 3.7, 1H, H2), 4.21 (app 
t, J 6.6, 1H, H5), 4.30 (d, J 7.0, 1H, H2‟), 4.38 (A of AB, JA-B 11.7, 1H, 
C(6)OCHaHbPh), 4.40-4.46 [stack, 2H, (including 1H, B of AB, JB-A 11.7, 
C(6)OCHaHbPh), H3‟], 4.57 (A of AB, JA-B 11.5, 1H, C(4)OCHaHbPh), 4.71 (A of 
AB, JA-B 11.7, 1H, C(2)OCHaHbPh), 4.72 (A of AB, JA-B 11.7, 1H, C(3)OCHaHbPh), 
4.82 (B of AB, JB-A 11.7, 1H, C(2)OCHaHbPh), 4.85 (B of AB, JB-A 11.7, 1H, 
C(3)OCHaHbPh), 4.92 (B of AB, JB-A 11.5, 1H, C(4)OCHaHbPh), 5.16 (d, J 3.6, 1H, 
H1), 7.23-7.41 (stack, 20H, OCH2Ph); c(125 MHz, CDCl3) 25.4 (CH3, 1  
C(CH3)2), 26.1 (CH3, 1  C(CH3)2), 52.1 (CH3, OCH3), 66.2 (CH2, C4‟), 68.6 (CH2, 
C6), 69.8 (CH, C5), 72.5 (CH2, C(2)OCH2Ph), 73.3 (CH2, C(3)OCH2Ph), 73.5 
(CH2, C(6)OCH2Ph), 74.8 (CH2, C(4)OCH2Ph), 75.0 (CH, C4), 75.4 (CH, C3‟), 75.6 
(CH, C2‟), 76.0 (CH, C2), 78.6 (CH, C3), 96.0 (CH, C1), 109.8 (C, (CH3)2C), 
[127.4, 127.5, 127.7, 127.8, 127.9, 128.2, 128.3, 128.4 (CH, Ph, some resonance 
overlap)], 137.9 (C, ipso Ph), 138.6 (C, ipso Ph), 138.7 (C, ipso Ph), 138.9 (C, ipso 
Ph), 169.9 (C, C=O); MS (TOF ES+) m/z 735.1 ([M + Na]+, 100%); HRMS (TOF 
ES+) calcd for C42H48O10Na ([M + Na]
+) 735.3145, found 735.3148. 
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3’,4’-O-isopropylidene-2’-O-(2,3,4,6-tetra-O-benzyl-D-galactopyranosyl)-
(1→2)-L-threitol (158) 
 
 
 
A solution of methyl ester 157 (350 mg, 0.49 mmol) in Et2O (2 mL) was added over 
5 min to a stirred suspension of LiAlH4 (28 mg, 0.74 mmol) in Et2O (3 mL).  After 
an initial vigorous reaction had subsided, the mixture was heated at reflux for 3 h 
and then cooled to r.t., poured into NH4Cl solution (5 mL) and H2O (5 mL).  The 
layers were separated and the aqueous phase was extracted with Et2O (3  10 
mL).  The organic layer and the ethereal extracts were combined and the mixture 
was dried (Na2SO4) and concentrated under reduced pressure.  The residue was 
purified by flash column chromatography (10% EtOAc in hexane) to afford alcohol 
158 as a colourless oil (320 mg, 95%).  Rf = 0.3 (25% EtOAc in hexane); []D
21 = + 
33.6 (c 1, CHCl3); max(film) / cm
-1: 3471 br (OH), 2933w, 2870w, 1497w, 1454m, 
1370m, 1253w, 1210m, 1155m, 1132m, 1077s, 1046s, 910m, 889w, 850m, 733s, 
696s; H(500 MHz, CDCl3) 1.26 (s, 3H, 1  C(CH3)2), 1.36 (s, 3H, 1  C(CH3)2), 
3.45-3.57 (stack, 2H, C(6)H2), 3.58-3.64 (stack, 2H, C(1‟)H2), 3.65-3.70 (m, 1H, 
H2‟), 3.85 (dd, J 8.4, 5.8, 1H, C(4‟)HaHb), 3.92-3.96 (m, 1H, C(4‟)HaHb), 4.00 (dd, J 
10.0, 2.6, 1H, H3), 4.02-4.04 (m, 1H, H4), 4.09 (dd, J 9.9, 3.7, 1H, H2), 4.16-4.21 
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(stack, 2H, H3‟, H5), 4.42 (A of AB, JA-B 11.8, 1H, C(6)OCHaHbPh), 4.46 (B of AB, 
JB-A 11.8, 1H, C(6)OCHaHbPh), 4.58 (A of AB, JA-B 11.4, 1H, C(4)OCHaHbPh), 4.71 
(A of AB, JA-B 11.6, 1H, C(2)OCHaHbPh), 4.76 (s, 2H, C(3)OCH2Ph), 4.89 (B of AB, 
JB-A 11.6, 1H, C(2)OCHaHbPh), 4.93 (B of AB, JB-A 11.4, 1H, C(4)OCHaHbPh), 4.96 
(d, J 3.7, 1H, H1), 7.23-7.40 (stack, 20H, OCH2Ph), OH resonance not observed; 
c(125 MHz, CDCl3) 24.9 (CH3, 1  C(CH3)2), 26.3 (CH3, 1  C(CH3)2), 62.0 (CH2, 
C1‟), 65.5 (CH2, C4‟), 68.7 (CH2, C6), 69.8 (CH, C5), 72.5 (CH2, C(3)OCH2Ph), 
73.4 (CH2, C(6)OCH2Ph), 74.6 [(CH, C4) and (CH2, C(2)OCH2Ph) resonance 
overlap], 74.7 (CH2, C(4)OCH2Ph), 75.3 (CH, C3‟), 76.2 (CH, C2), 79.5 (CH, C3), 
81.9 (CH, C2‟), 100.0 (CH, C1), 109.3 (C, (CH3)2C), [127.4, 127.6, 127.7, 128.0, 
128.1, 128.2, 128.3, 128.4, 128.5 (CH, Ph, some resonance overlap)], 137.6 (C, 
ipso Ph on C(2)OBn), 138.0 (C, ipso Ph on C(6)OBn), 138.4 (C, ipso Ph on 
C(3)OBn), 138.6 (C, ipso Ph on C(4)OBn); MS (TOF ES+) m/z 707.1 ([M + Na]+, 
100%); HRMS (TOF ES+) calcd for C41H48O9Na ([M+Na]
+) 707.3196, found 
707.3231. 
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(2’’S,3’’S,4’’R)-2’’-Azido-1-O-[3’,4’-O-isopropylidene-2’-O-(2,3,4,6-tetra-O-
benzyl-D-galactopyranosyl)-(1→2)-L-threitol]-3’’,4’’-O-isopropylidene-
octadecane-1’’,3’’,4’’-triol (160) 
 
 
 
Tf2O (80 µL, 0.49 mmol) was added dropwise over 2 min to a solution of alcohol 
158 (320 mg, 0.47 mmol) and 2,6-di-tert-butylpyridine (120 µL, 0.52 mmol) in 
CH2Cl2 (5 mL) at 0 °C.  After 30 min, the reaction mixture was diluted with CH2Cl2 
(15 mL) and the resulting solution washed sequentially with H2O (2  30 mL) and 
brine (10 mL), dried (Na2SO4) and filtered.  Removal of the solvent under reduced 
pressure provided crude triflate 159 as a colourless oil [Rf = 0.7 (25% EtOAc in 
hexane)], which was used immediately in the next etherification step.  A solution of 
alcohol 78 (180 mg, 0.47 mmol) in DMF (3 mL) was treated with NaH (60% 
dispersion in mineral oil, 40.0 mg, 1.00 mmol) at 0 ºC.  After 20 min, a solution of 
triflate 159 (assuming 100% conversion, 0.47 mmol) in THF (2 mL) was added 
dropwise over 2 min.  The resulting solution was stirred at this temperature for 1 h 
and then at r.t. for 12 h.  The reaction was then quenched by the addition of MeOH 
(1 mL) followed by NaHCO3 solution (5 mL) and extraction with Et2O (3  10 mL).  
The combined organic fractions were washed with brine (10 mL) and dried 
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(Na2SO4), filtered and the solvent was removed under reduced pressure.  The 
residue was purified by flash column chromatography (eluent: 10% EtOAc in 
hexane) to provide ether 160 as a colourless oil (355 mg, 72%); Rf = 0.3 (10% 
EtOAc in hexane); []D
20 = + 14.0 (c 1, CHCl3); max(film) / cm
-1: 2923s, 2854m, 
2098m (N3), 1497w, 1454m, 1369m, 1249m, 1216m, 1097s, 1058s, 859w, 736m, 
698s; H(500 MHz, CDCl3) 0.86 (t, J 6.8, 3H, CH2CH3), 1.21-1.29 (stack, 30H, alkyl 
chain methylenes, 2  C(CH3)2), 1.33 (s, 3H, 1  C(CH3)2), 1.35 (s, 3H, 1  
C(CH3)2), 1.39-1.55 (stack, 2H), 3.40 (ddd, J 9.7, 7.3, 2.5, 1H, H2”), 3.45-3.50 (m, 
1H, C(6)HaHb), 3.51-3.63 (stack, 4H, C(6)HaHb, C(1‟)HaHb, C(1”)HaHb), 3.76-3.86 
(stack, 4H, C(1”)HaHb, C(4‟)HaHb, H3” or H4”, H2‟), 3.95 (dd, J 10.1, 2.7, 1H, H3), 
3.97 (dd, J 8.4, 6.6, 1H, C(4‟)HaHb), 3.99-4.01 (m, 1H, H4), 4.02-4.07 (stack, 2H, 
H2, H3” or H4”), 4.22-4.28 (stack, 2H, H5, H3‟), 4.38 (A of AB, JA-B 11.8, 1H, 
C(6)OCHaHbPh), 4.42 (B of AB, JB-A 11.8, 1H, C(6)OCHaHbPh), 4.56 (A of AB, JA-B 
11.5, 1H, C(4)OCHaHbPh), 4.71(A of AB, JA-B 11.7, 1H, C(3)OCHaHbPh), 4.72 (A of 
AB, JA-B 12.1, 1H, C(2)OCHaHbPh)], 4.76 (B of AB, JB-A 12.1, 1H, C(2)OCHaHbPh), 
4.78 (B of AB, JB-A 11.7, 1H, C(3)OCHaHbPh), 4.91 (B of AB, JB-A 11.5, 1H, 
C(4)OCHaHbPh), 5.11 (d, J 3.7, 1H, H1), 7.19-7.31 (stack, 18H, OCH2Ph), 7.32-
7.36 (stack, 2H, OCH2Ph); c(125 MHz, CDCl3) 14.1 (CH3, CH2CH3), 22.7 (CH2), 
25.4 (CH3, 1  C(CH3)2), 25.7 (CH3, 1  C(CH3)2), 26.3 (CH3, 1  C(CH3)2), 26.4 
(CH2), 28.2 (CH3, 1  C(CH3)2), 29.4 (CH2), 29.5 (CH2), [29.6, 29.6, 29.7, 29.7 
(CH2, alkyl chain, resonance overlap)], 31.9 (CH2), 59.9 (CH, C2”), 65.9 (CH2, 
C4‟), 68.8 (CH2, C6), 69.3 (CH, C5), 71.1 (CH2, C1‟), 72.5 (CH2, C1”), 72.9 (CH2, 
C(3)OCH2Ph), 73.0 (CH2, C(2)OCH2Ph), 73.5 (CH2, C(6)OCH2Ph), 74.7 (CH2, 
C(4)OCH2Ph), 75.0 (CH, C4), 75.5 (CH, C3” or C4”), 76.0 (CH, C3‟), 76.4 (CH, 
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C2), 76.7 (CH, C2‟), 77.7 (CH, C4” or C3”), 78.9 (CH, C3), 97.0 (CH, C1), 108.3 
(C, (CH3)2C of 1,2-anti diol), 109.1 (C, (CH3)2C of 1,2-syn diol), [127.39, 127.41, 
127.49, 127.51, 127.7, 127.8, 127.9, 128.19, 128.22, 128.3, 128.4 (CH, Ph, some 
resonance overlap)], 138.1 (C, ipso Ph), 138.78 (C, ipso Ph), 138.82 (C, ipso Ph), 
138.9 (C, ipso Ph); m/z (TOF ES+) 1072.8 ([M + Na]+, 100%); HRMS m/z (TOF 
ES+) calcd for C62H87N3O11Na ([M + Na]
+) 1072.6238, found 1072.6246. 
 
 
 
(2’’S,3’’S,4’’R)-2’’-Amino-1-O-[3’,4’-O-isopropylidene-2’-O-(2,3,4,6-tetra-O-
benzyl-D-galactopyranosyl)-(1→2)-L-threitol]-3’’,4’’-O-isopropylidene-
octadecane-1’’,3’’,4’’-triol (161) 
 
 
 
PMe3 (240 µL of a 1.0 M soln in THF, 0.240 mmol) was added dropwise over 5 
min to a solution of azide 160 (200 mg, 0.194 mmol) in THF / H2O (2 mL, 15:1).  
The reaction mixture was stirred at r.t. for 2 h and then concentrated under 
reduced pressure.  The residual H2O was removed by co-evaporation with toluene 
(3  3 mL) to provide the crude amine product.  Purification of the residue by flash 
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column chromatography (40% EtOAc in hexane) afforded amine 161 as a 
colourless oil (175 mg, 88%); Rf = 0.3 (40% EtOAc in hexane); []D
22 = + 8.0 (c 1, 
CHCl3); max(film) / cm
-1: 3032 br (NH), 2922s, 2853m, 1497w, 1454m, 1369m, 
1246m, 1214m, 1095s, 1054s, 856m, 734s, 697s; H(500 MHz, CDCl3) 0.88 (t, J 
7.1, 3H, CH2CH3), 1.22-1.31 (stack, 30H, alkyl chain methylenes, 1  C(CH3)2 from 
each acetal), 1.33 (s, 3H, 1  C(CH3)2 from acetal protecting C(3‟‟)OH and 
C(4‟‟)OH), 1.39 (s, 3H, 1  C(CH3)2 from acetal protecting C(3‟)OH and C(4‟)OH), 
1.46-1.60 (stack, 2H), 3.40 (dd, J 9.5, 5.9, 1H, C(6)HaHb), 3.47-3.57 (stack, 3H, 
[including 3.50 (dd, J 9.5, 6.7, 1H, C(6)HaHb)], H2”, C(1”)HaHb, C(6)HaHb)), 3.62 (A 
of ABX, JA-B 11.6, JA-X 2.8, 1H, C(1‟)HaHb), 3.68 (B of ABX, JB-A 11.4, JB-X 4.7, 1H, 
C(1‟)HaHb), 3.75-3.79 (m, 1H, H2‟), 3.82-3.88 (stack, 2H, C(4‟)HaHb, C(1”)HaHb), 
3.94-4.01 (stack, 3H, H3, H4, C(4‟)HaHb), 4.05-4.11 (stack, 2H, H2, H5), 4.16-4.21 
(m, 1H, H4”), 4.34-4.41 (stack, 3H, [including 4.40 (A of AB, JA-B 11.8, 1H, 
C(6)OCHaHbPh)], H3”, H3‟, C(6)OCHaHbPh)), 4.46 (B of AB, JB-A 11.8, 1H, 
C(6)OCHaHbPh), 4.53 (A of AB, JA-B 11.4, 1H, C(4)OCHaHbPh), 4.76 (A of AB, JA-B 
11.7, 1H, C(2)OCHaHbPh), 4.77 (A of AB, JA-B 11.6, 1H, C(3)OCHaHbPh), 4.85 (B 
of AB, JB-A 11.6, 1H, C(3)OCHaHbPh), 4.90 (B of AB, JB-A 11.4, 1H, 
C(4)OCHaHbPh), 4.92 (B of AB, JB-A 11.7, 1H, C(2)OCHaHbPh), 4.97 (d, J 3.7, 1H, 
H1), 7.22-7.38 (stack, 18H, OCH2Ph), 7.43 (br d, 2H, OCH2Ph), NH2 resonance 
not observed; c(125 MHz, CDCl3) 14.1 (CH3, CH2CH3), 22.7 (CH2), 24.5 (CH3, 1  
C(CH3)2), 24.7 (CH3, 1  C(CH3)2), 26.1 (CH3, 1  C(CH3)2), 26.5 (CH3, 1  
C(CH3)2), 26.9 (CH2), [29.3, 29.4, 29.53, 29.6, 29.67, 29.70 (CH2, alkyl chain, 
resonance overlap)], 31.9 (CH2), 52.1 (CH, C2”), 65.7 (CH2, C4‟), 69.2 (CH2, C6), 
69.6 (CH2, C1”), 70.1 (CH, C5), 70.5 (CH2, C1‟), 72.7 (CH2, C(3)OCH2Ph), 73.5 
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(CH2, C(6)OCH2Ph), 73.9 (CH2, C(2)OCH2Ph), 74.7 (CH, C4), 74.8 (CH2, 
C(4)OCH2Ph), 75.00 (CH, C3‟), 75.04 (CH, C3”), 75.4 (CH, C2), 76.7 (CH, C4”), 
77.7 (CH, C2‟), 79.1 (CH, C3), 97.6 (CH, C1), 108.7 (C, (CH3)2C for acetal 
protecting C(3‟‟)OH and C(4‟‟)OH), 109.7 (C, (CH3)2C for acetal protecting C(3‟)OH 
and C(4‟)OH), [127.6, 127.7, 127.8, (CH, Ph, some resonance overlap)], [128.2, 
128.3, 128.4 (CH, Ph, some resonance overlap)], 128.7 (CH, Ph), 137.7 (C, ipso 
Ph), 137.8 (C, ipso Ph), 138.4 (C, ipso Ph), 138.5 (C, ipso Ph); MS (TOF ES+) m/z 
1046.5 ([M + Na]+, 100%), 1024.5 ([M + H]+, 80); HRMS (TOF ES+) m/z 
1024.6521 ([M + H]+). C62H90NO11 requires 1024.6514; 1046.6349 ([M + Na]
+). 
C62H89NO11Na requires 1046.6333. 
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(2’’S,3’’S,4’’R)-2’’-Hexacosanoylamino-3’’,4’’-O-isopropylidene-1-O[3’,4’-O-
isopropylidene-2’-O-(2,3,4,6-tetra-O-benzyl-D-galactopyranosyl)-(1→2)-L-
threitol]octadecane-1’’,3’’,4’’-triol (162) 
 
 
 
A screw-capped glass tube containing a solution of hexacosanoic acid (91 mg, 
0.23 mmol) in oxalyl chloride (2.0 mL, 23 mmol) was closed tightly and heated at 
70 ºC for 2 h. The volatiles were then evaporated under a stream of argon and the 
tube then placed on a high vacuum line for at least 2 h to remove the residual 
volatiles.  The resulting acid chloride was used directly without further purification.  
A solution of freshly prepared acid chloride 47 (105 mg, 0.23 mmol) in CH2Cl2 (0.5 
mL) was added dropwise over 2 min to a solution of amine 161 (154 mg, 0.15 
mmol) and NEt3 (42 µL, 0.30 mmol) in CH2Cl2 (1.0 mL) at 0 ºC.  The reaction 
mixture was stirred at r.t. for 12 h and then diluted with CH2Cl2 (10 mL), washed 
sequentially with NaHCO3 solution (10 mL), brine (2 mL) and then dried over 
Na2SO4. The drying agent was removed by filtration and the filtrate concentrated 
under reduced pressure. Purification of the residue by flash column 
chromatography provided amide 162 as a white solid (179 mg, 85%). Rf = 0.3 
(15% EtOAc in hexane); mp 69-70 ºC; []D
20 = + 41.6 (c 1, CHCl3); max(film) / cm
-1: 
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3283 br (N-H), 2919s, 2851s, 1641m (C=O), 1543w, 1497w, 1468m, 1455m, 
1369m, 1246m, 1216m, 1157m, 1098s, 1064s, 860w, 735m, 698m; H(500 MHz, 
CDCl3) 0.86 (t, J 6.8, 6H,  CH2CH3), 1.18-1.30 (stack, 73H, alkyl chain 
methylenes, 1  C(CH3)2 from acetal protecting C(3‟)OH and C(4‟)OH, 1  C(CH3)2 
from acetal protecting C(3‟‟)OH and C(4‟‟)OH), 1.34 (s, 3H, 1  C(CH3)2 from 
acetal protecting C(3‟)OH and C(4‟)OH), 1.37 (s, 3H, 1  C(CH3)2 from acetal 
protecting C(3‟‟)OH and C(4‟‟)OH), 1.40-1.66 (stack, 5H, alkyl chain methylenes), 
2.00-2.14 (stack, 2H, C(2‟”)HaHb), 3.41 (dd, J 9.5, 2.6, 1H, C(1”)HaHb), 3.45-3.55 
(stack, 4H, C(6)HaHb, C(1‟)HaHb), 3.67 (dd, J 9.5, 3.7, 1H, C(1”)HaHb), 3.75-3.81 
(stack, 2H, H2‟, C(4‟)HaHb), 3.92-3.98 (stack, 4H, H3, C(4‟)HaHb, H3”, H4”), 4.00-
4.02 (m, 1H, H4), 4.05 (dd, J 10.1, 3.7, 1H, H2), 4.08-4.16 (m, 1H, H2”), 4.20-4.26 
(stack, 2H, H5, H3‟), 4.39 (A of AB, JA-B 11.8, 1H, C(6)OCHaHbPh), 4.42 (B of AB, 
JB-A 11.8, 1H, C(6)OCHaHbPh), 4.55 (d, J 11.5, 1H, C(4)OCHaHbPh), 4.70 (A of 
AB, JA-B 12.0, 1H, C(2)OCHaHbPh), 4.72 (A of AB, JA-B 11.7, 1H, C(3)OCHaHbPh), 
4.77 (B of AB, JB-A 11.7, 1H, C(3)OCHaHbPh), 4.78 (B of AB, JB-A 12.0, 1H, 
C(2)OCHaHbPh), 4.91 (d, J 11.5, 1H, C(4)OCHaHbPh), 5.05 (d, J 3.7, 1H, H1), 5.74 
(br d, J 9.3, 1H, N-H), 7.20-7.36 (stack, 20H, OCH2Ph); c(125 MHz, CDCl3) 14.1 
(CH3, 2  CH2CH3), 22.7 (CH2), 25.3 (CH3, 1  C(CH3)2), 25.7(CH2), 25.8 (CH3, 1  
C(CH3)2), 26.3 (CH3, 1  C(CH3)2), 26.5 (CH2), 28.0 (CH3, 1  C(CH3)2), 29.0 
(CH2), [29.3, 29.4, 29.5, 29.6, 29.7 (CH2, alkyl chain, resonance overlap)], 31.9 
(CH2), 36.8 (CH2, C2‟”), 48.1 (CH, C2”), 65.8 (CH2, C4‟), 68.8 (CH2, C6), 69.3 (CH, 
C5), 70.5 (CH2, C1‟), 71.3 (CH2, C1”), 72.8 (CH2, C(3)OCH2Ph), 73.2 (CH2, 
C(2)OCH2Ph), 73.5 (CH2, C(6)OCH2Ph), 74.7 (CH2, C(4)OCH2Ph), 74.8 (CH, C4), 
76.0 (CH, C3‟), 76.15 (CH, C3” or C4”), 76.20 (CH, C2), 76.3 (CH, C2‟), 77.8 (CH, 
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C4” or C3”), 79.0 (CH, C3), 96.5 (CH, C1), 107.8 (C, (CH3)2C of acetal protecting 
C(3‟‟)OH and C(4‟‟)OH), 109.1 (C, (CH3)2C of acetal protecting C(3‟)OH and 
C(4‟)OH), [127.3, 127.4, 127.5, 127.6, 127.70, 127.75, 127.8 (CH, Ph, some 
resonance overlap)], [128.1, 128.2, 128.3, 128.4 (CH, Ph, some resonance 
overlap)], 137.9 (C, ipso Ph), 138.6 (C, ipso Ph), 138.7 (C, 2  ipso Ph), 172.4 (C, 
C=O); MS (TOF ES+) m/z 1425.0 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for 
C88H139NO12Na ([M+Na]
+) 1425.0195, found 1425.0200. 
 
 
 
Galp-α-(1→2)-ThrCer (149) 
 
 
 
TFA (150 µL) was added dropwise over 1 min to a solution of diacetal 162 (50 mg, 
0.036 mmol) in CH2Cl2 / H2O (10:1, 0.6 mL).  After stirring for 2 h at r.t., the 
reaction mixture was concentrated under reduced pressure and the residual TFA 
was removed by co-evaporation with Et2O (3  3 mL) to provide crude tetraol as a 
white solid (48 mg, quant.), which was used in the next step without further 
purification.  Pd(OH)2/C (20 mg, 0.014 mmol, 10% wet) was added to a solution of 
the crude benzylated compound (48 mg, 0.036 mmol) in THF/CH3OH (3:1, 5 mL).  
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H2 gas was bubbled through the stirred suspension for 8 h.  The reaction mixture 
was then filtered, washed with CHCl3/CH3OH (8:2, 100 mL) and concentrated 
under reduced pressure to provide the crude product, which was purified by flash 
column chromatography (15% CH3OH in CHCl3) to afford the fully deprotected 
compound 149 as a white solid (26 mg, 75%). Rf = 0.4 (15% CH3OH in 
chloroform); mp 84-85 ºC; []D
20 = + 56 (c 0.1, 2:1 CHCl3/CH3OH); max(film) / cm
-1 
3303 v br (OH), 2944m, 2833m, 1677w (C=O), 1450w,  1217m, 1031s, 762s, 
667m; H(400 MHz, 2:1 CDCl3/CD3OD) 0.84 (t, J 6.7, 6H, 2  CH2CH3), 1.15-1.33 
(stack, 67H, alkyl chain methylenes), 1.34-1.65 (stack, 5H, alkyl chain 
methylenes), 2.20 (t, J 7.6, 2H), 3.52-3.76 (stack, 9H), 3.77-3.90 (stack, 6H), 3.92 
(br d, J 3.0, 1H), 4.03-4.07 (m, 1H), 4.12-4.19 (m, 1H), 5.15 (d, J 4.1, 1H), OH 
resonances not observed; C(100 MHz, 2:1 CDCl3/CD3OD) 14.1 (CH3, 2  
CH2CH3), 23.1 (CH2), 26.25 (CH2), 26.28 (CH2), [29.8, 29.9, 30.03, 30.06, 30.12 
(CH2, alkyl chain, resonance overlap)], 32.3 (CH2), 32.8 (CH2), 36.7 (CH2), 49.8 
(CH), 62.3 (CH2), 62.9 (CH2), 69.5 (CH), 70.1 (CH), 70.5 (CH), 71.1 (CH2), 72.2 
(CH2), 72.3 (CH), 72.7 (CH), 73.3 (CH), 74.6 (CH), 78.1 (CH), 96.2 (CH), 175.2 (C, 
C=O); MS (TOF ES+) m/z 984.9 ([M + Na]+, 100%); HRMS (TOF ES+) calcd for 
C54H107NO12Na ([M+Na]
+) 984.7691, found 984.7701. 
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